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proteins that impede reprogramming. I developed a biophysical method to purify heterochromatic regions,
using sucrose gradients to isolate chromatin fragments that are resistant to sonication. Sequencing of the
purified material (Gradient-seq) revealed the genomic landscape of structural heterochromatin in human
fibroblasts, which is transcribed at low levels and contains largely distinct H3K9me3 and H3K27me3
domains, as well as unmarked regions. Gradient-seq also uncovered subtypes of H3K9me3 and H3K27me3
domains that are structurally euchromatic, a distinction corroborated by increased gene transcription,
hypomethylation at CpG islands, decreased association with the nuclear lamina, and increased activation
during hepatic reprogramming. Using quantitative proteomics, we found 172 proteins associated with
heterochromatin after gradient sedimentation and H3K9me3-directed IP. The identified proteins include
known transcriptional repressors and are enriched for proteins shown to impede reprogramming to
pluripotency. We show that the RNA-binding protein RBMX, one of the proteins most enriched by gradient
sedimentation and H3K9me3 IP, is a functional regulator of heterochromatin. RBMX and the related protein
RBMXL1 are required for silencing of select heterochromatinized genes, and depletion of these proteins in
fibroblasts renders H3K9me3-marked hepatocyte genes more competent for activation during
reprogramming to the hepatic lineage. Thus, our biophysical method for heterochromatin isolation has
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ABSTRACT 
THE HUMAN HETEROCHROMATIN LANDSCAPE: GENOMIC SUBTYPES, 
BOUND PROTEINS, AND CONTRIBUTIONS TO CELL IDENTITY 
Justin S. Becker 
Kenneth S. Zaret 
 
Large portions of mammalian genomes are packaged into structurally compact 
heterochromatin, which protects genome integrity and suppresses transcription of lineage-
inappropriate genes. Characterization of heterochromatic regions has relied on genomic 
mapping of associated histone modifications, such as H3K9me3 and H3K27me3, and 
purification of proteins interacting with these modifications. Heterochromatic regions 
marked by H3K9me3 have been shown to impede gene activation during reprogramming 
to pluripotency, and I find that H3K9me3 domains can similarly impede conversion of 
fibroblasts to hepatocytes. However, both H3K9me3 and H3K27me3 can be found in 
transcriptionally active chromatin, limiting the accuracy of histone marks alone for 
identifying heterochromatin domains or bound proteins that impede reprogramming. I 
developed a biophysical method to purify heterochromatic regions, using sucrose 
gradients to isolate chromatin fragments that are resistant to sonication. Sequencing of 
the purified material (Gradient-seq) revealed the genomic landscape of structural 
heterochromatin in human fibroblasts, which is transcribed at low levels and contains 
largely distinct H3K9me3 and H3K27me3 domains, as well as unmarked regions. 
Gradient-seq also uncovered subtypes of H3K9me3 and H3K27me3 domains that are 
structurally euchromatic, a distinction corroborated by increased gene transcription, 
hypomethylation at CpG islands, decreased association with the nuclear lamina, and 
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increased activation during hepatic reprogramming. Using quantitative proteomics, we 
found 172 proteins associated with heterochromatin after gradient sedimentation and 
H3K9me3-directed IP. The identified proteins include known transcriptional repressors 
and are enriched for proteins shown to impede reprogramming to pluripotency. We show 
that the RNA-binding protein RBMX, one of the proteins most enriched by gradient 
sedimentation and H3K9me3 IP, is a functional regulator of heterochromatin. RBMX and 
the related protein RBMXL1 are required for silencing of select heterochromatinized 
genes, and depletion of these proteins in fibroblasts renders H3K9me3-marked 
hepatocyte genes more competent for activation during reprogramming to the hepatic 
lineage. Thus, our biophysical method for heterochromatin isolation has allowed us to 
create a genome-wide map of chromatin compaction in human cells, to identify chromatin 
domain subtypes that impede conversion between differentiated lineages, and to discover 
novel heterochromatin proteins that contribute to this reprogramming barrier. 
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PREFACE 
This dissertation is a series of chapters organized around published and submitted 
manuscripts of which I am the primary author. Chapter 2 presents a review article that was 
published in TRENDS in Genetics in January 2016. Chapter 4 presents a research 
manuscript that has been submitted for publication. The experimental and analytical 
methods used during my thesis research, in particular for the manuscript in Chapter 4, are 
presented Chapter 3. These chapters all closely resemble the text of the submitted or 
published work, with alterations to reflect the format and organization of the thesis. The 
opening chapter discusses the relevant literature for the topics in covered in this 
dissertation, including a description of gaps in the field prior to my work, which goes 
beyond the more limited scope of the review in Chapter 2. Meanwhile, Chapter 5 presents 
the major conclusions from my thesis research and contextualizes them in relation to 
existing literature, while also presenting avenues for future investigation. Included as an 
Appendix at the end of the document is an additional manuscript to which I contributed as 
third author during my graduate work, which was published in Genes and Development. 
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CHAPTER 1: INTRODUCTION 
In multicellular organisms, a fixed complement of chromosomes is able to instruct 
the development of the hundreds of different cell types, each with distinct morphologies 
and functions, which makes possible the complex physiologies of eukaryotes. As an 
organism develops, there is generally no change in the sequence of DNA or the number 
of genes, and thus the diversity of cell fates must be achieved through the selective 
activation and repression of different groups of genes, with each cell type having a 
different signature of gene activity. In humans, it is estimated that less than 60 percent of 
the genomic sequence with evidence for transcription is copied into RNA in a given specific 
cell type (Djebali et al., 2012). Thus, the mechanisms that selectively induce or suppress 
gene activity are central to understanding how diverse cell types are produced during the 
course of normal development or tissue regeneration (Zaret, 2008; Hemberger et al., 
2009; Adam and Fuchs, 2016). Subsequent conversion of cells to a different cell type of 
interest, such as for therapeutic replacement of tissue destroyed by disease (Wu and 
Hochedlinger, 2011), requires a rewiring of the gene expression signatures that are 
established during development, to activate genes required for the function of the new cell 
type and extinguish expression of inappropriate genes (Vierbuchen and Wernig, 2012; 
Papp and Plath, 2013). 
A gene’s activity in any given cell type is closely related to the physical structure 
of the chromatin fiber, with active regions being associated with a more open and 
accessible conformation, while transcriptionally silent regions of DNA exhibit a denser 
packaging of nucleosomes. Physical compaction of chromatin is understood to play a 
causal role in gene silencing, by reducing the accessibility of the DNA template to binding 
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by transcription factors and other machinery necessary for transcription (Workman and 
Kingston, 1998; Li et al., 2007). On the spectrum of chromatin accessibility, regions with 
the highest level of compaction are termed “heterochromatin,” which classically have been 
identified cytologically by their enhanced uptake of DNA dyes and dark appearance in an 
electron microscope (Heitz, 1928; Brown, 1966; Underwood et al., 2016). By contrast, 
“euchromatin” refers to the portion of chromatin that has a more open or decondensed 
physical structure, appearing light in electron micrographs, and where the majority of 
transcriptional activity is confined. 
Heterochromatin formation occurs and has been most frequently studied at highly 
repetitive, noncoding regions of the genome, such as regions flanking mammalian 
centromeres and telomeres (Pardue and Gall, 1970; Fanti et al., 1998; Guenatri et al., 
2004; Probst and Almouzni, 2008), or at sequences with propensity for parasitic self-
duplication, such as DNA- or RNA-based transposable elements (Pimpinelli et al., 1995; 
Kazazian, 2004). The packaging of such loci into dense heterochromatin structures 
prevents mutagenic recombination between repetitive sequences (Fanti et al., 1998; 
Peters et al., 2001) and suppresses the activity of transposons (Slotkin and Martienssen, 
2007; Montoya-Durango et al., 2009). Thus, heterochromatin serves to protect genome 
integrity in addition to silencing inappropriate transcription (Eden et al., 2003; Peng and 
Karpen, 2008). In metazoans, such repeat-rich regions form heterochromatin in most or 
all cell types in the body, and thus are termed “constitutive heterochromatin” (Brown, 1966; 
Saksouk et al., 2015). By contrast, regions of “facultative heterochromatin” are dynamic 
during development, forming at particular stages or in a lineage-specific fashion (Brown, 
1966; Trojer and Reinberg, 2007). One classic example of facultative heterochromatin is 
the inactivation of one of the two X chromosomes in females, which is silenced in early 
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development to maintain proper gene dosage and which appears as a compacted, 
electron dense Barr body (Heard, 2005; Peters et al., 2002; Rego et al., 2008). Facultative 
heterochromatin also plays an important role in cell fate control, by stably repressing 
lineage-inappropriate gene expression (Trojer and Reinberg, 2007; Allan et al., 2012; Xu 
et al., 2014a; Snitow et al., 2016). The hallmark chromatin staining pattern of particular 
cell types, such as the “clock-faced chromatin” of antibody-secreting plasma cells (Jinn-
Fei and el-Labban, 1986), illustrates the dramatic and specific rearrangements in 
condensed heterochromatin that can accompany cell differentiation. 
 
1.1 Properties of heterochromatin and role in cell identity 
Defining features of heterochromatin include its physically dense structure and reduced 
transcriptional output. Early biophysical studies showed that the darkly staining 
heterochromatin masses in vertebrate nuclei had a structure that was more resistant to 
mechanical shearing with a sonifier or pressure cell, and that these regions could be 
physically isolated from the more heavily sheared euchromatic fibrils by differential 
centrifugation (Doenecke and McCarthy, 1975; Frenster et al., 1963). These studies 
showed that the shearing-resistant heterochromatin structures had minimal transcriptional 
activity, contained repetitive DNA satellites, had a higher ratio of histone protein to DNA, 
and were dependent on linker histone for their resistance to shearing (Doenecke and 
McCarthy, 1975; Duerksen and McCarthy, 1971; Frenster et al., 1963). The condensed 
nature of heterochromatic sequences is more typically assessed by resistance to cleavage 
by nucleases such as DNase I and II and micrococcal nuclease (MNase) (Gottesfeld et 
al., 1975; Wallrath and Elgin, 1995; Hamid et al., 1996), where the limited activity of the 
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nucleases is assumed to mirror inaccessibility to transcriptional machinery. Moreover, 
genetic studies of position-effect variegation (PEV) showed that compact heterochromatic 
structures, when placed adjacent to active genes via chromosomal rearrangement, can 
spread laterally along chromosomes into nearby loci and dominantly suppress 
transcription (Tartof et al., 1984; Wallrath and Elgin, 1995). This phenomenon was 
classically observed in the case of the white gene in Drosophila fruit flies, where 
juxtaposition of the gene near pericentromeric or telomeric sequences caused a mosaic 
pattern of gene expression and eye color in the developing fly (Tartof et al., 1984; Wallrath 
and Elgin, 1995). More recent work has recapitulated this phenomenon in mammalian 
systems using reporter transgenes that can be silenced by proximity to both repetitive and 
gene-containing forms of heterochromatin (Ayyanathan et al., 2003; Tchasovnikarova et 
al., 2015). Additional conserved properties of heterochromatin include spatial proximity to 
the nuclear lamina (Csink and Henikoff, 1996; Guelen et al., 2008; Poleshko et al., 2013) 
or nucleoli (Sadoni et al., 1999; van Koningsbruggen et al., 2010), as well as replication 
late in S phase (O’Keefe et al., 1992). 
Among the diverse post-translational modifications that are observed on histone 
tails, di- and tri-methylation at the specific residue histone 3 lysine 9 (H3K9me2 and 
H3K9me3) is  highly enriched over repeat-rich heterochromatic sequences in organisms 
ranging from Schizosaccharomyces pombe to humans (Nakayama et al., 2001; Schotta 
et al., 2002; Peters et al., 2003; Martens et al., 2005). The gene Su(var)3-9 was discovered 
as a powerful suppressor of PEV in Drosophila with dominance over most PEV enhancers 
(Tschiersch et al., 1994), and it encodes a SET domain-containing enzyme that catalyzes 
the demethylation and trimethylation of H3K9, with a particular role in pericentromeric 
H3K9me3 (Rea et al., 2000; Czermin et al., 2001; Schotta et al., 2002). There are two 
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mammalian homologues of this enzyme, SUV39H1 and SUV39H2, which are required for 
the integrity of pericentromeric heterochromatin, the silencing of satellite repeat 
transcription, and the accuracy of mitotic and meiotic chromosome segregation (Aagaard 
et al., 1999; Peters et al., 2001). Suv39h1/h2 double-mutant mice show perinatal lethality 
after E12.5, reduced size, hypogonadism in males, and increased tumorigenesis (Peters 
et al., 2001). In mammals, in addition to the SUV39H proteins, the enzyme SETDB1/ESET 
also catalyze H3K9me2 and H3K9me3 deposition (Schultz et al., 2002), while 
G9a/EHMT2 and GLP/EHMT1 contribute to H3K9me2 only (Tachibana et al., 2001, 2002, 
2005). SETDB1 plays in important role in pluripotent cells by repressing transcription 
factor genes for developmental lineages and trophectoderm (Bilodeau et al., 2009; Yeap 
et al., 2009; Yuan et al., 2009; Lohmann et al., 2010), while G9a and GLP are required for 
the stable silencing of pluripotency genes like Oct3/4 during early differentiation (Feldman 
et al., 2006; Epsztejn-Litman et al., 2008; Liu et al., 2015). Consistent with these 
observations, deletion of Setdb1 in mice causes lethality around the time of implantation 
(Dodge et al., 2004), while loss of either G9a or GLP in mice is lethal by day E12.5 
(Tachibana et al., 2002, 2005). 
The H3K9me2/3 marks are not known to directly interfere with RNA transcription 
or directly affect chromatin structure, but rather serve as a “landing platform” for 
complexes involved in various aspects of transcriptional repression (Beisel and Paro, 
2011; Black et al., 2012). The methylated lysine 9 residue is directly bound by the 
chromodomain of Heterochromatin Protein 1 (HP1) (Bannister et al., 2001; Lachner et al., 
2001), which is a suppressor of PEV in Drosophila (Eissenberg et al., 1990) and has three 
isoforms in mammals: HP1α/CBX5, HP1β/CBX1, and HP1γ/CBX3 (Fodor et al., 2010). 
HP1 has the ability to self-oligomerize and interact simultaneously with more than one 
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nucleosome, features that may help to directly drive chromatin compaction (Canzio et al., 
2011). Moreover, HP1 proteins interact directly with a variety of repressive chromatin 
modifiers, such as DNA methyltransferases (DNMTs) and histone deacetylases (HDACs) 
(Eissenberg and Elgin, 2014). This is consistent with observations that H3K9 methylation 
are epistatic to DNA methylation at CpG nucleotides and histone deacetylation at 
pericentromeric repeats and embryonically silenced genes, sites where these three 
chromatin features coincide (Lehnertz et al., 2003; Epsztejn-Litman et al., 2008). HP1 
further interacts with the co-repressor KAP1/TRIM28/TIF1β (Ryan et al., 1999); both 
proteins not only localize to H3K9me3-marked chromatin but also can in turn recruit H3K9 
methyltransferases to act on nearby nucleosomes (Schultz et al., 2002; Eissenberg and 
Elgin, 2014), providing a mechanism for heterochromatin spread (Al-Sady et al., 2013). 
Importantly, forced tethering of the fission yeast methyltrasferase Clr4 to chromatin is 
sufficient to drive gene repression, and when an H3K9 demethylase is ablated, this 
repression is stable through multiple mitotic and meiotic generations even after removal 
of the tethered Clr4 (Audergon et al., 2015; Ragunathan et al., 2015). These findings 
establish the potential of H3K9me3 to function in epigenetic inheritance and its causal role 
in gene silencing. Similar results have been obtained in mammalian cell culture systems, 
where ectopic recruitment of HP1 or KAP1 can drive heritable H3K9me3 spreading and 
gene silencing over distances of multiple kilobases (Ayyanathan et al., 2003; Groner et 
al., 2010; Hathaway et al., 2012). 
In addition to H3K9me3, trimethylation of a different histone 3 residue, lysine 27 
(H3K27me3), also has important roles in transcriptional repression and chromatin 
compaction (Margueron and Reinberg, 2011). H3K27 methylation is exclusively catalyzed 
by a single protein complex, Polycomb Repressive Complex 2 (PRC2), which in mammals 
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can contain either of two methyltransferases EZH1 or EZH2 (Müller et al., 2002; Czermin 
et al., 2002; Kuzmichev et al., 2002; Ferrari et al., 2014). This complex was named 
‘Polycomb’ because its genetic disruption in Drosophila led to improper body 
segmentation (Lewis, 1978), associated with aberrant de-repression of Hox transcription 
factor genes  (Lewis, 1978; Duncan, 1982). Recent genome-wide mapping studies have 
revealed a global correlation between H3K27me3 and transcriptional repression (Barski 
et al., 2007), and genes marked by H3K27me3 are markedly enriched for transcription 
factors involved in cell fate transitions, a result corroborated in diverse organisms and 
developmental lineages (Lee et al., 2006; Boyer et al., 2006; Schwartz et al., 2006; 
Bracken et al., 2006; Xu et al., 2014a). H3K27me3 generated by PRC2 promotes binding 
by the chromodomain-containing Polycomb Repressive Complex 1 (PRC1) (Lee et al., 
2007), which can directly compact nucleosome arrays in vitro (Francis et al., 2004). 
However, other studies have found that the chromatin structure of H3K27me3-marked 
promoters can remain accessible to binding by general transcription factors and RNA 
polymerase II (Breiling et al., 2001; Dellino et al., 2004). These and other studies have 
suggested that H3K27me3-associated repression is mediated at least partially through 
blocking the transcriptional initiation or elongation of an engaged RNA polymerase  
(Breiling et al., 2001; Dellino et al., 2004; Stock et al., 2007; Kanhere et al., 2010). Thus, 
it remains unclear to what extent the H3K27me3 mark is associated with the highly 
compact chromatin structure that is characteristic of heterochromatin. 
Although the term “facultative heterochromatin” is more frequently associated in 
the literature with H3K27me3 (eg, (Trojer and Reinberg, 2007)), regions marked by 
H3K9me3 show substantial developmental rearrangement. Differentiated human cells 
have megabase-sized domains of H3K9me3 that are expanded in both size and number 
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in comparison to pluripotent embryonic stem (ES) cells (Hawkins et al., 2010), consistent 
with a large increase in total H3K9me3 levels by mass spectrometry (Sridharan et al., 
2013). Differentiation-specific H3K9me3 domains encompass several genes required for 
pluripotency, as well as numerous gene family clusters (encoding zinc finger transcription 
factors, adhesion proteins, olfactory receptors, and mediaters of neurotransmission) with 
cell type-specific function (Hawkins et al., 2010; Soufi et al., 2012; Vogel et al., 2006). 
These large H3K9me3 domains are observed in diverse human cell lines and tissues, with 
substantial regions of overlap as well as divergence when comparing different tissues 
(Soufi et al., 2012; Becker et al., 2016). H3K9me3 is also strongly enriched with domains 
mapped by their association with the nuclear lamina (lamina-associated domains, or 
LADs), which also undergo developmental rearrangement (Guelen et al., 2008). 
Meanwhile, H3K27me3-enriched regions can span hundreds of kilobases and, similar to 
H3K9me3-marked regions, cover a larger fraction of the genome in differentiated cells 
compared to ES cells (Pauler et al., 2009; Hawkins et al., 2010). Comparison of H3K9me3 
and H3K27me3 domains in somatic cells reveals some regions of overlap but largely 
distinct positioning in the genome (Hawkins et al., 2010; Chandra et al., 2012). This is 
similar to the observation that H3K9me3 and H3K27me3 both contribute to silencing on 
the inactive X chromosome but occupy distinct spatial domains (Chadwick and Willard, 
2004; Heard, 2005; Nozawa et al., 2013). Comparable to findings for H3K9me3, earlier 
studies suggested that coverage for the dimethyl mark H3K9me2 increases after exit from 
pluripotency (Wen et al., 2009). Other groups have challenged this result, arguing that it 
is dependent on the threshold set for defining H3K9me2-enriched regions (Filion and van 
Steensel, 2010), though mass spectrometry data also reveals an increase in H3K9me2 
levels in mouse fibroblasts compared to ES cells (Sridharan et al., 2013). Regardless, 
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enrichment of H3K9me2 can be found in common among H3K9me3- and H3K27me3-
marked regions (Chandra et al., 2012), suggesting that the two trimethyl marks allow more 
specific delineation of two flavors of repressive chromatin. 
 
1.2 Heterochromatin as a barrier to cell reprogramming 
The epigenetic mechanisms that enforce cell type-specific transcription programs must be 
overcome when cells are “reprogrammed” or converted to other cell fates, such as 
pluripotency (Graf and Enver, 2009; Vierbuchen and Wernig, 2012). In 2006, it was shown 
that overexpression of four genes is sufficient to convert differentiated cells, such as skin 
fibroblasts, to induced pluripotent stem (iPS) cells, which closely resemble ES cells and 
have the ability to give rise to any cell type in the embryo (Takahashi and Yamanaka, 
2006; Takahashi et al., 2007). The four genes overexpressed in the original iPS 
technique—OCT4, SOX2, KLF4, and CMYC (henceforth, “OSKM”)— all encode master 
transcription factors expressed in pluripotent ES cells (Boyer et al., 2005; Takahashi and 
Yamanaka, 2006).  Additional combinations of genes are capable of generating iPS cells 
(Buganim et al., 2012; Shu et al., 2013), with all such methods fundamentally relying on 
lineage-specifying transcription factors to rewire gene expression programs toward a 
desired fate (van Oevelen et al., 2013). 
Among cellular conversion techniques, iPS cells represent a highly successful 
example of reprogramming, as the cells produced closely resemble non-reprogrammed 
ES cells on the functional, transcriptional, and epigenetic level (Maherali et al., 2007; 
Wernig et al., 2007; Cahan et al., 2014). The technique also has tremendous utility in 
biomedicine, since iPS cells derived from a patient can be differentiated to a cell type of 
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interest, enabling the production of patient-specific cells for therapeutic transplantation 
(Wu and Hochedlinger, 2011; Hanna et al., 2007; Wang et al., 2015) or for modeling of 
diseases affecting tissues that cannot be cultured ex vivo (Moretti et al., 2010; Toma et 
al., 2015). Nonetheless, transcription factor-driven iPS reprogramming remains a highly 
inefficient process, with only a small fraction of the starting cell population (generally 
<0.1%) reaching the iPS state, through a process that appears to be stochastic (Hanna et 
al., 2009), and the duration of the process lasts over one month for human cells 
(Vierbuchen and Wernig, 2012; Papp and Plath, 2013). Although expression of the iPS 
reprogramming factors for a few days is sufficient to cause widespread downregulation of 
the somatic transcriptional program in the majority of cells, activation of the pluripotency 
network is more delayed (Brambrink et al., 2008; Stadtfeld et al., 2008; Polo et al., 2012; 
Tanabe et al., 2013). Among genes repressed in the starting cell type, a particular subset 
of pluripotency markers—so-called “late-reprogramming genes”—are only expressed in 
the final stages of the reprogramming process and are highly predictive of successful iPS 
conversion (Buganim et al., 2012; Polo et al., 2012). 
Our laboratory previously mapped the genome-wide binding of the OSKM factors 
after 48 hours of expression in human fibroblasts (Soufi et al., 2012). This work showed 
that the factors are able to engage their gene targets in a range of chromatin contexts. Yet 
there are megabase-sized stretches of chromatin that lack binding for all four factors, even 
though the factors were able to bind such sites in ES cells (Soufi et al., 2012). These 
regions, defined by their differentiation-specific impediment to OSKM binding, were 
termed “Differentially Bound Regions” (DBRs) (Soufi et al., 2012). The DBRs, which 
average ~2 MB in size, closely correspond to domains of H3K9me3 present in fibroblasts 
and absent in pluripotent ES cells. In addition to H3K9me3, the DBRs have several other 
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features of heterochromatin: resistance to DNase-I digestion, transcriptional repression, 
overlap with LADs, and an enrichment for repetitive elements (Soufi et al., 2012). The 
DBRs also contain genes essential for pluripotency, including NANOG, SOX2, DPP2, 
DPPA4, GDF3, and ZFP42. Strikingly all of these genes were previously shown to be 
delayed in activation until the late stages of reprogramming  (Buganim et al., 2012; Polo 
et al., 2012), suggesting that a failure of the reprogramming factors to access the DNA 
within heterochromatic DBRs was a key underlying mechanism for the inefficiency of iPS 
conversion. Indeed, reducing H3K9me3 levels through knockdown of SUV39H1/H2 
methyltransferase caused an increase in OCT4 and SOX2 binding within DBRs (Soufi et 
al., 2012), concomitant with an increase in the rate and number of human iPS colonies 
formed (Onder et al., 2012; Soufi et al., 2012). In the murine system, similar results have 
been shown for shRNA against SETDB1, which caused one of the largest increases in 
iPS colony formation in a screen of 615 chromatin-related genes (Cheloufi et al., 2015). 
Mouse iPS reprogramming is also enhanced by inhibition or knockdown of the H3K9me2-
related enzymes G9a and GLP (Shi et al., 2008; Sridharan et al., 2013), as well as by 
knockdown of HP1 isoforms, with the strongest effect seen for HP1γ/CBX3 (Sridharan et 
al., 2013). Thus, perturbation of H3K9me3-related heterochromatin has emerged as a 
major strategy for enhancing conversion to pluripotency. 
Heterochromatin structures over core pluripotency loci not only impede the rate of 
the reprogramming process, but also are a major cause for cells arresting in non-
pluripotent states. In a plate of cells expressing the reprogramming factors, many go on 
to become “partially reprogrammed” cells, which express a subset of undifferentiated 
markers and can be stably propagated, but lack expression of many late reprogramming 
genes and have limited developmental potential (Mikkelsen et al., 2008; Fussner et al., 
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2011). In partially reprogrammed cells, core pluripotency genes retain H3K9me3 (Chen et 
al., 2013), high levels of DNA methylation (Mikkelsen et al., 2008; Fussner et al., 2011), 
and a compact chromatin structure (Fussner et al., 2011). Erasure of heterochromatin 
marks by knockdown of SETDB1 or SUV39H1, overexpression of the H3K9 demethylase 
KDM4B, or inhibition of DNA methyltransferases are sufficient to drive partially 
reprogrammed cells to the iPS state (Chen et al., 2013; Mikkelsen et al., 2008). These 
findings reveal that failure to convert H3K9me3-marked heterochromatin to active 
euchromatin is a major restriction point on the path to the iPS state.  Moreover, even in 
fully reprogrammed human iPS cells, there exist large domains with aberrant non-CpG 
methylation compared to compared to ES cells (Lister et al., 2011), and 21 out of 22 of 
these domains fall within heterochromatic DBRs (Soufi et al., 2012). Thus, 
heterochromatin contributes to the persistent epigenetic signatures that remain in iPS 
cells, highlighting the challenge of activating these regions of chromatin during 
transcription factor-mediated reprogramming. 
Moreover, the barrier imposed by H3K9me3-marked heterochromatin on 
reprogramming is not specific to particular transcription factor combinations. 
Reprogramming to pluripotency can also be carried out by somatic cell nuclear transfer 
(SCNT), a long-established technique (Gurdon et al., 1958) involving transfer of a nucleus 
from a differentiated cell into an enucleated egg in order to restore the developmental 
potential of the donor nucleus. SCNT allows for the cloning of mice to produce viable 
offspring (Wakayama et al., 1998), but most of the resulting embryos arrest at an early 
developmental stage (Pasque et al., 2011a). By generating transcriptomic data for two-
cell mouse embryos, Zhang and colleagues curated large genomic regions called 
“Reprogramming Resistant Regions” (RRRs), which become acquire transcriptional 
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activity in normal fertilized embryos but remain aberrantly silenced in SCNT-derived 
embryos (Matoba et al., 2014). The RRRs, which ranged from 100 to 800 kilobases in 
size, had high levels of H3K9me3 in the donor nuclei and were enriched for LINE and LTR 
repeat elements (Matoba et al., 2014), similar to the DBRs discovered for human iPS 
reprogramming (Soufi et al., 2012). Knockdown of SUV39H1/H2 or overexpression of the 
H3K9 demethylase KDM4D ameliorated the RRR expression defect and allowed as much 
as 80% of the embryos to reach the blastocyst stage, compared to less than 20% in 
controls (Matoba et al., 2014). This dramatic improvement in the viability and 
developmental competence of SCNT is consistent with previous results after deletion of 
G9a methyltransferase (Epsztejn-Litman et al., 2008). Moreover, these findings suggest 
that H3K9me2/3-marked regions pose an impediment not only to the activity of the OSKM 
factors but also to the coordinated action of the diverse components of the egg cytoplasm. 
In addition to influencing the kinetics of the reprogramming process, dissolution of 
heterochromatin may be instrumental to the pluripotent state itself. Electron spectroscopic 
imaging (ESI) allows high-resolution analysis of chromatin structures, including detection 
of nucleosomes, calculation of inter-fiber distances, and distinguishing of chromatin from 
protein-based complexes (Ahmed et al., 2010). In pluripotent cells of the developing 
embryonic epiblast, ESI reveals a dispersed network of 10-nm fibers and an absence of 
blocks of highly compacted chromatin, which is seen at later stages of development in the 
primitive endoderm or trophectoderm cells (Ahmed et al., 2010). These densely packed 
heterochromatin fibers are also absent in cultured ES or iPS cells, while they remain in 
partially reprogrammed cells (Fussner et al., 2011). ES cells also lack dense 
heterochromatin structures detected by electron microscopy (Underwood et al., 2016) 
and, compared to differentiated cells, have fewer and less intense H3K9me3 foci 
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(Meshorer and Misteli, 2006). These observations, along with the finding that ES-cell 
chromatin has a higher rate of exchange of linker histone and HP1 (Meshorer and Misteli, 
2006), has led to the conclusion that pluripotency represents a more globally accessible 
chromatin state (Gaspar-Maia et al., 2011). This model is supported by the elevated global 
transcriptional output of ES cells, leaky transcription of tissue-specific genes, and 
expression of satellite repeats and LINE and SINE retrotransposons (Efroni et al., 2008), 
which demonstrates that heterochromatin function—in addition to structure—is different 
between pluripotent and differentiated cells. 
Given the reduction or absence of traditional hallmarks of heterochromatin in 
pluripotent cells, it is currently unclear whether the profound influence of H3K9me3 
removal on reprogramming to pluripotency will apply generally to other cell-conversion 
techniques, or whether it is purely a byproduct of the unique features of the pluripotent 
state. A variety of methods exist for reprogramming somatic cells directly to another 
differentiated lineage, without going to through a pluripotent intermediate, by 
overexpressing tissue-specific transcription factors (Ladewig et al., 2013). Before the iPS 
era, Weintraub and colleagues showed that ectopic MyoD expression was sufficient to 
convert fibroblasts to muscle progenitors (Davis et al., 1987), and now diverse 
transcription factor combinations have been discovered for converting fibroblasts to 
cardiomyocytes (Ieda et al., 2010), neurons (Vierbuchen et al., 2010), hepatocytes (Sekiya 
and Suzuki, 2011; Huang et al., 2011), as well as for causing cells to switch lineages within 
the hematopoietic (Xie et al., 2004) or pancreatic (Zhou et al., 2008) compartments. 
Directly reprogrammed cells are typically shown to have undergone a cell fate change by 
their morphology, expression of characteristic marker genes, and rescue of tissue function 
in vivo in transplantation experiments (Zhou et al., 2008; Sekiya and Suzuki, 2011; Huang 
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et al., 2011). However, in nearly all cases, transcriptome-wide assessment reveals 
substantial differences between directly reprogrammed cells and the native cell types they 
mimic (Cahan et al., 2014; Morris et al., 2014).. Transcriptomes of engineered cell types 
reveal persistent expression of genes specific to the starting cell type, failure to completely 
induce the gene networks of the desired cell population, and, in some cases, aberrant 
induction of genes for additional developmental lineages that share some of the same 
transcription factors (Marro et al., 2011; Cahan et al., 2014; Morris et al., 2014). Thus, 
whereas iPS reprogramming is an inefficient but highly faithful conversion to the 
pluripotent state, directed conversion methods often achieve high yields of reprogrammed 
cells but are – as a class – less faithful to their intended lineage (Cahan et al., 2014). 
There is great interest in developing techniques to generate large numbers of 
functional human hepatocytes in vitro, which could allow therapeutic transplantation of 
patient-derived cells for metabolic liver disease (Haridass et al., 2008; Asgari et al., 2013) 
and improved screening of pharmaceuticals for pharmacokinetics and toxicity (Sahi et al., 
2010). Two recent reports describe the reprogramming of human fibroblasts to a 
hepatocyte-like state, which they termed human induced hepatocytes (hiHeps), using 
different combinations of endodermal transcription factors that both included HNF1A and 
HNF4A (Huang et al., 2014; Du et al., 2014). The resulting cells exhibit hepatocyte 
morphology, express marker genes like albumin and α-1-antitrypsin, and demonstrate 
aspects of normal liver metabolism like glycogen synthesis, LDL update, and detoxification 
of certain xenobiotic drugs (Huang et al., 2014; Du et al., 2014). However, analysis of 
hiHep transcriptomes reveal widespread differences compared to native hepatocytes in 
culture, including hepatocyte-specific transcription factor and metabolic genes that remain 
uninduced in the reprogrammed cells (Huang et al., 2014; Du et al., 2014). The hiHep 
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cells are capable of engrafting in the livers of mouse models of liver failure (Huang et al., 
2014; Du et al., 2014), including fumarylacetoacetate hydrolase (FAH)-deficient animals 
(Azuma et al., 2007), which represents an improvement over previous work using cells 
differentiated from pluripotent stem cells (Ji et al., 2013; Du et al., 2014; Vallier, 2014). 
However, in vivo engraftment and expansion has only been demonstrated in hiHep cells 
after cell immortalization with to disable cell-cycle checkpoints (tumorigenic manipulations 
that preclude therapeutic use), and, even so, the engrafted hiHep cells secreted an order 
of magnitude less albumin (Du et al., 2014) or required an order of magnitude more 
transplanted cells to rescue mouse survival (Huang et al., 2014) compared to native fetal 
hepatocytes. A particular challenge in the differentiation or reprogramming of cells to the 
mature hepatic fate is the activation of a panel genes encoding enzymes of the 
cytochrome P450 family, which are critical for drug metabolism and excretion (Vallier, 
2014). However, the role of H3K9me3 or heterochromatin in impeding activation of these 
gene classes has not been explored, and no manipulations of chromatin state have been 
shown to improve conversion to the hepatic lineage. 
 
1.3 The regulation and composition of mammalian heterochromatin 
Given the role of H3K9me3-dependent heterochromatin in impeding cell reprogramming, 
the mechanisms that control H3K9me3 deposition—and, in particular, the processes that 
establish H3K9me3 domains in a cell type-specific manner—might be targeted in order to 
influence reprogramming efficiency or allow access to specific cell fates. However, very 
little is known about the protein machinery that mediates the observed dynamics in 
H3K9me3 domains among developmental stages and different lineages (Allan et al., 2012; 
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Soufi et al., 2012; Becker et al., 2016). Since H3K9me3 methyltransferases are 
constitutively expressed and do not themselves recognize specific DNA sequences 
(Aagaard et al., 1999; Tachibana et al., 2001; Marmorstein, 2003), additional mechanisms, 
such as transcription factor- or RNA-mediated recruitment of methyltransferases, are 
required to explain the selectivity of H3K9me3 deposition. 
 Several transcription factors have been shown to play a role in heterochromatin 
establishment, though in many cases such mechanisms were described for constitutively 
heterochromatic repeats as opposed to gene-containing domains. Gfi1b, Sall1, Zeb1, and 
certain Pax family transcription factors all bind to pericentromeric satellites, which contain 
sequence motifs for each of these factors within the repeated unit (Vassen et al., 2006; 
Yamashita et al., 2007; Bulut-Karslioglu et al., 2012). Gfi1b is known to directly interact 
with SUV39H1 and G9a, suggesting a direct role in H3K9me3 deposition (Vassen et al., 
2006). Meanwhile, Pax3 and Pax9 are required in mouse fibroblasts for the silencing of 
major satellite transcription and for the integrity of pericentromeric heterochromatin, but 
the mechanism by which their binding leads to repression rather than persistent activity is 
unclear and may involve a transient state of transcript generation (Bulut-Karslioglu et al., 
2012). The roles of Gfi1b, Pax3, and Pax9 in constitutive heterochromatin is surprising 
given the cell type-specific expression of these factors (Vassen et al., 2006; Bulut-
Karslioglu et al., 2012), suggesting that alternative mechanisms maintain pericentromeric 
heterochromatin depending on the lineage and the factors expressed. 
 An important regulator of H3K9me3 recruitment is Krüppel-associated box 
(KRAB)-associated protein 1 (KAP1), also known as TRIM28 or TIF1β (Iyengar and 
Farnham, 2011). KAP1 is the obligate co-repressor for KRAB domain-containing zinc 
finger transcription factors (KRAB-ZNFs), a family of hundreds of recently evolved 
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transcription factors that are specific to tetrapods (Friedman et al., 1996; Kapopoulou et 
al., 2016). KAP1 interacts directly with both HP1 and SETDB1, and thus it acts as a 
molecular link between the sequence-specific binding of KRAB-ZNFs and the subsequent 
deposition and propagation of H3K9me3 (Ryan et al., 1999; Schultz et al., 2002; Iyengar 
and Farnham, 2011). Phosphorylation of KAP1 at serine 824, which occurs in response 
to DNA damage, causes a global reduction in chromatin compaction (Ziv et al., 2006), and 
mutations mimicking constitutive phosphorylation of this residue promote iPS 
reprogramming (Seki et al., 2010) Ectopic tethering of KAP1 or a KRAB domain is 
sufficient to induce spreading of H3K9me3 over distances of tens of kilobases and 
mitotically heritable gene silencing (Ayyanathan et al., 2003; Groner et al., 2010; Gilbert 
et al., 2014). However, recent findings suggest that KRAB-ZNF mediated recruitment of 
KAP1 may not have a widespread role in heterochromatin domain formation. Deletion of 
KAP1’s RBCC domain, which is required for KAP1-KRAB interaction, predominantly 
affects KAP1 binding at the 3’ end of ZNF genes (Iyengar et al., 2011). These genes 
represent a small subset of KAP1’s chromatin binding, do not significantly change 
expression upon loss of KAP1 (Iyengar et al., 2011), and may not be heterochromatic 
given evidence of transcriptional elongation (Blahnik et al., 2011). While KAP1 is required 
for the silencing of endogenous retroviruses (Rowe et al., 2010; Ecco et al., 2016), no 
study has reported the elimination of a large (>10 kb) H3K9me3 domain upon loss of a 
specific KRAB-ZNF or even KAP1 itself. 
 Indeed, a challenge for transcription factor-dependent models of H3K9me3 
domain formation is the sheer size of these domains. While lateral propagation of 
H3K9me3 from a single nucleation site, such as a transcription factor binding motif, is 
compatible with experimental evidence (Groner et al., 2010; Hathaway et al., 2012) and 
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mathematical modeling (Hodges and Crabtree, 2012) for distances of tens of kilobases, 
such mechanisms to not account for the creation of H3K9me3 domains of multiple 
megabases, as is observed in differentiated human cells (Hawkins et al., 2010; Chandra 
et al., 2012; Soufi et al., 2012). The formation of such domains may involve the 
coordinated action of many reiterated transcription factor binding events, or may 
alternatively involve mechanisms unrelated to local sequence motifs. 
 In addition to transcription factor-dependent mechanisms, it has been shown that 
nucleation and maintenance of heterochromatin domains in some cases depends upon 
noncoding RNA (ncRNA). Such RNA-based mechanisms have been best elucidated in 
the fission yeast S. pombe, where maintenance of pericentromeric heterochromatin 
requires the RNA interference (RNAi) pathway (Volpe et al., 2002), which is activated by 
low-level transcription of the pericentromeric repeats themselves (Djupedal et al., 2005; 
Kato et al., 2005). Repeat-derived ncRNAs are processed into small interfering RNAs 
(siRNAs) and stay tethered to the site of nascent heterochromatin transcription by RNA-
RNA base pairing; this creates a binding platform for the recruitment of additional 
machinery involved in transcriptional silencing, including an H3K9me3 methyltransferase 
(Bühler et al., 2006; Zhang et al., 2008; Bayne et al., 2010). More recently, additional 
ncRNA-based mechanisms that are distinct from RNAi, such as those involving RNA 
processing factors and the RNA exosome, have been implicated in heterochromatin 
establishment in fission yeast (Bühler et al., 2007; Reyes-Turcu et al., 2011). 
Whether RNAi contributes to heterochromatin in mammals remains controversial, 
in part owing to inconsistent evidence for heterochromatin-derived siRNAs (Saksouk et 
al., 2015). However, accumulating data suggest that other forms of ncRNA may have a 
substantial role in regulating mammalian heterochromatin. Several groups have observed 
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that, at some heterochromatin regions, the presence of H3K9me3 is compatible with 
simultaneous low-level transcription (Martens et al., 2005; Terranova et al., 2005; Lu and 
Gilbert, 2007). HP1a binds directly to RNA, including transcripts derived from satellite 
repeats, and this interactions is required for its localization to and function at 
pericentromeric heterochromatin (Maison et al., 2002; Muchardt et al., 2002; Maison et 
al., 2011). In normal mouse embryogenesis, pericentromeric heterochromatin formation 
requires an early burst of transcription from these regions (Probst et al., 2010; Casanova 
et al., 2013), and ectopic addition of satellite-derived dsRNAs is sufficient to rescue 
defective heterochromatin formation in an H3.3 mutant (Santenard et al., 2010). Away 
from the centromere, LINE-1 retrotransposons undergo a similar early developmental 
burst in transcription that precedes their silencing (Fadloun et al., 2013), and regions of 
persistent LINE-1 transcription on the X chromosome are found in close proximity to genes 
silenced by X inactivation, suggesting a possible direct role in silencing (Chow et al., 
2010). Finally, a ribosomal-derived ncRNA has been shown not only to participate in 
silencing of ribosomal DNA, but also to initiate widespread heterochromatin formation and 
loss of pluripotency when ectopically expressed in human ES cells (Savić et al., 2014). 
The mechanisms and protein machinery that link the transcription of such ncRNAs to 
H3K9me3 deposition and chromatin compaction are largely undefined. Moreover, it 
remains to be determined what are the relative contributions of RNA-based versus 
transcription factor-based mechanisms in the formation of the megabase-scale domains 
of facultative heterochromatin that emerge during mammalian development (Hawkins et 
al., 2010). 
 To identify new proteins involved in the regulation of H3K9me3, some groups have 
performed chromatin immunoprecipitation (ChIP) to isolate H3K9me3-marked chromatin 
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fragments, followed by mass spectrometry (MS) to define the protein content of those 
fragments (Soldi and Bonaldi, 2013; Engelen et al., 2015; Ji et al., 2015). An alternative 
approach is the use of MS-based proteomics after pulldown of soluble complexes with an 
H3K9me3 peptide bait, which has been used to identify “reader” complexes interacting 
directly with the mark (Vermeulen et al., 2010; Eberl et al., 2013). Each of these studies 
profiled interacting proteins for multiple histone modifications, and the H3K9me3-
associated proteins were not further studied to investigate a functional role in H3K9me3 
or gene repression, nor were their genomic locations mapped (Vermeulen et al., 2010; 
Eberl et al., 2013; Soldi and Bonaldi, 2013; Engelen et al., 2015; Ji et al., 2015). 
Nonetheless, large numbers of H3K9me3-associated proteins were identified with no 
previously characterized role in heterochromatin. The identified H3K9me3 readers 
included several transcription factors with zinc finger domains (non-KRAB), including 
POGZ, CHAMP1/ZNF828, ZNF282D, ANDP, and ZMYM4, which were also shown to 
interact directly or indirectly with HP1 isoforms (Eberl et al., 2013; Vermeulen et al., 2010). 
Other groups have shown, by ChIP-MS, that H3K9me3-marked chromatin fragments are 
enriched for components of the nuclear scaffold/matrix, including Scaffold Attachment 
Factor (SAF)-A/HNRNPU, SAFB1, SAFB2, and SAFB-like transcriptional modulator, as 
well as Matrin3 (MATR3) (Soldi and Bonaldi, 2013), consistent with a tethering of 
heterochromatin to nuclear structures. Surprisingly, simple inspection of these H3K9me3-
related proteomic datasets reveals large number of RNA-binding proteins. A published list 
of H3K9me3 readers (Vermeulen et al., 2010) includes several heterogeneous 
ribonucleoproteins (HNRNPs) (HNRNPA1, HNRNPA2, HNRNPA2B1, HNRNPK, and 
HNRNPL) as well as the RNA-binding proteins NONO and SFPQ, which are involved in 
splicing but have also been shown to act as corepressors for hormone receptors (Mathur 
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et al., 2001; Dong et al., 2009). A H3K9me3-directed ChIP-MS study in the same cell type 
identified all of these same proteins as well as scores of additional RNA-processing factors  
(Transformer-2 protein homologs A and B; serine/arginine-rich splicing factors (SRSFs) 1, 
2, 3, 6, and 7; RNA binding motif protein, X-linked (RBMX); etc) (Soldi and Bonaldi, 2013). 
The specific RNA-binding protein HNRNPK has recently been found to interact with 
SETDB1 and KAP1, promote H3K9me3 deposition at gene promoters and endogenous 
retroviruses, and impede iPS reprogramming (Bao et al., 2015; Thompson et al., 2015). 
However, for the larger set of H3K9me3-associated RNA-binding proteins, their role in 
heterochromatic silencing is unexplored, as is whether RNA interaction is required for the 
interaction with H3K9me3-marked chromatin. These studies suggest that the composition 
and regulation of mammalian heterochromatin is likely to involve a wider diversity of 
factors than the canonical chromodomain proteins and repressive histone modifiers. 
 
1.4 H3K9me3 outside of heterochromatin and avenues for investigation 
Although H3K9me3 is enriched at both repetitive and gene-containing regions of 
repressed heterochromatin, care must be taken when inferring the relationship between 
H3K9me3-associated proteins and heterochromatin per se. First, two of the most 
comprehensive ChIP-MS datasets (Engelen et al., 2015; Ji et al., 2015) were prepared 
using murine ES cells, which appear to completely lack the highly compacted chromatin 
structures present in differentiated cells  (Meshorer and Misteli, 2006; Fussner et al., 2011; 
Underwood et al., 2016). These findings illustrate that H3K9me3 deposition can in the 
absence of the high levels of physical compaction that are typically thought to define 
heterochromatic regions. Second, even in differentiated cells, the H3K9me3 mark is 
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present in actively transcribed regions of chromatin. Work in both Drosophila and 
mammalian cells has shown an increase in H3K9me3 and HP1 within in gene bodies upon 
transcriptional induction (Piacentini et al., 2003; Vakoc et al., 2005), and indeed HP1 
appears to promote transcriptional elongation at least some genes (Piacentini et al., 2003, 
2009; Riddle et al., 2012), with certain phosphorylated forms of mammalian HP1γ 
localizing preferentially to active chromatin (Lomberk et al., 2006). 
In general, levels of H3K9me3 within transcribed gene bodies are quantitatively 
lower than regions of constitutive heterochromatin (Vakoc et al., 2005). However, specific 
regions have a seemingly paradoxical chromatin configuration with high levels of 
H3K9me3 coincident with gene transcription (Blahnik et al., 2011; Riddle et al., 2012). In 
human cells, this has been observed at clusters of KRAB-ZNF genes on chromosome 19, 
which feature large domains of H3K9me3 and HP1 binding (Vogel et al., 2006) 
overlapping with H3K36me3 (Blahnik et al., 2011), a mark that is associated with 
transcription elongation (Vakoc et al., 2006). Analysis of SNPs in RNA-seq data confirms 
that both alleles of the H3K9me3-marked ZNF genes are expressed (Blahnik et al., 2011). 
These clusters of genes are the same sites where KAP1 binding was observed to be most 
dependent upon interaction with KRAB domains (Iyengar et al., 2011), suggesting that 
KAP1 recruitment by KRAB-ZNF proteins to their own genes, previously proposed to be 
a negative feedback mechanism (O’Green et al., 2007), is compatible with gene 
expression (Blahnik et al., 2011; Valle-García et al., 2016) and therefore does not 
necessitate formation of repressive heterochromatin. The KRAB-ZNF clusters on 
chromosome 19 were also shown to have a distinct pattern of three-dimensional genomic 
contacts and, compared to other H3K9me3-marked regions, were classified as forming a 
distinct architectural subcompartment (Rao et al., 2014). Of note, this finding required 
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targeted analysis of chromosome 19 alone, and the approach lacked sensitivity to detect 
similar regions genome-wide (Rao et al., 2014). A similar chromatin state, with strong 
enrichment for H3K9me3 and HP1 coinciding with H3K36me3-marked, transcribed genes, 
has been observed on Drosophila chromosome 4 (Riddle et al., 2012). At present, no 
study has comprehensively defined regions of H3K9me3 that are permissive to 
transcription or have an accessible chromatin structure, and it is unknown whether such 
domains exist on human chromosomes other than chr19 or affect non-ZNF human genes. 
The finding of the H3K9me3 mark in the context of transcriptionally active 
chromatin suggests a limitation of approaches dependent upon this modification, such has 
H3K9me3 ChIP-MS (Soldi and Bonaldi, 2013; Engelen et al., 2015; Ji et al., 2015), to 
define with confidence the protein composition of repressive heterochromatin. Further 
work is necessary to determine whether, for example, the large number of RNA-binding 
proteins found to bind or co-precipitate with H3K9me3 (Vermeulen et al., 2010; Soldi and 
Bonaldi, 2013) are “contaminants” from euchromatic forms of H3K9me3 domains, or 
alternatively whether such proteins indeed contribute to highly compacted 
heterochromatin in mammalian cells, similar to RNA-based mechanisms known to 
regulate yeast or fly heterochromatin (Grewal and Elgin, 2007; Bühler et al., 2007; Reyes-
Turcu et al., 2011). A second limitation of H3K9me3-dependent approaches to define the 
heterochromatin proteome is the exclusion of heterochromatic regions marked by 
H3K27me3, as exemplified by regions on the inactive X chromosome (Plath et al., 2003; 
Rego et al., 2008), or possibly regions of heterochromatin that might exist despite the 
absence of either mark (as suggested by computational clustering of Drosophila and 
human chromatin states (Filion et al., 2010; Zhu et al., 2013)). Although some evidence 
suggests that H3K27me3-marked chromatin is more accessible to transcription factor 
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binding and hence may be less heterochromatic than H3K9me3-marked chromatin 
(Breiling et al., 2001; Dellino et al., 2004), this model would be best tested by a method 
that defined heterochromatic regions genome-wide based on chromatin structure, 
independent form histone mark, which could then be compared to H3K9me3 and 
H3K27me3 ChIP-seq profiles. Physical isolation of structurally compact regions as intact 
chromatin fragments would allow simultaneous analysis of their genomic localization and 
proteomic composition. Finally, to the extent that regions with heterochromatic structure 
diverge from H3K9me3 or H3K27me3 domains, it is important to assess the combinations 
of chromatin structures and histone marks that impart resistance to gene activation during 
cellular reprogramming, to gain insight into the barriers to cell fate conversion. 
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CHAPTER 2. H3K9ME3-DEPENDENT HETEROCHROMATIN: 
BARRIER TO CELL FATE CHANGES (REVIEW ARTICLE) 
 
The following chapter contains a review article that was published in TRENDS in Genetics 
in January 2016 (Vol. 32(1), pages 29-41). The content of the paper focuses on the 
connection between H3K9me3-marked heterochromatin and cell fate control, with 
particular emphasis on H3K9me3 as a barrier to cell reprogramming. The paper was co-
written by myself and Dario Nicetto, Ph.D. (co-first authors), with guidance from Dr. Zaret 
(senior author). 
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2.1 Modes of developmental gene silencing 
The diverse repertoire of cell types in multicellular organisms is achieved by the differential 
regulation of gene expression. While much effort has been expended to study how genes 
are activated, less is known about mechanisms by which cell type-inappropriate genes 
are repressed, even though this is a crucial aspect of cell fate control (Fisher and 
Merkenschlager, 2002; Hemberger et al., 2009; Meister et al., 2011). It has been long 
been appreciated that genetic material in the nucleus can be partitioned into two general 
categories: open ‘euchromatin,’ which has a relatively low density of DNA and high rates 
of gene transcription, and ‘heterochromatin,’ which has a relatively high density of DNA 
and low rates of gene transcription. Heterochromatin was originally discerned cytologically 
by the intensity of dark staining with DNA dyes (Heitz, 1928). The physically condensed 
state of these regions, reflected by their increased resistance to nucleases (Wallrath and 
Elgin, 1995) and their compact properties in biophysical assays (Frenster et al., 1963; 
Gilbert and Allan, 2001), is mechanistically linked to gene silencing, since compaction 
renders the DNA template less accessible to binding by the transcriptional machinery. 
Heterochromatin also has the property of spreading along chromosomes, which is 
illustrated by the compaction and silencing of transgenes integrated proximal to 
endogenous heterochromatin regions (Wallrath and Elgin, 1995; Elgin and Reuter, 2013). 
A large fraction of mammalian genomes is taken up by repeat-rich sequences—
including tandem-repeat satellites near centromeres and telomeres, retrotransposons, 
and endogenous retroviruses—which pose a risk to genome integrity through their 
potential for illicit recombination and self-duplication. Thus, in all cell types, there is utility 
in keeping such regions physically inaccessible and, consequently, transcriptionally silent, 
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by packaging them in condensed heterochromatin. Such repeat-rich regions are classified 
as ‘constitutive’ heterochromatin, as their silencing is universal across developmental 
lineages (Saksouk et al., 2015). By contrast, ‘facultative’ heterochromatin refers to regions 
whose compaction and silencing is dynamic in development, such as at cell type-specific 
genes and enhancers (Trojer and Reinberg, 2007). 
In organisms ranging from the fission yeast Schizosaccharomyces pombe to 
humans, repeat-rich constitutive heterochromatin is marked by dimethylation and 
trimethylation of histone 3 lysine 9 (H3K9me2 and H3K9me3) (Rea et al., 2000; Nakayama 
et al., 2001; Martens et al., 2005). In mammals, these covalent modifications are catalyzed 
by five members of the SET-domain containing family of methyltransferases. SETDB1 and 
the related enzymes SUV39H1 and SUV39H2 contribute to both H3K9me2 and H3K9me3 
(Rea et al., 2000; Schultz et al., 2002), while GLP and G9a (also called EHMT1 and 
EHMT2, respectively) catalyze H3K9me1 and H3K9me2 (Tachibana et al., 2001, 2002, 
2005). H3K9me2/me3 are bound by the chromodomain of Heterochromatin Protein 1 
(HP1, three isoforms in mammals), which can self-oligomerize and recruit repressive 
histone modifiers, contributing to heterochromatin compaction and spread (Bannister et 
al., 2001; Lachner et al., 2001; Canzio et al., 2011). The methyltransferases that deposit 
H3K9me2 and H3K9me3 are required to establish high levels of DNA methylation at CpG 
dinucleotides and low levels of histone acetylation, two other hallmarks of heterochromatin 
(Epsztejn-Litman et al., 2008; Lehnertz et al., 2003). By contrast, cell type-specific 
repression of many genes requires trimethylation of a different H3 residue, lysine 27 
(H3K27me3), which is catalyzed by the Polycomb repressive complex 2 (PRC2) (Boyer et 
al., 2006; Ezhkova et al., 2009; Lee et al., 2006; Xu et al., 2014a). This mode of 
“facultative” silencing is particularly prominent at many lineage-specifying transcription 
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factor genes, such as the homeobox (HOX) family (for detailed review of the role of PRC2 
and H3K27me3 in development, see: (Margueron and Reinberg, 2011; Beisel and Paro, 
2011)). 
The presence of H3K27me3 over gene promoters is highly correlated with gene 
repression (Hawkins et al., 2010; Margueron and Reinberg, 2011), yet it has been shown 
that H3K27me3-marked promoters remain accessible to binding by general transcription 
factors and a paused RNA polymerase (Breiling et al., 2001; Dellino et al., 2004). This 
contrasts with chromatin marked by H3K9me3, which occludes the DNA from binding by 
transcription factors with diverse DNA-binding domains (Soufi et al., 2012). Thus, 
H3K9me3-dependent and H3K27me3-dependent silencing appear to be mechanistically 
different based on the extent to which the chromatin is accessible to other factors (see 
Table 2-1). 
Although the H3K9me3 modification has been most often studied in the context of 
constitutive heterochromatin, genome-wide mapping studies have made clear its role in 
cell type-specific regulation of facultative heterochromatin (Hawkins et al., 2010; Vogel et 
al., 2006; O’Geen et al., 2007; Zhu et al., 2013). In differentiated human cells, H3K9me3 
forms large contiguous domains ranging in size from the kilobase to the megabase scale 
(Hawkins et al., 2010; Soufi et al., 2012; Vogel et al., 2006) (Figure 2-1). These domains 
or ‘patches’ expand in both number and size during differentiation from pluripotency, and 
they span numerous genes repressed in a cell type-specific manner (Hawkins et al., 
2010).  In particular, there is enrichment for H3K9me3 over gene family clusters, such as 
those for zinc finger transcription factors, olfactory receptors, and neurotransmitter-related 
genes (in non-neuronal cell types) (Hawkins et al., 2010; Vogel et al., 2006; O’Geen et al., 
2007), raising the possibility that H3K9me3 protects repetitive gene clusters from illicit 
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recombination similar to noncoding repeats, while also suppressing transcription. Such 
H3K9me3 domains are largely exclusive of the H3K27me3 domains that also expand 
during development (Hawkins et al., 2010; Pauler et al., 2009; Chandra et al., 2012), 
highlighting the different functions of these marks, although some developmental 
transcription factor genes are decorated by both modifications (Hawkins et al., 2010). 
The related repressive modification, H3K9me2, similarly forms megabase-scale 
domains that include genes; the domains have been called Large Organized Chromatin 
K9 modifications (LOCKs) (Wen et al., 2009). Interestingly, binding sites for the insulator 
protein CTCF were detected at the boundaries of these large domains, suggesting that 
presence of such H3K9me2-decorated patches might be intimately connected to higher-
order chromatin structures maintained by CTCF (Wen et al., 2009). Whether the 
boundaries of these H3K9me2 domains expand during differentiation from pluripotency 
has been a matter of dispute (Wen et al., 2009; Filion and van Steensel, 2010; Lienert et 
al., 2011), with some groups favoring a model of mostly invariant domains during 
development but local gain of H3K9me2 over select genes (Lienert et al., 2011). 
Nevertheless, the dimethyl mark is important for the silencing of lineage-inappropriate 
genes during differentiation (Wen et al., 2009; Lienert et al., 2011; Liu et al., 2015b), and 
mass spectrometry-based quantification of histone marks reveals an increase in both 
H3K9me3 and H3K9me2 in mouse fibroblasts compared with pluripotent cells (Sridharan 
et al., 2013).  Taken together, the findings in this section indicate that H3K9me2/3 
deposition is patterned according to cell identity and must be reset to specify new fates. 
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2.2 Heterochromatin: a barrier to cell reprogramming and cell fate plasticity 
The hallmarks of cell identity are erased when differentiated cells are reprogrammed to 
induced pluripotent stem (iPS) cells (see Box 1 - Methods of Cellular Reprogramming) 
(Takahashi and Yamanaka, 2006). This conversion process requires that reprogramming 
transcription factors bind to their targets in DNA and reactivate pluripotency genes that 
were silenced in development, suggesting that accessing heterochromatic regions is a 
necessary step to fully reprogram cells. However, only a minor fraction of the starting cells 
(<0.1%) successfully complete this process (Papp and Plath, 2013; Vierbuchen and 
Wernig, 2012), raising the question of what chromatin features contribute to such 
inefficiency. 
 
H3K9me3 heterochromatin impedes iPS reprogramming  
Insights into chromatin impediments to reprogramming emerged from determining where 
the canonical iPS reprogramming factors (Oct4, Sox2, Klf4, and cMyc; henceforth OSKM) 
first bind the genome shortly after they are expressed in human fibroblasts (Soufi et al., 
2012).  All four factors target open chromatin sites, but only OSK, while not M, also target 
sites containing nucleosomes and lacking evident histone marks, making them pioneer 
factors (Iwafuchi-Doi and Zaret, 2014; Soufi et al., 2012, 2015). However, there are 
megabase-scale chromatin regions in which none of the four factors can target DNA in 
fibroblasts, even though these same domains have binding sites for the factors in 
pluripotent cells (Soufi et al., 2012). Thus, the domains were called Differentially Bound 
Regions (DBRs). The DBRs overlap with domains enriched for H3K9me3 in fibroblasts 
but not in embryonic stem (ES) cells (see Figure 2-1), suggesting that H3K9me3 
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heterochromatin may mediate the impediment to OSKM binding. Indeed, knockdown of 
the SUV39H1/H2 methyltransferases increases Oct4 and Sox2 binding in these regions 
(Soufi et al., 2012). 
The DBRs encode diverse genes and repeat elements, including transcription 
factor genes essential for pluripotency, such as NANOG, SOX2, DPPA2, DPPA4, GDF3, 
and ZFP42 (Boyer et al., 2005; Soufi et al., 2012). Strikingly, all of these genes were 
independently shown to be delayed in activation until the late phases of reprogramming 
(Buganim et al., 2012; Polo et al., 2012), with endogenous SOX2 and NANOG highly 
restricted to cells that successfully reprogram (Buganim et al., 2012). The discovery that 
all four OSKM factors fail to bind within large patches of H3K9me3 heterochromatin (Soufi 
et al., 2012) that include key pluripotency genes provides mechanistic insight into the 
observation that these genes are more refractory to activation than others (Polo et al., 
2012; Buganim et al., 2012). The DBRs also encompass 21 out of 22 of the domains found 
to have aberrant non-CpG methylation in human iPS cells, compared with ES cells (Soufi 
et al., 2012; Lister et al., 2011). This indicates that some H3K9me3 domains, in addition 
to impeding the rate or efficiency of reprogramming, have a persistent effect in the final 
reprogrammed state of iPS cells, rendering the conversion to the ES state incomplete. 
These findings suggested that H3K9me3 removal might be an effective strategy to 
enhance the efficiency of reprogramming. Indeed, knockdown of the SUV39H1/H2 
methyltransferases, thereby reducing H3K9me3, causes a dramatic increase in the 
number and rate of appearance of human iPS colonies (Soufi et al., 2012). Independently, 
in a screen of 22 chromatin modifiers, short hairpin RNA (shRNA) against SUV39H1 was 
found to cause the strongest increase in human iPS colony formation (Onder et al., 2012). 
Similar results have been obtained for the other H3K9 methyltransferases, in that 
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reprogramming efficiency is improved in murine neural progenitor cells after G9a inhibition 
(Shi et al., 2008) and in murine fibroblasts after depletion of G9a, GLP, or SETDB1 (with 
additive effects in combination) (Sridharan et al., 2013).  It is thus unclear which 
methyltransferase is most responsible for stabilizing the differentiated state. The yield of 
fully reprogrammed murine iPS colonies is also enhanced by perturbation of other 
heterochromatin components, such as knockdown of individual HP1 isoforms (e.g., 
HP1g/Cbx3) (Sridharan et al., 2013), inhibition of histone deacetylases (Huangfu et al., 
2008; Liang et al., 2010; Mali et al., 2010), or inhibition of DNA methylation (Mikkelsen et 
al., 2008).  Loss of DNA methylation enhances removal of H3K9me3 in the presence of a 
transcriptional stimulus (Hathaway et al., 2012), and thus the effects of DNA 
methyltransferase inhibition on reprogramming efficiency may act through similar 
mechanisms as SUV39H1 knockdown, although this has not been definitively 
investigated.  
Other components of repressive chromatin that oppose iPS reprogramming 
appear to act at sites outside of DBRs. Demethylation of H3K27me3 by Utx is required for 
reprogramming (Mansour et al., 2012), while the repressive histone variant macroH2A 
inhibits it (Gaspar-Maia et al., 2013; Pasque et al., 2012), but both observations are linked 
to a common class of pluripotency genes that activate in early reprogramming (Gaspar-
Maia et al., 2013; Mansour et al., 2012), in contrast to most DBR genes (Buganim et al., 
2012; Soufi et al., 2012).  In further contrast to H3K9me3, the H3K27me3 
methyltransferase EZH2 is required for iPS reprogramming, consistent with its role in 
maintaining pluripotency (Buganim et al., 2012; Onder et al., 2012; Pereira et al., 2010). 
Thus, iPS reprogramming depends upon continued deposition of H3K27me3 at certain 
loci, simultaneous with H3K27me3 removal by Utx at other loci. Finally, reduction of 
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another mediator of gene silencing, MBD3 (a component of the NuRD histone remodeling 
and deacetylase complex), can allow a high fraction of cells to reprogram to the iPS state 
and to do so in a more synchronous manner  (Rais et al., 2013; Luo et al., 2013). However, 
this co-repressor thwarts reprogramming factor activity at sites they already bind (Rais et 
al., 2013), and its role in regulating H3K9me3 domains or preventing factor binding to 
heterochromatic genes has not been explored. 
 
Paucity of heterochromatin defines the pluripotent state  
A reduction in inaccessible H3K9me3-marked heterochromatin not only speeds 
conversion to pluripotency by enhancing transcription factor binding, but it also appears 
to be a fundamental hallmark of the pluripotent state. Using electron spectroscopy imaging 
(ESI), Bazett-Jones and colleagues identified remarkable differences in chromatin 
compaction between embryonic epiblast cells and subsequent lineage-restricted stages 
of development (primitive endoderm and trophectoderm), with the former characterized by 
a highly dispersed network of 10-nm fibers and the latter showing blocks of highly 
compacted chromatin (Ahmed et al., 2010). Studies of mouse ES cells in culture revealed 
similar findings by ESI (Hiratani et al., 2010) and a reduction in the number and intensity 
of nuclear foci that stain positively for H3K9me3 (Meshorer and Misteli, 2006). 
Furthermore, the chromatin of pluripotent cells shows a higher rate of exchange of 
chromosomal proteins such as linker histone and HP1, indicative of a more dynamic and 
accessible chromatin state (Meshorer and Misteli, 2006). Consistent with such 
accessibility, ES cells have elevated levels of global transcriptional activity, including 
expression of repetitive sequences and mobile elements, which are repressed in 
differentiated cells (Efroni et al., 2008). Importantly, depletion of proteins involved in 
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maintaining chromatin accessibility (Efroni et al., 2008) or introduction of elements that 
promote heterochromatin formation (Savić et al., 2014) results in impaired ES cell self-
renewal and altered differentiation capacity. Thus, the developmental plasticity of early 
embryonic cells, much like the ability of differentiated cells to complete reprogramming, is 
tightly linked to the accessibility of chromatin. 
The necessity of heterochromatin erasure for the pluripotent state is further 
illustrated by studies of ‘partially reprogrammed’ cells that appear during iPS conversion. 
These cells lack induction of the pluripotency gene network and have limited 
developmental potential, but express the reprogramming factors and have downregulated 
their somatic program (Mikkelsen et al., 2008; Sridharan et al., 2009). Nuclear imaging 
with ESI revealed that partially reprogrammed cells, but not iPS cells, have highly 
compartmentalized heterochromatin structures containing dense chromatin fibers, similar 
to differentiated cells (Fussner et al., 2011). This is consistent with the persistence of DNA 
methylation and H3K9me3 over specific pluripotency loci, including Oct4 and Nanog, in 
these cells (Mikkelsen et al., 2008; Fussner et al., 2011; Chen et al., 2013). Meanwhile, 
erasure of H3K9me3, via depletion of Setdb1 or Suv39h1 or overexpression of the Kdm4b 
demethylase, is sufficient to allow partially reprogrammed cells to progress to full iPS cells 
(Chen et al., 2013). These findings suggest that H3K9me3 is not only a barrier to 
pluripotency factor binding in the earliest stages of reprogramming (Soufi et al., 2012), but 
also opposes late maturation steps necessary for pluripotency. 
 
Heterochromatin opposes reprogramming by somatic cell nuclear transfer  
In contrast to the reliance of iPS reprogramming on defined factors, somatic cell nuclear 
transfer (SCNT, see Box 1) utilizes the diverse factors of the egg cytoplasm, acting en 
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masse, to restore pluripotency, and the resulting process proceeds more rapidly (Jullien 
et al., 2011). Yet, recent evidence suggests that H3K9me3 heterochromatin presents a 
barrier to even this form of reprogramming.  Zhang and colleagues performed detailed 
transcriptomic analysis of two-cell mouse embryos derived by normal fertilization and 
SCNT, and they identified ‘reprogramming resistant regions’ (RRRs) containing transcripts 
that were silenced only in the SCNT condition (Matoba et al., 2014). The authors found 
that the RRRs had features of heterochromatin including selective marking by H3K9me3 
and enrichment for LINE and LTR-type repeat elements in the genome. Injection of mRNA 
for the H3K9 demethylase Kdm4d into the embryo or knockdown of Suv39h1/h2 in donor 
nuclei improved the expression of genes within the RRRs. Importantly, either approach 
for reducing H3K9me3 caused dramatic improvements in the developmental potential of 
the SCNT-derived embryos, with as much as 80% of the embryos reaching the blastocyst 
stage, compared with less than 20% in controls (Matoba et al., 2014). Similarly, dramatic 
increases in the number of cleavage stage SCNT-derived embryos were observed for 
donor nuclei lacking G9a (Epsztejn-Litman et al., 2008). Other methods to reduce 
heterochromatin integrity – including inhibition of histone deacetylases (Bui et al., 2011; 
Iager et al., 2008), reduction in DNA methylation (Blelloch et al., 2006), or depletion of 
macroH2A (Pasque et al., 2011b) – all improved embryo derivation by SCNT. 
Taken together, the current evidence suggests that heterochromatin, and in 
particular H3K9me3-marked domains, presents a barrier to reprogramming to 
pluripotency.  The H3K9me3 heterochromatic barrier applies regardless of the cell 
conversion methodology (SCNT versus defined factors) and impairs both the efficiency of 
reprogramming and the quality of the cells produced (Figure 2-2). 
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2.3 H3K9me3 as a regulator of cell fate in vivo 
The crucial function of H3K9me3 in impeding cell reprogramming (Soufi et al., 2012; Chen 
et al., 2013; Matoba et al., 2014) and in silencing lineage-specific genes (Hawkins et al., 
2010; Zhu et al., 2013) suggests that heterochromatin helps maintain cellular identity. 
Thus, patterns of H3K9me3 must be reorganized during cell fate transitions in 
development, both in the early embryo (see (Fadloun et al., 2013a; Burton and Torres-
Padilla, 2014) for review) and in terminal lineage maturation. 
  
Maintaining and exiting pluripotency: H3K9me3 and transcription factor crosstalk  
In pluripotent stem cells, transcription factor networks ensure that H3K9me2/me3 is 
deposited over genes for cell differentiation and removed from essential pluripotency 
regulators. In murine ES cells, Setdb1 has been shown to occupy and repress genes 
encoding developmental regulators (Bilodeau et al., 2009) and to act as a co-repressor of 
Oct4, thereby suppressing trophoblast genes (Lohmann et al., 2010; Yeap et al., 2009; 
Yuan et al., 2009).  Similarly, Loh et al. elegantly demonstrated that in murine ES cells 
Oct3/4 positively regulates the expression of the demethylases Kdm3a and Kdm4c to 
remove H3K9me2 and H3K9me3, respectively, from Tcl1 and Nanog, guaranteeing the 
maintenance of cell renewal in ES cells (Loh et al., 2007). 
Upon implantation of embryos in vivo or differentiation of ES cells in vitro, there is 
a progressive and irreversible silencing of Oct3/4 and other pluripotency-associated 
genes, including Nanog, Stella, and Rex-1. Deposition of H3K9me2 at these sites, and in 
turn DNA methylation, is dependent on the methyltransferases GLP and G9a (Epsztejn-
Litman et al., 2008; Feldman et al., 2006; Liu et al., 2015b). G9a prevents Oct3/4 
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reactivation when differentiated ES cells are returned to pluripotency culture conditions 
(Feldman et al., 2006) (Figure 2-2, dashed line). Meanwhile, mutations in GLP that disrupt 
its H3K9me1-recognition domain result in decreased H3K9me2, a delay in silencing of 
pluripotent genes during ES differentiation, and abnormal embryonic development in vivo 
(Liu et al., 2015b). The reverse H3K9me2 dynamics are seen at the master germ-line 
regulator genes Ddx4 and DazI, which show high levels of H3K9me2 in ES cells and lose 
the modification in in vitro-generated mature primordial germ cell-like cells (Kurimoto et 
al., 2015).  A reduction in H3K9me2 occurs at lamina-associated domains (LADs), which 
normally associate with the nuclear periphery, and is coupled to a relative depletion in 
H3K27me3 (Kurimoto et al., 2015), a mark enriched at the borders of LADs (Harr et al., 
2015). The overall picture highlights crosstalk between H3K9me2 and H3K27me3 and a 
direct role for H3K9me2/me3 in the developmental control of gene expression. 
  
Requirement of H3K9me2/me3 deposition for normal embryonic development  
The importance of H3K9me2/me3 establishment in completing developmental transitions 
is illustrated by genetic loss-of-function studies in mouse embryos. G9a- and GLP-null 
embryos show early lethality, characterized by dramatic morphological abnormalities 
associated with alteration in gene expression and chromatin organization (Tachibana et 
al., 2002, 2005). Homozygous inactivation of SETDB1 also leads to embryonic lethality 
around the time of implantation, an even earlier stage compared with G9a and GLP 
mutants, as well as defects in inner cell mass growth (Dodge et al., 2004).  Although single 
knockouts of either SUV39H1 or SUV39H2 in mice show no developmental defects, 
double-null mice are born at sub-Mendelian ratios and show prenatal lethality linked to 
genome instability (Peters et al., 2001).  Furthermore, knockout of HP1b results in 
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dramatic genomic instability and leads to perinatal lethality, likely caused by defects in the 
development of neuromuscular junctions and cerebral cortex (Aucott et al., 2008).  
The distinct lethal phenotypes seen for the different classes of H3K9me-related 
methyltransferases and associated factors reflect their diverse contributions during 
development.  G9a, GLP, and SETDB1 regulate early lineage commitment (Bilodeau et 
al., 2009; Lohmann et al., 2010; Yeap et al., 2009; Yuan et al., 2009; Feldman et al., 2006; 
Epsztejn-Litman et al., 2008; Tachibana et al., 2005), while SUV39H1/H2 are involved in 
genome stability (Peters et al., 2001) and maintenance of fully differentiated cell identity 
(Soufi et al., 2012; Onder et al., 2012; Matoba et al., 2014). 
 
H3K9me3 contributes to lineage restriction in mature cell types  
The role of H3K9me3-decorated heterochromatin in controlling terminal differentiation and 
ensuring the stability of cell identity emerges in two recent studies. Amigorena and co-
workers, studying the molecular mechanisms underlying naive T cell differentiation into 
distinct T helper (Th) cells subtypes, revealed an interplay between SUV39H1 and HP1α 
to maintain a high ratio of H3K9me3 over H3K9ac at key Th1 genes, the latter of which 
must be silenced in Th2 cells (Allan et al., 2012). Applying both genetic and 
pharmacological loss-of-function approaches, the authors showed that in SUV39H1- and 
HP1α-deficient conditions, Th2 cell lineage stability is compromised and cellular plasticity 
towards the Th1 fate is increased. This phenotype is also seen in disease-related 
conditions: a Th2-mediated allergic lung inflammation is reduced upon depletion of 
H3K9me3 (Allan et al., 2012). In a genome-wide approach, Casaccia and collaborators 
analyzed differentiation processes in the brain and showed that silencing of H3K9-related, 
but not H3K27-related, methyltransferases impairs oligodendrocyte differentiation, altering 
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their response to electric stimulation (Liu et al., 2015a). Taken together, these studies 
indicate that H3K9me3 and H3K27me3 have different roles in developmental gene 
silencing and cell identity maintenance, depending on the cell lineage. 
 
2.4 Molecular control of H3K9me3 deposition 
Since H3K9 methyltransferases are broadly expressed (Aagaard et al., 1999; Tachibana 
et al., 2001) and are not known to make specific base contacts with DNA (Marmorstein, 
2003), additional factors are required to explain the site-selectivity of H3K9me3 deposition 
and the developmental dynamics of H3K9me3 domains.  In this section, we consider 
protein and RNA-based mechanisms by which H3K9me3-based heterochromatic domains 
are established. 
 
Transcription factor-based recruitment of heterochromatin  
A growing number of sequence-specific transcription factors have been found to recruit 
the heterochromatin machinery to particular gene promoters. The retinoblastoma (Rb) 
protein interacts with both SUV39H1 and HP1, and it is required for cell cycle-regulated 
H3K9me3 at the cyclin E promoter (Nielsen et al., 2001). Also important for 
heterochromatin establishment is a large, tetrapod-specific family of zinc finger (ZNF) 
transcription factors containing Krüppel-associated (KRAB) domains. Krüppel-associated 
box zinc finger proteins (KRAB-ZNFs), which mostly have lineage-specific expression, 
repress transcription of target genes by binding the co-repressor KAP1 (also known as 
TRIM28 and TIF1b), which in turn interacts with HP1, SETDB1, and histone deacetylases 
(Friedman et al., 1996; Ryan et al., 1999; Schultz et al., 2002). Experimental tethering of 
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a KRAB domain to a genomic site results in spreading of H3K9me3 and silencing of gene 
promoters as far as 15 kb away (Groner et al., 2010).  Yet mutant forms of KAP1 that 
cannot bind KRAB-ZNFs nonetheless retain many of their genomic binding sites (Iyengar 
et al., 2011), suggesting that there is still much to learn about KAP1 recruitment. 
Murine satellite repeats contain reiterated binding sequences for transcription 
factors, such as Gfi1b, Sall1, Zeb1, and select Pax family members (Vassen et al., 2006; 
Yamashita et al., 2007; Bulut-Karslioglu et al., 2012).  Specifically, Pax3 and Pax9 
contribute to H3K9me3 deposition and transcriptional repression at major satellites and 
are required for the integrity of pericentric heterochromatin (Bulut-Karslioglu et al., 2012), 
a startling finding given that these factors are expressed only in select cell types. The 
alternative factors that sustain constitutive heterochromatin in Pax3/9-negative cell types, 
and the role of these factors in recruiting H3K9me3 to domains containing genes, are not 
presently understood. 
 
Contribution of RNA to heterochromatin formation  
In addition to the role of transcription factors, noncoding RNA (ncRNA) can function as a 
binding platform to establish heterochromatin at specific genomic positions. In the fission 
yeast S. pombe, heterochromatin formation at pericentromeres (Volpe et al., 2002) and 
other sites (Hall et al., 2002) depends upon the components of the RNA interference 
(RNAi) pathway and, paradoxically, requires transcription of the locus to be silenced 
(Djupedal et al., 2005; Kato et al., 2005). Double-stranded RNAs (dsRNAs) transcribed 
from these regions are processed into small interfering RNAs (siRNAs) by Dicer, which in 
turn guide the silencing machinery, including an H3K9 methyltransferase, to the site of 
nascent heterochromatin transcription by RNA-RNA base pairing (Bühler et al., 2006; 
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Zhang et al., 2008; Bayne et al., 2010). (For review of the role of RNAi in heterochromatin, 
see (Grewal and Elgin, 2007; Bühler and Moazed, 2007)).  In S. pombe, there are 
additional mechanisms by which ncRNA can establish heterochromatin, independent of 
RNAi, involving a growing number of RNA processing factors and components of the RNA 
exosome (Bühler et al., 2007; Reyes-Turcu et al., 2011). Meanwhile, in mammals, despite 
initial reports that Dicer was required for silencing of pericentric heterochromatin 
(Fukagawa et al., 2004; Kanellopoulou et al., 2005), heterochromatin-derived dsRNA has 
not been consistently detected across cell systems (Saksouk et al., 2015). 
While the mechanisms by which ncRNA may establish heterochromatin in 
mammals remain poorly understood, emerging evidence suggests its contribution is 
significant. Transcription of mammalian heterochromatin has been observed despite the 
presence of H3K9me3 over the same regions (Martens et al., 2005; Terranova et al., 2005; 
Lu and Gilbert, 2007). The localization of HP1a at pericentromeric heterochromatin is 
dependent on its interaction with RNA, specifically its binding via its hinge domains to 
sense-oriented repeat transcripts (Maison et al., 2002; Muchardt et al., 2002; Maison et 
al., 2011). Strikingly, injection of pericentromere-derived dsRNA in the early mouse 
embryo is sufficient to rescue the phenotype of a mutant with defects in constitutive 
heterochromatin (Santenard et al., 2010). During normal development, an early burst of 
major satellite transcription precedes and is required for H3K9me3 deposition (Probst et 
al., 2010; Casanova et al., 2013). Also, dynamics in major satellite transcription, which in 
turn modulate pericentromeric binding of HP1, are important for the cell fate transition of 
epithelial-to-mesenchymal transition (Millanes-Romero et al., 2013).  Along the 
chromosome arms, LINE-1 repeats undergo a wave of transcription early in development 
(Fadloun et al., 2013b), and transcripts derived from these elements may contribute to the 
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silencing of nearby genes on the inactive X chromosome (Chow et al., 2010).  Finally, in 
human ES cells, addition of another ncRNA derived from rDNA arrays is sufficient to 
induce widespread H3K9me3 deposition outside the nucleolus and to promote exit from 
pluripotency (Savić et al., 2014).  These findings suggest an intimate relationship between 
RNA and H3K9me3 establishment, although the nature of the interactions and the RNA-
binding proteins involved are in need of further elucidation. 
 
2.5 Concluding Remarks 
Recent work suggests that large domains of H3K9me2/3 form in a cell type-specific 
manner (Hawkins et al., 2010; Soufi et al., 2012), but the protein machinery responsible 
for such precise developmental dynamics remain largely mysterious (see Box 2 - 
Outstanding Questions). First, the mechanisms and relative contributions of RNA-
dependent versus transcription factor-dependent H3K9me3 recruitment must be defined 
for these regions, and it is not presently understood how either process can nucleate 
H3K9me3 deposition over a domain as large as multiple megabases (Hawkins et al., 2010; 
Zhu et al., 2013).  In addition, simple inspection of the large H3K9me3 patches on a 
genomic level shows that they can terminate precisely over a local domain, suggesting a 
type of boundary. Elucidating these mechanisms for the initiation and delimitation of 
H3K9me2/3 domains will enable more targeted strategies to perturb H3K9me3-dependent 
heterochromatin at specific sites, possibly to enhance reprogramming in a manner tailored 
to the starting and desired cell types. 
As RNAi-based knockdown of all five H3K9 methyltransferases has been found to 
promote reprogramming to pluripotency (Chen et al., 2013; Onder et al., 2012; Soufi et 
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al., 2012; Sridharan et al., 2013), it will be important to carefully dissect the unique and 
redundant roles of each enzyme in the establishment of specific H3K9me2/3 domains in 
diverse cellular contexts, and the relative contributions of the dimethyl and trimethyl forms. 
This would be facilitated by the creation of conditional knockouts of these genes, alone 
and in combination. Mapping of H3K9me2/3 domains in specific lineages and 
developmental stages, coupled with conditional deletion of methyltransferases, will reveal 
the enzymes responsible for tissue-specific domains and their contribution to 
developmental gene regulation. 
Finally, studies of lineage-specific H3K9me2/3 domains should investigate if they 
similarly impede direct conversion or transdifferentiation between two differentiated fates 
(see Box 1). Whether perturbation of heterochromatin components can universally 
improve the fidelity of these direct conversions, or whether the role of H3K9 methylation 
in reprogramming is pluripotency- or tissue-specific, will be an exciting avenue for further 
investigation. 
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2.6 Supporting text boxes 
 
Box 1.  Methods of Cellular Reprogramming 
 
Reprogramming refers to the erasure of the identity of a cell to convert it to a different type 
of cell, most commonly the conversion of a specialized fate to an earlier, undifferentiated 
state. Multiple techniques (see (Yamanaka and Blau, 2010)) now exist to transform 
differentiated cells into cells that are pluripotent, which means that they can give rise to 
any cell type in the embryo. 
 
Somatic cell nuclear transfer (SCNT) 
Seminal work in the 1950s established that transfer of a nucleus from a differentiated cell 
into an enucleated egg induces a restoration of developmental potential and the 
production of viable embryos (Gurdon et al., 1958). SCNT has been used to successfully 
clone mammals, such as sheep (Wilmut et al., 1997) and mice (Wakayama et al., 1998). 
Nonetheless, the frequency at which SCNT gives rise to viable organisms is low, with most 
resulting embryos exhibiting phenotypic and gene expression abnormalities (Matoba et 
al., 2014; Pasque et al., 2011a). Elegant studies have revealed specific molecular events 
required to complete reprogramming after SCNT (Jullien et al., 2011, 2014), but given the 
complexity of the egg cytoplasm that is mediating the process, the underlying mechanism 
is likely to involve myriad factors acting in concert. 
 
Generating induced pluripotent stem (iPS) cells  
Takahashi and Yamanaka made a critical breakthrough by defining a specific set of four 
transcription factors that, when ectopically overexpressed, are sufficient to convert a 
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differentiated cell into an iPS cell (Takahashi and Yamanaka, 2006). The factors originally 
identified – Oct4, Sox2, Klf4, and cMyc – are central regulators of the pluripotency gene 
network in ES cells (Boyer et al., 2005), and additional combinations of factors capable of 
generating iPS cells have since been reported (Buganim et al., 2012; Shu et al., 2013). In 
all cases, the resulting iPS cells meet stringent criteria for pluripotency, such as ability to 
rescue tetraploid blastocysts and contribute to the germline, and on the transcriptional 
level most iPS lines are highly similar to ES cells derived from the pluripotent inner cell 
mass (Buganim et al., 2012; Shu et al., 2013; Wernig et al., 2007). However, iPS 
reprogramming is a highly inefficient process, as it proceeds to completion only in a small 
fraction of cells (generally <0.1%) and at long latency (weeks to months) (Vierbuchen and 
Wernig, 2012; Papp and Plath, 2013). 
 
Direct cell fate conversion  
The strategy of ectopically expressing defined cocktails of lineage-specific transcription 
factors has been used to convert or transdifferentiate differentiated cells to other 
developmental lineages, without going through a pluripotent intermediate (Davis et al., 
1987; Graf and Enver, 2009; Ladewig et al., 2013). Despite the promise of these 
techniques, the reprogrammed cells generally exhibit substantial gene expression 
differences from their native counterparts, limiting their in vivo functionality and therapeutic 
utility (Cahan et al., 2014; Morris et al., 2014). 
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Box 2.  Outstanding questions 
 
What are the proteins and ncRNAs that control the cell type-specific locations and 
boundaries of large H3K9me3 domains across the mammalian genome? 
To what extent do Suv39h and Setdb1 have specific, non-redundant roles in repressing 
cell identity genes, and how does this relate to the distinct embryonic phenotypes upon 
deletion of these H3K9me3-related methyltransferases? 
How do H3K9me2- and H3K9me3- arked chromatin domains differ in their exclusion of 
transcription factors and resistance to gene activation? 
What are the relative contributions of H3K27me3 and H3K9me3 to developmental gene 
regulation in different lineages, and to what extent do they cooperate in cell fate 
establishment? 
Does H3K9me3-dependent heterochromatin impede direct conversion between 
differentiated cell types, similar to its role in limiting reprogramming to pluripotency? 
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2.7 Tables and Figures 
 
domain properties H3K9me3 domains H3K27me3 domains 
Genomic distribution Constitutive heterochromatin and tissue-specific sites1-3 Tissue-specific sites
1,4-8 
Chromatin accessibility Prevent binding by diverse TFs2 Allow binding by general TFs and paused RNA polymerase9-10 
Presence at ‘poised’ genes, 
competent for activation  
Downstream of some 
H3K4me3-marked promoters11 
Overlapping with H3K4me3 at 
many promoters12-13 
Timing of gene reactivation 
during iPS reprogramming 
Latest stages of 
reprogramming2,14-15 
Early-to-mid stages of 
reprogramming16 
Major methyltransferases 
and role in reprogramming 
SETDB1, SUV39H1/H2: 
impede iPS conversion2,15,17 
PRC2 complex (EZH2 or EZH1): 
required for generating iPS14,17-18 
 
Table 2-1. Differences between H3K9me3 and H3K27me3 Heterochromatin 
Domains 
TFs = transcription factors. References: 1(Hawkins et al., 2010), 2(Soufi et al., 2012), 3(Liu 
et al., 2015a), 4(Boyer et al., 2006), 5(Lee et al., 2006), 6(Ezhkova et al., 2009), 7(Zhu et 
al., 2013), 8(Xu et al., 2014a), 9(Breiling et al., 2001), 10(Dellino et al., 2004), 11(Matsumura 
et al., 2015), 12(Bernstein et al., 2006), 13(Voigt et al., 2012), 14(Buganim et al., 2012), 
15(Chen et al., 2013), 16(Mansour et al., 2012), 17(Onder et al., 2012), 18(Pereira et al., 
2010). 
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Figure 2-1. Megabase-scale domains of H3K9me3 vary by cell type and match 
regions resistant to reprogramming factor binding. 
Shown is a 25-Mb segment of human chromosome 16, visualized in the UCSC Genome 
Browser. The purple tracks show H3K9me3 signals by chromatin immunoprecipitation and 
sequencing (ChIP-seq), normalized by input-subtraction, for the selected cell/tissue types. 
All ChIP-seq data come from the Roadmap Epigenomics Mapping Consortium 
(GSE16368). Note the close correspondence between the H3K9me3-enriched domains 
in foreskin fibroblasts (red arrows) and the fibroblast Differentially Bound Regions (DBRs, 
black bars), which are regions that fail to be targeted by pluripotency reprogramming 
factors in fibroblasts but are bound in ES cells (Soufi et al., 2012).  Each of these regions 
lack H3K9me3 enrichment in ES cells, as well as in select other tissues (blue asterisks). 
Green arrows indicate representative H3K9me3 domains in other tissues that are absent 
in fibroblasts. 
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Figure 2-2. H3K9me2/3 heterochromatin domains impede diverse forms of cellular 
reprogramming. 
The diagram shows major cell fate transitions (black arrows) that occur during 
differentiation and reprogramming and the role of H3K9me2/3 in these transitions. The 
leftmost black arrow indicates conversion of differentiated cells to pluripotency, which can 
be carried out by nuclear transfer to an enucleated egg or by overexpression of 
pluripotency transcription factors. In both cases, pluripotency genes inside H3K9me3 
domains are more resistant to activation, and the success rate of reprogramming is 
improved when H3K9me3 levels are reduced (Chen et al., 2013; Matoba et al., 2014; 
Onder et al., 2012; Soufi et al., 2012). Thus, H3K9me3 domains impede reprogramming 
to pluripotency (red inhibitory arrows). When embryonic stem (ES) cell-derived 
differentiated cells are returned into ES culture conditions, thereby encouraging de-
differentiation (dashed black arrow), the loss of an H3K9me2 methyltransferase increases 
  51 
the appearance of undifferentiated colonies and the expression of pluripotency genes 
(Feldman et al., 2006). In contrast to reprogramming, the differentiation of pluripotent cells 
in culture (upper black arrow) is promoted by increases in H3K9me2/3 (Loh et al., 2007; 
Savić et al., 2014). Although H3K9me2/3 domains form in a tissue-specific manner over 
the course of development (rightmost black arrows), the role of these domains in the 
directed conversion of cells across developmental lineages (bottom black arrow) remains 
to be investigated. Abbreviations: iPS, induced pluripotent stem cell reprogramming; 
SCNT, somatic cell nuclear transfer. 
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CHAPTER 3. METHODS 
3.1 Experimental methods  
Cell Culture 
Human BJ foreskin fibroblasts were obtained from Stemgent (08-0027) at passage 6 and 
cultured in Eagle’s Minimum Essential Medium (EMEM) (Sigma-Aldrich M2279) 
supplemented with 10% fetal bovine serum (FBS, Hyclone SH30071) and 2mM L-
glutamine (Gibco) at 37°C and 5% CO2. 
 
Preparation of crosslinked chromatin lysates 
BJ fibroblast cells were grown to ~80% confluence in 150-mm dishes (5 - 20 plates per 
chromatin batch, ~4 x 106 cells per plate). Cells were crosslinked directly in the culture 
dishes, at room temperature, by addition of 2 ml formaldehyde solution (50 mM HEPES-
KOH, pH 7.5, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 11% formaldehyde) to 20 ml 
media, for 1% final formaldehyde concentration. After 10 min, crosslinking was quenched 
by addition of glycine to a final concentration of 125 mM, followed by incubation for 5 min 
at room temperature. Cells were harvested from the plate with a plastic cell lifter, pelleted 
at 200 g for 4 min (4°C), and washed three times with ice-cold PBS. All subsequent steps 
were performed on ice or in centrifuges cooled to 4°C. To enrich for nuclei, cells were 
allowed to swell for 10 minutes in 4 ml Hypotonic Lysis Buffer (20 mM HEPES-KOH pH 
7.5, 20 mM KCl, 1 mM EDTA, 10% glycerol, 1% IGEPAL CA-630, 0.25% Triton-X, 1 mM 
DTT, 0.2 mM PMSF, Protease Inhibitor Cocktail - Roche #11873580001) and were 
mechanically dounced for 50 strokes. Nuclei were pelleted at 1,350 g for 4 min, washed 
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with hypotonic buffer, and pelleted again at the same speed. Pellets were resuspended in 
10 ml Nuclear Wash Buffer (10 mM Tris-HCl pH 8.0, 200 mM NaCl, 1 mM EDTA, 0.5 mM 
EGTA, 1 mM DTT, 0.2 mM PMSF, Protease Inhibitor Cocktail) and incubated for 10 min, 
rocking. Nuclei were pelleted at 1,350 g for 4 min and resuspended in 0.5 - 1 ml Sonication 
Lysis Buffer (10 mM Tris-HCl pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.5% 
N-lauroylsarcosine, 0.1% sodium deoxycholate, 1 mM DTT, 0.2 mM PMSF, Protease 
Inhibitor Cocktail) and transferred to 15-ml polystyrene tubes. Sonication was performed 
in polystyrene tubes using a Diagenode Bioruptor UCD-200 (power HI, cycles of 30s on / 
30s off) for at least 25 cycles. After sonication, lysates were transferred to microcentrifuge 
tubes, supplemented with Triton-X to 1% final concentration (to promote chromatin 
solubility), and centrifuged at 20,000 g to pellet debris. Supernatants were transferred to 
new tubes, snap-frozen in liquid nitrogen, and stored at -80°C while chromatin shearing 
was assessed by agarose gel electrophoresis of purified DNA (as described for chromatin 
immunoprecipitation, below). Sonication was repeated as necessary until the majority of 
DNA was 200-400bp, with only a faint trail of larger material. 
 
Chromatin immunoprecipitation 
Immunoprecipitation was performed using Dynabead Protein G magnetic beads (Thermo 
Fisher, 10004D) saturated with the antibody of interest, such as anti-H3K9me3 (Abcam 
ab8898) or anti-mouse IgG control (Abcam ab46540). 5 μg of antibody and 25 ul of 
Dynabead slurry were used per 25 μg of chromatin (according to mass of purified DNA 
measured by nanodrop), with scaling as necessary. Dynabeads were first washed twice 
with 800 μl PBS, using a magnetic rack, and then resuspended in a volume of PBS that 
is 4X the original slurry volume. This suspension was supplemented with the desired 
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amount of antibody, mixed, and incubated on a rotating rack at 4°C for 2 - 6 hours, to allow 
antibody conjugation. Sonicated, crosslinked chromatin lysates (see above) were thawed 
on ice, and the desired mass of chromatin (25 μg or more) was aliquoted a low-retention 
1.5-ml tube (Axygen MCT-150-L-C) tubes. Chromatin was diluted to 1 ml final volume with 
ice-cold Chromatin IP Buffer (10 mM Tris-HCl pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5 mM 
EGTA, 0.1% N-lauroylsarcosine, 1% Triton 1 mM DTT, 0.2 mM PMSF, Protease Inhibitor 
Cocktail). A separate aliquot of chromatin (one-fifth the mass) was reserved as the input 
sample. Antibody-conjugated beads were washed twice with Chromatin IP buffer and then 
resuspended in the 1-ml sample of chromatin. Immunoprecipitations were incubated for 
16 hours at 4°C on a rotating rack. Using a magnetic rack, the unbound lysate was 
aspirated, and the beads were washed 5 times with 900 μl ice-cold ChIP RIPA Buffer (50 
mM HEPES, pH 7.5, 500 mM LiCl, 1 mM EDTA, 1% IGEPAL CA-630, 0.7% sodium 
deoxycholate, Protease Inhibitor Cocktail) and once with 900 μl ice-cold TE buffer (10 mM 
Tris-HCl, pH 8.0, 1 mM EDTA). Chromatin was eluted in 200 μl ChIP Elution Buffer (50 
mM Tris-HCl, pH 8.0, 10 mM EDTA, 1% SDS) at 65°C for 30 min, shaking, and the eluate 
was transferred to a new tube. Reserved input sample was similarly diluted at least 3-fold 
in Chromatin IP Buffer, to 200 μl final volume. To purify DNA from ChIP eluate and Input, 
samples were decrosslinked by heating at 65°C for 18 hours. Chromatin was diluted with 
200 μl TE and treated with 8 μl RNase A (10 mg/ml stock, Roche #10109169001), followed 
by incubation for 2 hours at 37°C. Protein was degraded by addition of 4 μl Proteinase K 
(20 mg/ml stock, Roche #03115828001) and incubation for 2 hours at 55°C. DNA was 
purified by two rounds of extraction with 400 μl phenol-chloroform-isoamyl alcohol. The 
extracted aqueous phase was supplemented with 16 μl of 5 M NaCl and 1.5 μl glycogen 
(20 mg/ml stock, Roche #10901393001). DNA was precipitated by addition of 2 volumes 
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(800 μl) 100% EtOH and overnight incubation at -20°C. DNA was pelleted at 20,000 g for 
10 min (4°C), washed with 500 μl 80% EtOH, and pelleted again. The DNA pellet was air-
dried and dissolved in 200 μl TE buffer. DNA yield was quantified by Quant-iT PicoGreen 
dsDNA Assay (Thermo Fisher P7589). Five-fold serial dilutions of the input DNA were 
prepared in DNA and were used as a standard curve when analyzing ChIP eluates by 
qPCR, in order to quantify sequence recovery as percent input. 
 
Sucrose gradient sedimentation of chromatin 
For preparative gradients used for proteomic and sequencing studies, crosslinked and 
sonicated chromatin was purified (see above) from near-confluent BJ fibroblasts in 20 150-
mm plates (at least 8 x 107 cells, 0.5 mg DNA) per gradient. Chromatin lysates were 
prepared in 0.5 mL Sonication Lysis Buffer (see above) to allow the majority of the sample 
to be loaded on a single gradient. Prior to running gradients, chromatin shearing efficiency 
was verified by purifying DNA from a 5 μl chromatin aliquot (as described above for ChIP 
input DNA), while the remaining lysate was snap-frozen in liquid nitrogen and stored at -
80°C. Empirically, we found that achieving sufficient levels of DNA shearing, comparable 
to standard ChIP, was important to achieve robust heterochromatin enrichment via 
sucrose gradient sedimentation.  
6-40% linear sucrose gradients in Chromatin IP buffer were poured into 12-mL 
Ultra-Clear centrifuge tubes (Beckman #344059, 14 x 89 mm), using a Hoefer SG-15 
gradient maker fitted with a two-way stopcock (Bio-Rad #7328102). Gradients were 
prepared by loading the chambers of the gradient maker with two solutions of 
approximately equal weight: 5.7 mL of 40% Sucrose Solution (40% sucrose, 10 mM Tris-
HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 1% Triton-X, 0.1% N-
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lauroylsarcosine, 1 mM DTT, 0.2 mM PMSF, Protease Inhibitor Cocktail) and 6.4 mL of 
6% Sucrose Solution (6 mL of 40% Sucrose Solution, plus 34 mL of: 10 mM Tris-HCl, pH 
8.0, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 1% Triton-X,  0.1% N-lauroylsarcosine, 
1 mM DTT, 0.2 mM PMSF, Protease Inhibitor Cocktail), which are gradually mixed as the 
solutions exit the gradient maker. Gradients were filled bottom-up, beginning with the 
heavier 40% Sucrose Solution. To load the gradients, 455 μl of thawed chromatin lysate 
was mixed with 65 μl of the 40% Sucrose Solution, for a 5% final concentration of sucrose, 
and then the resulting sample was layered gently on the 6-40% gradients with a 1-mL 
pipet. Gradients were spun on a Beckman SW 41 Ti rotor at 41,000rpm for 3 hours (4°C), 
using conditions similar to those developed by Bickmore and colleages (Gilbert et al, 
2004). Slow acceleration and deceleration settings were used. After sedimentation, 
gradients were fractionated top-down using a micropipet, generating 24 fractions of 
500µL. 30µL of each fraction used for DNA purification (performed as for ChIP samples, 
see above) to allow fraction-specific qPCR studies; the remaining samples were snap-
frozen and stored at -80°C. 
The fractions found by qPCR to have the strongest enrichment for heterochromatic 
regions (fractions #10-17) were pooled as the “structural heterochromatin (strucHC) 
fraction”, while fraction #2 (second fraction from the top) was used as the “euchromatin 
fraction.” Both samples were dialyzed to Chromatin IP buffer (10 mM Tris-HCl pH 8.0, 100 
mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% N-lauroylsarcosine, 1% Triton 1 mM DTT, 
0.2 mM PMSF, Protease Inhibitor Cocktail) to remove sucrose. Dialysis was performed 
for two rounds of five hours each using Slide-A-Lyzer G2 Casettes 7K MWCO (Thermo 
Fisher). 5% of the dialyzed chromatin samples (approximately 250 ng DNA for strucHC 
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fraction) were used for DNA purification, using the same procedure as for ChIP eluates 
above, to enable subsequent qPCR and sequencing studies. For purification of proteins 
from gradient fractions, equal DNA equivalents were used for both the euchromatin and 
strucHC fractions, based on Quant-iT PicoGreen dsDNA Assay (Thermo Fisher P7589). 
Prior to protein precipitation, the dialyzed fractions were buffered by adding Tris-HCl pH 
8.0 (to 100 mM final concentration) and then decrosslinked by heating at 65°C overnight 
followed by 99°C for 30 min. The proteins were precipitated in 6 volumes acetone 
(overnight at -20°C), pelleted at 3,600 g, washed once with ice-cold acetone, resuspended 
in 8M urea, and quantified by Bradford Assay (Bio-Rad #500-0006). Alternatively, the 
dialyzed strucHC and euchromatin fractions were used for chromatin IP against H3K9me3 
or IgG control (using above ChIP protocol). For these IP eluates in ChIP Elution Buffer, 
one-twelfth of the sample was used for DNA purification, as above. For protein analysis, 
the remaining eluate was run in a cetrifugal evaporator to reduce the volume to ~25 μl, 
mixed with 4X NuPAGE LDS Sample Buffer (Thermo Fisher NP0007) and β-mercapto-
ethanol (2.5% final concentration), and decrosslinked by heating at 99°C for 30 min. 
 
Proteomics analysis of chromatin samples 
Proteins were prepared for mass-spectrometry by in-gel digestion. Samples were mixed 
with 4X NuPAGE LDS Sample Buffer (Thermo Fisher NP0007) and β-mercaptoethanol 
(2.5% final concentration) and loaded into NuPAGE Novex 4-12% Bis-Tris Protein Gels 
(Thermo Fisher NP0335). Gels were run at 100V in NuPAGE MOPS SDS Running Buffer 
(Thermo Fisher NP0001) and washed three times with dH2O for five minutes each. Gels 
were stained with SimplyBlue SafeStain (Thermo Fisher LC6060) for 1 hour at room 
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temperature, photographed, and destained in dH2O overnight. Gels were then incubated 
in 40% ethanol, 10% acetic acid for 1-2 hours to fix and further destain. Lanes were 
excised and cut into five pieces that were digested in separate tubes (but pooled prior to 
nLC-MS/MS). Each piece was further diced into ~1 mm3 cubes and transferred to clean 
microcentrifuge tubes. 
Gel slices were reduced with 10 mM DTT for 1 hour at 56°C, alkylated using 55 
mM iodoacetamide for 45 minutes (room temperature in dark) and digested overnight with 
trypsin at room temperature at a concentration of 12.5 ng/μl. Digestion was interrupted 
adding 1% formic acid. Samples were then desalted using in-house prepared C18 
microcolumns, and the five peptide samples from the same gel lane were combined. Nano 
liquid chromatography was performed using a Thermo Scientific Easy nLC 1000 equipped 
with a 75 µm x 18 cm in-house packed column using Reprosil-Pur C18-AQ (3 µm, Dr. 
Maisch GmbH). Buffer A was 0.1% formic acid and Buffer B was 0.1% formic acid in 
acetonitrile. Peptides were resolved using a 165 min gradient from 2 to 28% B at a flow 
rate of 300 nL/min. The HPLC was coupled online to an Orbitrap Elite mass spectrometer 
(Thermo Scientific) for the first replicate and a Q-Exactive (Thermo Scientific) for the 
second and the third replicate operating in positive mode. Spectra were acquired using a 
data dependent acquisition (DDA) method, performing the full MS scan in the orbitrap at 
60,000 (Elite) and 70,000 (Q-Exactive) resolution. The MS/MS was performed for both 
instruments at 17,500 resolution in the orbitrap mass analyzer. Loop count was set to 15 
(Elite) and 12 (Q-Exactive) and collision energy was set to 20. Database searching was 
performed using MaxQuant v1.5.2.8 (Cox and Mann, 2008), using all standard settings 
unless otherwise stated. Database used was Human UniProt (v July 2015). For protein 
quantification the iBAQ option (Schwanhäusser et al., 2011) was enabled and adopted. 
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qPCR analysis of gradient fractions 
Purified DNA samples from gradient fractions were quantified with Quant-iT PicoGreen 
dsDNA Assay (Thermo Fisher P7589) and diluted with TE buffer to 0.1 ng/μl, to allow 
loading of equal DNA mass per qPCR reaction. DNA concentrations were verified after 
dilution by repeat PicoGreen assay and were adjusted as needed. 10 μl qPCR reactions 
were prepared in 384-well optical plates with 2 μl DNA sample, 0.1 μl primer mix (10μM 
each primer), and 5μL Power SYBR Green PCR Master Mix (Thermo Fisher #4367659). 
Plates were in a 7900HT Real-Time PCR machine (Thermo Fisher #4329001), using the 
following thermal cycler protocol: 50°C for 4 min, 95°C for 10 min, followed by 40 cycles 
of 95°C for 15 s then 54°C for 15 s then 72°C for 45 s, with a dissociation curve generated 
to verify that a single PCR product was generated. qPCR results for each fraction were 
normalized to the input sample. Primer sequences for detecting sites inside and outside 
DBRs were from (Soufi et al., 2012) and are listed in the table below. All PCR amplicons 
correspond to Oct4/Sox2 binding sites: bound in fibroblasts and ES cells for non-DBR 
sites, and bound only in ES cells for DBR sites (Soufi et al., 2012). 
 
Table 3-1. Primers used for qPCR analysis of Gradient Fractions and H3K9me3 
ChIP. 
primer name forward primer (5' - 3') reverse primer (5' - 3') location 
Ch3_DBR_3 TGGTCTTGAATTCCTGGCTG GCTTAAGAATCGTCCGGAGG DBR site 
Ch3_DBR_4 ACCGCCATACCCAACTTG GATGGCCCTAGGTCTTTAATGG DBR site 
Ch20_DBR_2 ATCAAGTGCCAGGAATGGAG ATGGAGCCCGAATTTCTCAG DBR site 
Ch20_DBR_5 AATTTCAAGCGGAGCCCTAG TCAGAAACCCTATTGAAGCCTC DBR site 
Ch22_DBR_2 GCCATTCGTGTGCAGAAAAG CTGTCCATAGTCAGCGTTCC DBR site 
Ch22_DBR_5 CCTCAAGGGATTGGAAGATCTC GGTGCCCAGATTAAATGTTCC DBR site 
DPPA4 TCCACCTCACCTCTTCTT GTATTAGTAATTCAACCCAGACAA DBR site 
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NANOG TGTTGAACCATATTCCTGAT TCTACCAGTCTCACCAAG DBR site 
Ch3_nonDBR_1 CATGGAGCAATTGTGAATAAATGTG ATTAGGCTGGGGCTTTCTG intergenic 
Ch3_nonDBR_2 CCTCCAGTATCAACCGAAGAG TCCGAAGACTCCTACTCACAC promoter 
Ch3_nonDBR_3 AAATGCTAAGAGGGTGTGGG GAGAGTTGCCAGGAACAGAG gene body 
Ch20_nonDBR_1 CCCCGCAGACAATGACTATTAG AGGTGTGAGCGTTCGATATG intergenic 
Ch20_nonDBR_3 GGACCACAGCACGGAAAC CCTTCTCACTCCTCTTCTCCG promoter 
Ch22_nonDBR_2 GGGCTTGCATAGTGAAAACATG ACGGTAGAGGACAGGGAAG gene body 
Ch22_nonDBR_3 CAGATTAATGTTTGCCAGGGC AATATTTCCATTGCTCCAAAATTTCC gene body 
Ch22_nonDBR_4 CCCCTATCATTGTGAGAGTGTG CAATTTACCCGCCACATCAC promoter 
 
 
Preparation of Gradient-seq and ChIP-seq libraries 
Approximately 50 ng of purified DNA was used for each library, and two biological 
replicates (independent gradients) were sequenced per sample type. For samples 
containing large DNA fragments (including the structural heterochromatin fraction, IPs off 
of this fraction, and the input to the gradient), the pure DNA was first sheared in a Covaris 
S220 sonicator using snap-cap microTUBEs (Covaris #520045)  for 5 min (settings: 175W 
peak power, 10% duty factor, 200 cycles/burst) to produce 150-350 bp fragments. 
Libraries were then prepared using the NEBNext Ultra DNA Library Prep Kit for Illumina 
(New England Biolabs E7370S), and amplified using 8 - 9 cycles of PCR using NEBNext 
Multiplex Oligos for Illumina (New England Biolabs E7335S and E7500S). For H3K9me3 
ChIP-seq and ChIP Input libraries, the adapter-ligated DNA was size-selected using 
Agencourt Ampure XP beads (Beckman Coulter A63881), following the protocol in the 
NEBNext Ultra kit for a 200-bp average insert size. The libraries for Gradient-seq were not 
size-selected. Library yield and fragment size distribution was assessed on a Bioanalyzer 
2100 instrument (Agilent Technologies), using the DNA 1000 kit (Agilent Technologies 
5067-1504).  
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Western blotting 
Whole-cell protein extracts were prepared by resuspending cells in RIPA extraction buffer 
(25 mM Tris, pH 7.5, 150 mM NaCl, 1% Na-deoxycholate, 1% IGEPAL CA-630, 0.1% 
SDS) supplemented with Protease Inhibitor Cocktail (Roche #11873580001). 
Suspensions were incubated on ice for 10 minutes and sonicated for 15 s on HI using a 
Diagenode Bioruptor UCD-200. Samples were centrifuged at 20,000 g for 10 min (4°C) to 
pellet debris, and the supernatant was transferred to new tubes. Protein content was 
quantified by BCA assay (Thermo Fisher Scientific #23227). Protein samples were mixed 
with 4X NuPAGE LDS Sample Buffer (Thermo Fisher Scientific NP0007) and 10X 
NuPAGE Sample Reducing Agent (Thermo Fisher Scientific NP0009), and were 
denatured at 70°C for 10 min. Samples were loaded in NuPAGE Novex 4-12% Bis-Tris 
Protein Gels (NP0335), and run using NuPAGE Running Buffers (NP0001; NP0002). Wet 
transfer to PVDF membranes (100V for 1.5 hr) was performed using NuPAGE Transfer 
Buffer (NP0006) containing 20% methanol, and membranes were blocked overnight in 5% 
nonfat dairy milk in TBS-T (20 mM Tris, pH 7.5, 150 mM NaCl, 0.1% Tween-20). Primary 
antibodies were diluted in 1% milk/TBS-T at the following concentrations: anti-GAPDH 
(1:1000, Santa Cruz Biotechnology sc-365062), anti-SUV39H1 (1:1000, Bethyl 
Laboratories A302-127A), anti-RBMX (1:1000, Cell Signaling Technology #14794), anti-
H3K9me3 (1:1000, Abcam ab8898), and anti-Histone H3 (1:3000, Abcam ab1791). HRP-
conjugated secondary antibodies (Santa Cruz Biotechnology sc-2004, sc-2005) were 
diluted 1:5,000 in 1% milk/TBS-T. Blots were developed using SuperSignal West Pico 
Chemiluminescent Substrate (Thermo Fisher Scientific #34080) and visualized with an 
Amersham Imager 600 (GE Healthcare Life Sciences). 
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Immunostaining 
Cells were grown on plates coated with collagen I (Corning #354236), washed twice briefly 
with PBS, and fixed in 4% paraformaldehyde in PBS for 20 minutes at room temperature. 
Fixed cells were washed 3 times with PBS (all washes 5-10 minutes at room temperature, 
rocking), permeablized with ice-cold 0.1% Triton-X in PBS for 10 minutes, and washed 
twice TBS-T (20 mM Tris-HCl pH 7.4, 150mM NaCl, 0.05% Tween-20). Samples were 
blocked with 4% donkey serum (Sigma-Aldrich D9663) in PBS for 1-2 hours at room 
temperature or overnight at 4°C. Primary antibodies added in blocking solution and 
incubated overnight at 4°C, using the following concentrations: anti-human-albumin 
(1:100, Bethyl Laboratories A80-229A), anti-alpha-1-antitrypsin (1:200, Thermo Fisher 
Scientific RB-367), anti-FOXA3 (1:300, Santa Cruz Biotechnology sc-5361), anti-HNF1A 
(1:150, Santa Cruz Biotechnology sc-6547), and anti-HNF4A (1:150, Santa Cruz 
Biotechnology sc-8987). Cells were washed 3 times with TBS-T and then incubated with 
AlexaFluor 488- or 594-conjugated secondary antibodies raised in donkey (Thermo Fisher 
Scientific) at a 1:500 dilution in PBS, for 45 minutes at room temperature, protected from 
light. Samples were then washed 3 times with PBS, counterstained with 1μg/mL DAPI 
(Thermo Fisher, D1306) in PBS for 10 minutes, and washed with PBS once. Fluorescence 
images were taken using a Nikon eclipse TE2000-U microscope controlled by Nikon 
elements software and equipped with the appropriate filters. 
 
Lentivirus production 
Lentiviral plasmids pWPI.1-FOXA3, pWPI.1-HNF1A, and pWPI-HNF4A were kindly 
provided by the laboratory of Lijian Hui (Huang et al., 2014). Plasmid DNA was purified 
from bacteria using the EndoFree Plasmid Maxi Kit (Qiagen #12362). 293T cells were 
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grown in DMEM High Glucose (Thermo Fisher Scientific #11995) supplemented with 10% 
FBS (Hyclone SH30071) and seeded in 10-cm dishes at a density of 8 x 105 cells/plate. 
After 24 hours, transfection mixtures were prepared by mixing 2.5 μg lentiviral vector, 1.7 
μg packaging plasmid psPAX2 (Addgene #12260), 0.8 μg envelope plasmid pMD2.G 
(Addgene #12259), and 30 μl Fugene 6 Transfection Reagent (Promega E2691) with 570 
μl OptiMEM-I Reduced Serum Medium (Thermo Fisher Scientific #31985070), per plate. 
Transfection mixtures were vortexed, incubated for 15 min, and added drop-wise to plates 
containing 10 mL media. Media was changed 16 hours after transfection. 60 hours later, 
media containing viral particles was collected. Debris was pelleted at 800 g for 10 min 
(4°C), and the supernatant was passed through a 0.45 μm syringe filter (Millipore 
SLHV033RS). Viral particles were concentrated by ultracentrifugation at 25,000 rpm for 
1.5 hr (4°C) with an SW-32 swinging bucket rotor (Beckman Coulter), and the viral pellet 
was resuspended in pure DMEM for 1/100th the original supernatant volume. Viral titer 
was determined immunostaining for FOXA3, HNF1A, and HNF4A in fibroblasts three days 
after infection with serial dilutions of concentrated virus. Dilutions of virus that produced 
10-35% transgene-expressing cells were used to calculate the multiplicity of infection 
(MOI), and in turn the titer, using the relationship MOI = (-1) * ln(1 - [proportion infected]). 
 
hiHep reprogramming 
Transdifferentiation of fibroblasts to hiHep cells was carried out as previously described 
(Huang et al., 2014). BJ fibroblasts growing in complete EMEM (see above) were plated 
on collagen I-coated plates at a density of 3 x 104 cells per well in 12-well format. One day 
after plating, cells were infected with a cocktail of three lentiviruses (pWPI.1-FOXA3, 
pWPI.1-HNF1A, and pWPI.1-HNF4A), with an MOI of 1.25 per virus, in media containg 
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4.5 μg/ml polybrene. One day after infection, virus-containing media was removed, cells 
were washed twice with PBS, and fresh complete EMEM was added. On the second day 
after infection, medium was switched to Human Maintenance Medium (HMM): DMEM/F12 
(Hyclone SH30023.01) supplemented with 0.544 mg/L ZnCl2, 0.75 mg/L ZnSO4·7H2O, 0.2 
mg/L CuSO4·5H2O, 0.025 mg/L MnSO4·1H2O, 2 g/L Bovine serum albumin (Sigma-
Aldrich), 2 g/L galactose (Sigma-Aldrich G0750), 0.1 g/L ornithine (Sigma-Aldrich O2375), 
0.03 g/L proline (Sigma-Aldrich P5607), 0.61 g/L nicotinamide (N0636), 1X Insulin-
transferrin-sodium selenite media supplement (Sigma-Aldrich I1884), 40 ng/ml TGF-α 
(Peprotech AF-100-16A), 40 ng/ml EGF (Peprotech AF-100-15), 10 μM dexamethasone 
(Sigma-Aldrich D4902), and 1% FBS (Hyclone SH30071). Media was changed with fresh 
HMM every 48 hours. Cells were analyzed for hepatic markers at 12-14 days after lentiviral 
infection. 
 
siRNA transfection experiments 
All knockdown experiments were performed with two cycles siRNA transfection, three 
days apart. The following Silencer Silect siRNAs from Thermo Fisher Scientific were used:  
Negative Control No. 1 siRNA (#4390843), SUV39H1 siRNA (s13660), RBMX siRNA “#1” 
(s56033), RBMX siRNA “#2” (s56035), and RBMX siRNA “#3” (s223747). Transfections 
were performed using 10 nM final concentration of siRNA and 2.5 μl/ml final concentration 
Lipofectamine RNAiMAX (Thermo Fisher Scientific #13778150). 10X transfection 
mixtures were prepared by adding 100 nM siRNA and 25 μl/ml Lipofectamine to OptiMEM-
I Reduced Serum Medium (Thermo Fisher Scientific #31985070) and incubating for 10 
min at room temperature. On day 0, cells were reverse transfected by seeding a 0.9X 
volume of cells/media into wells containing 0.1X volume of 10X transfection mixture. After 
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24 hours, siRNA-containing media was replaced with normal culture media. After 3 days, 
forward transfections were performed on adherent cells by adding 0.1X volume of 10X 
transfection mixture drop-wise to 0.9X volume of culture media. Media was again replaced 
24 hours after transfection. RNA or protein was harvested on day 6, three days after the 
second siRNA transfection. For experiments performed with uninfected, proliferating 
fibroblasts, cells were passaged over the course of this six-day time-course, as needed to 
prevent over-growth. 
 Knockdown experiments in cells expressing hepatic transcription factors were 
performed as follows. First, on day -1, cells were infected as a batch (single well or plate) 
with pWPI.1-FOXA3, pWPI.1-HNF1A, and pWPI.1-HNF4A lentiviruses (MOI of 1.25 per 
virus), in media containg 4.5 μg/ml polybrene. 24 hours after infection, on day 0, virus-
containing media was removed, cells were washed twice with PBS, and cells were 
detached from the plate and split for reverse siRNA transfection. The remainder of the six-
day siRNA time-course was performed as described as above, except that, on day 4, 
media was changed to HMM (see above under “hiHep reprogramming”) to promote 
hepatic induction. By infecting cells with factors prior to splitting for transfection with 
specific siRNAs, we ensure similar dosage of factors across the conditions being 
compared. 
 
RNA isolation and Reverse Transcription-PCR 
Total RNA was isolated using the ZR-96 Quick-RNA kit (Zymo Research, R1052), which 
includes an on-column DNase I treatment step, and eluted in 30 μL RNase-free dH2O. 
cDNA was prepared using the High Capacity cDNA Reverse Transcription Kit (Thermo 
Fisher #4368814). For detection of transcripts from liver genes in fibroblast 
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heterochromatin, TaqMan-based quantitative PCR was performed using using the 
TaqMan assays listed below and TaqMan Gene Expression Master Mix (Thermo Fisher 
#4369016), and data was normalized to an average of GAPDH and 18SRNA endogenous 
controls. For detection of transcripts normally expressed in fibroblasts, qPCR was 
performed using Power SYBR Green PCR Master Mix (Thermo Fisher #4367659), and 
data was normalized using the GAPDH primer as an endogenous control (see primers 
listed below). qPCR reactions were run in 384-well format on an 7900HT Real-Time PCR 
machine (Thermo Fisher #4329001), using the following thermal cycler protocol: 50°C for 
2 min, 95°C for 10 min, followed by 45 cycles of 95°C for 15 s then 60°C for 1 min. For 
SYBR-based qPCR reactions, a dissociation curve was generated to verify that a single 
PCR product was generated. 
 
Table 3-2. TaqMan Gene Expression Assays used for RT-PCR experiments. 
transcript target Thermo Fisher Scientific TaqMan ID 
human GAPDH Hs02758991_g1 
human RNA18S5 Hs03928990_g1 
human FOXA2 Hs00232764_m1 
human NR1H4 Hs01026590_m1 
human DSC2 Hs00951428_m1 
human DSG2 Hs00170071_m1 
human ONECUT1 Hs00413554_m1 
human CYP2C9 Hs04260376_m1 
human CYP2C19 Hs00426380_m1 
human SERPINA7 Hs02384980_m1 
human HNF4G Hs01071345_m1 
human F9 Hs01592597_m1 
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Table 3-3. Primers for SYBR-based RT-PCR experiments. 
transcript forward primer (5' - 3') reverse primer (5' - 3') 
hGAPDH CCAGGTGGTCTCCTCTGACTTC TCATACCAGGAAATGAGCTTGACA 
hSUV39H1 GTCATGGAGTACGTGGGAGAG CCTGACGGTCGTAGATCTGG 
hSUV39H2 TCGATACGGCAATGTGTCTC ACAATGCTATTCGGGGAAGA 
Hrbmx CAGTTCGCAGTAGCAGTGGA TCGAGGTGGACCTCCATAA 
hRBMXL1 AGCAGCTCACGTGATGGATA GATCACTTCGGCTGCTTGAG 
 
 
Preparation of polyA-selected RNA libraries 
Two biological replicates were sequenced per experimental condition. Purified total RNA 
was diluted to 50 μl in BTE buffer (10 mM Bis-tris, pH 6.7, 1 mM EDTA), denatured by 
heating at 65°C for 5 minutes, and place immediately on ice. Oligo(dT)25 Dynabeads 
(Thermo Fisher Scientific #61002) were washed three times in 2x Oligo-dT Binding Buffer 
(2xOBB: 20 mM Tris, pH 7.5, 1 M LiCl, 2 mM EDTA), resuspended in 50 μl 2xOBB, and 
mixed with an equal volume of denatured RNA. RNA and beads were incubated at room 
temperature for 10 min, shaking. Beads were washed three times with Oligo-dT Washing 
Buffer (10 mM Tris, pH 7.5, 150 mM LiCl, 1mM EDTA), and eluted in 10 μl BTE buffer by 
heating at 80°C for 2 min. Strand-specific cDNA libraries were generated using the 
NEBNext Ultra Directional RNA Library Prep Kit for Illumina (New England Biolabs, 
E7420S). This protocol includes a heat-based mRNA step (15 min at 94°C in first-strand 
cDNA synthesis buffer), and actinomycin D (Sigma-Aldrich A1410) is added during first-
strand cDNA synthesis to inhibit DNA-dependent DNA polymerase activity and prevent 
template switching. Adapter-ligated cDNAs were amplified by 12 cycles of PCR with 
NEBNext Multiplex Oligos for Illumina (New England Biolabs E7335S and E7500S). 
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Library yield and fragment size distribution was assessed on a Bioanalyzer 2100 
instrument (Agilent Technologies), using the DNA 1000 kit (Agilent Technologies 5067-
1504). 
 
Next-generation sequencing 
Libraries were quantified by qPCR using the KAPA Library Quantifcation Kit for Illumina 
(KAPA Biosystems KK4824). Libraries were diluted to 8 nM concentration and pooled for 
multiplexing, and then their diluted concentrations were checked a second time using the 
KAPA kit, adjusting as necessary. Diluted libraries were denatured in 0.2 M NaOH, loaded 
into the cartridge of the NextSeq 500/550 High Output v2 kit (Illumina FC-404-2005, 75 
cycles) at a concentration of 3.2 pM in the kit’s Hybridization Buffer, and sequenced in an 
Illumina NextSeq 500 machine. 
 
 
3.2 Computational and statistical analyses 
Tests of statistical significance 
Repeated measurements being compared between two samples were analyzed for 
significance by two-tailed Student’s T-test. Distributions of unequal sizes, such as gene 
expression values for two different sets of genes, were compared by Wilcoxon rank sum 
test, implemented in R using the wilcox.test() function (paired=FALSE). Paired 
distributions (equal size) were analyzed by Wilcoxon signed rank test, using R’s 
wilcox.test() function (paired=TRUE). Correction for multiple comparisons, where noted, 
were performed using the Benjamini-Hochberg procedure, implemented via DAVID 
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Bioinformatics tools or the p.adjust() function in R, and a 5% FDR cutoff was applied. For 
testing the significance of overlaps between two sets drawn from a common pool, the 
hypergeometric test was used, implemented with the dhyper() function in R.  
 
Alignment and visualization of Gradient-seq and ChIP-seq data 
For new sequencing data generated in these studies, sequencer output was demultiplexed 
(bcl2fastq using BaseSpace) to produce FASTQ files for individual samples. Sequenced 
reads were aligned to the hg19 assembly of the human genome using bowtie2 v2.1.0 
(Langmead and Salzberg, 2012), run with the ‘--very-sensitive’ parameter. Bowtie output 
files were converted to .bam files using samtools v1.1, and then to .bed files using bedtools 
v2.20.1 ‘bamtobed’ (Quinlan and Hall, 2010). For each sample, reads mapping to the 
same genomic position (duplicate reads) were collapsed to a single entry (unique reads). 
75bp sequencing reads were extended to 200 bp, to match the average size of DNA prior 
to library preparation. Meanwhile, all ChIP-seq data obtained from public consortia (see 
Table 3-4 below) were downloaded from GEO as aligned, unique reads with lengths of 
200 bp. 
To generate input-normalized genome coverage tracks, BED files were converted 
to BedGraph files using genomeCoverageBed (bedtools v2.20.1) and normalized to the 
number of millions of reads sequenced (rpm), to correct for lane or sample biases. For 
each sample’s normalized BedGraph, the normalized BedGraph for the corresponding 
input sample was subtracted on a basepair-by-basepair basis. The resulting subtracted 
BedGraph was converted to a bigWig file using bedGraphToBigWig (v4). 
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Table 3-4. Publicly available ChIP-seq datasets used for genome browser tracks or 
domain calling. 
Listed below are ChIP-seq datasets from the Roadmap Epigenomics Mapping Consortium 
(“Roadmap”) (Bernstein et al., 2010) and the ENCODE project (ENCODE Project 
Consortium, 2012) that were used for generation of input-subtracted genome browser 
tracks. Asterisks indicate datasets that were also used for calling enriched genomic 
domains for a given histone mark. 
Human cell type ChIP type Source GEO accession # 
foreskin fibroblasts H3K9me3 * Roadmap GSM817236, GSM817239 
foreskin fibroblasts H3K27me3 * Roadmap GSM817237, GSM817240, GSM958154 
foreskin fibroblasts Input * Roadmap GSM817246, GSM817247, GSM958168 
foreskin fibroblasts H3K4me3 Roadmap GSM817235, GSM941718, GSM958158 
foreskin fibroblasts H3K36me3 Roadmap GSM817238, GSM817241, GSM958149 
liver H3K9me3 * Roadmap GSM537695, GSM537710, GSM669986 
liver Input * Roadmap GSM670008, GSM669910, GSM621629 
IMR90 fibroblasts H3K9me3 Roadmap GSM469974 
IMR90 fibroblasts Input Roadmap GSM521926 
skeletal muscle H3K9me3 Roadmap GSM621632 
skeletal muscle Input Roadmap GSM621641 
cord blood CD3+ cells H3K9me3 Roadmap GSM537637 
cord blood CD3+ cells Input Roadmap GSM537619 
naïve CD8+ T cells H3K9me3 Roadmap GSM613812 
naïve CD8+ T cells Input Roadmap GSM613816 
PBMCs H3K9me3 Roadmap GSM613878 
PBMCs Input Roadmap GSM613893 
K562 cells H3K9me3 ENCODE GSM733776 (2 replicates) 
K562 cells H3K27me3 ENCODE GSM733658 (2 replicates) 
K562 cells H3K36me3 ENCODE GSM733714 (2 replicates) 
K562 cells Input ENCODE GSM733780 
 
 
Calling enriched genomic domains 
Genomic domains enriched in ChIP-seq or Gradient-seq datasets were called using a 10-
kb sliding window algorithm with a 500-bp sliding step, implemented using custom scripts. 
For every 10-kb window in the genome, the number of reads for the genomic feature of 
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interest (normalized to the number of reads sequenced) was divided by the number of 
reads in that window for the corresponding input file (also normalized to the number of 
reads sequenced). Divide-by-zero errors were avoided by spiking in a small value into 
both numerator and denominator (0.25 reads per million reads sequenced). Enriched 
domains were initially formed by taking all 10-kb windows whose signal-over-input value 
exceeds a threshold, after averaging all replicates. For human H3K9me3 ChIP-seq 
(produced by our lab or the Epigenomics Roadmap), the signal-over-input values form a 
bimodal distribution; consequently, we used kmeans clustering (via the kmeans() function 
in R) to find the partition between the “unenriched” and “enriched” modes of the 
distribution. This led to the selection of 1.23 as the threshold for the BJ fibroblast H3K9me3 
ChIP-seq produced in this study and 1.41 as the threshold for the foreskin fibroblast 
H3K9me3 ChIP-seq produced by the Epigenomics Roadmap (see Table 3-4) – values 
that reflect the different dynamic ranges of the two datasets and yield highly concordant 
domain maps (86% overlap). Similarly, kmeans clustering was used to select a threshold 
of 1.30 for the human liver H3K9me3 ChIP-seq from the Epigenomics Roadmap (Table 3-
4). For other genomic datasets, fixed enrichment thresholds were applied, instead of 
kmeans clustering, to ensure fair comparisons. For example, the strucHC sequencing has 
similar dynamic range as our H3K9me3 ChIP-seq data, and thus the same threshold of 
1.23 was applied. For H3K27me3 ChIP-seq data from the Epigenomics Roadmap, the 
same threshold was used as the Roadmap H3K9me3 data (1.41). Rates of domain 
overlap among these datasets were similar across a wide range of chosen threshold 
values and were further corroborated by threshold-free correlation analyses. 
 Once enriched 10-kb windows were chosen, all adjacent enriched 10-kb windows 
were merged into contiguous domains. To increase the local resolution of the domain 
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calls, an edge-pruning step was applied, whereby 500-bp steps were removed from either 
end of each domain until a 500-bp step is encountered with a signal-over-input value of at 
least 1.2. (This step serves to eliminate “overhangs” where a local region of strong signal 
causes an entire 10kb window to be called as enriched. Empirically, this pruning step 
removes 5% or less of the total domain coverage.) Finally, any remaining overlaps among 
domains were merged, to produce the final domain calls. 
For calling euchromatin domains, a small modification was made because of the 
close similarity of the euchromatin fraction (containing the majority of chromatin 
fragments) to the gradient input. To increase contrast for domain-calling, the euchromatin 
signal was normalized to the strucHC signal (instead of the input). A threshold of 1.2 was 
applied, based on the bimodal distribution of euchromatin-over-strucHC values. The 
remainder of the domain-calling procedure was as described above. 
Intermediate signal domains were defined by taking all regions outside of strucHC 
and euchromatin domains that also had sequencing signal in both gradient replicates. 
Thus, uninformative regions without sequencing data were not assigned a structural type. 
The strucHC subtype of H3K9me3 or H3K27me3 domains are simply regions of overlap 
between the strucHC domains and histone mark domains. Among the remaining regions 
for each histone mark, the euchromatic subtype was called by selecting regions where the 
exact same 10-kb window met enrichment criteria for both euchromatin and the histone 
mark. (In other words, it was not sufficient for there merely to be overlap between one 
euchromatic 10-kb window and a nearby 10-kb window enriched for the histone mark; 
both properties had to co-occur in the same window, ensuring the stringency of the 
euchromatic calls.) Finally, remaining regions enriched for the histone mark that were 
neither strucHC nor euchromatic were called as intermediate. 
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Correlation analysis of Gradient-seq and ChIP-seq datasets 
As for domain calling (see above), the genome was divided into 10-kb sliding windows 
(500-bp sliding step). For each window, the number of reads for the genomic sample of 
interest (normalized to the number of reads sequenced) was divided by the number of 
reads in that window for the corresponding input file (also normalized to the number of 
reads sequenced). As above, divide-by-zero errors were avoided by spiking in a small 
value into both numerator and denominator (0.25 reads per million reads sequenced). 
Using the cor() function in R, we computed the pairwise Spearman correlation among the 
samples in terms of their signal-over-input values, across all 10-kb windows genome-wide. 
Spearman correlation values were used to construct a heatmap using the “pheatmap” 
package in R. The dendrogram distances and clustering were set according to 
dissimilarity, where dissimilarity = [ 1 - (Spearman correlation) ]. Similar correlations and 
identical clustering were obtained by Pearson correlation.  
 
Defining genes sets overlapping chromatin domains 
The hg19 Refseq gene table was downloaded from the UCSC Table Browser. Refseq 
genes were defined as “inside” a chromatin domain of interest if at least 50% of the gene 
body overlapped that domain class. If there were multiple overlaps of the Refseq gene 
with different domains in that category, these overlaps were summed together, and the 
Refseq gene was said to overlap the domains as long as the sum met the 50% cutoff. 
Many Refseq genes have the same gene symbol; for analyses at the gene symbol level 
(such as gene expression by mRNA-seq), genes symbols were said to overlap the domain 
if any of their associated Refseq genes met the 50% cutoff. Results regarding gene 
expression in chromatin domain types were highly invariant to the percentile cutoff chosen. 
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Computing histone mark enrichment over domains 
A large number of ChIP-seq datasets for human fibroblast histone marks were 
downloaded from GEO (see Table 3-5 below for full list). This included all histone marks 
profiled in fibroblasts by the Roadmap Epigenomics Mapping Consortium (Bernstein et 
al., 2010), as well as data from Narita and colleagues (Chandra et al., 2012) to enable 
inclusion of H3K9me2. The Roadmap data was downloaded as aligned reads, while the 
Narita lab data was downloaded as raw reads and aligned using bowtie v1.  
The following procedure was used to compute histone mark levels within domains 
of interest, such as strucHC domains (as in Figure 4-2B) or different types of H3K9me3 
domains (as in Supplementary Figure 4-3A). First, each domain in the genome was 
divided into 100 equally sized bins. For each histone mark ChIP-seq experiment, the read 
pileup per bin was determined. These pileups per bin were then normalized for ChIP-seq 
sequencing depth (number of millions of reads) and the length of the bin in kb. For each 
bin of each domain, the normalized pileups were averaged across all replicate ChIP-seq 
datasets for that mark (from the same cell type and data source). These averages were 
then subtracted by the results for the corresponding input samples (from the matching 
replicates/batches of chromatin, also normalized for sequencing depth and bin size). This 
yielded a topography of histone mark enrichment or depletion across each individual 
domain, broken into a vector of 100 values for the 100 bins. An average of these vectors 
was then taken across all domains of that type in the genome, weighted by domain length. 
For clarity of display, only the 13 most well-studied histone marks are plotted in 
Figure 4-2B and Supplementary Figure 4-3A, using the datasets indicated with a 
checkmark in Table 3-5 below. When available, datasets from primary foreskin fibroblasts 
were prioritized over IMR90 fibroblasts, given the greater similarity of the former to the BJ 
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foreskin fibroblasts used in our own experiments. However, we note that results between 
IMR90 and foreskin fibroblasts were in agreement in all cases, and all acetylated 
modifications not included in these figures were similarly depleted from strucHC and 
H3K9me3 domains (data not shown). 
 
Table 3-5. ChIP-seq datasets used for computing histone mark signal over 
genomic domains. 
Datasets used for results presented in Figure 4-2B and Supplementary Figure 4-3A are 
indicated with a check mark in the final column. Remaining datasets below yielded 
concordant results (data not shown), as explained above.  
ChIP type Cell type Source GEO accession # Data 
shown? 
H3K4me1 foreskin fibroblasts Roadmap GSM817234, GSM941717, GSM958164 ü 
H3K4me3 foreskin fibroblasts Roadmap GSM817235, GSM941718, GSM958158 ü 
H3K9me3 foreskin fibroblasts Roadmap GSM817236, GSM817239 ü 
H3K27ac foreskin fibroblasts Roadmap GSM1127076, GSM1127060, 
GSM958163 
ü 
H3K27me3 foreskin fibroblasts Roadmap GSM817237, GSM817240, GSM958154 ü 
H3K36me3 foreskin fibroblasts Roadmap GSM817238, GSM817241, GSM958149 ü 
Input foreskin fibroblasts Roadmap GSM817246, GSM817247, GSM958168 ü 
H3K4me2 IMR90 fibroblasts Roadmap GSM521899, GSM521900 ü 
H3K9ac IMR90 fibroblasts Roadmap GSM469973, GSM521912 ü 
H3K9me1 IMR90 fibroblasts Roadmap GSM752986, GSM752987 ü 
H3K79me1 IMR90 fibroblasts Roadmap GSM521904, GSM521906, 
GSM521907, GSM521908 
ü 
H3K79me2 IMR90 fibroblasts Roadmap GSM521909, GSM521911 ü 
H4K20me1 IMR90 fibroblasts Roadmap GSM521915, GSM521917 ü 
Input IMR90 fibroblasts Roadmap GSM521926, GSM521927, 
GSM521928, GSM521929, 
GSM521930, GSM521931, 
GSM521932, GSM521933 
ü 
H3K9me2 IMR90 fibroblasts Chandra et 
al., 2012 
GSM942082, GSM942084 ü 
Input IMR90 fibroblasts Chandra et 
al., 2012 
GSM942119 ü 
H3K9me3 IMR90 fibroblasts Chandra et 
al., 2012 
GSM942075  
H2AK5ac IMR90 fibroblasts Roadmap GSM521866, GSM521868  
H2AK9ac IMR90 fibroblasts Roadmap GSM818012, GSM818013  
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H2BK5ac IMR90 fibroblasts Roadmap GSM818017, GSM832837, GSM832838  
H2BK12ac IMR90 fibroblasts Roadmap GSM521871, GSM521873, GSM521874  
H2BK15ac IMR90 fibroblasts Roadmap GSM521875, GSM521877, GSM521878  
H2BK20ac IMR90 fibroblasts Roadmap GSM521879, GSM521880  
H2BK120ac IMR90 fibroblasts Roadmap GSM521869, GSM521870  
H3K4ac IMR90 fibroblasts Roadmap GSM521893, GSM521894  
H3K4me1 IMR90 fibroblasts Roadmap GSM521895, GSM521897, GSM521898  
H3K4me3 IMR90 fibroblasts Roadmap GSM469970, GSM521901  
H3K9me3 IMR90 fibroblasts Roadmap GSM469974, GSM521913, GSM521914  
H3K14ac IMR90 fibroblasts Roadmap GSM521881, GSM521883  
H3K18ac IMR90 fibroblasts Roadmap GSM469965, GSM521884  
H3K23ac IMR90 fibroblasts Roadmap GSM521885, GSM521886  
H3K27ac IMR90 fibroblasts Roadmap GSM469966, GSM469967, GSM521887  
H3K27me3 IMR90 fibroblasts Roadmap GSM469968, GSM521889  
H3K36me3 IMR90 fibroblasts Roadmap GSM521890, GSM521892  
H3K56ac IMR90 fibroblasts Roadmap GSM521902, GSM521903  
H4K5ac IMR90 fibroblasts Roadmap GSM469975, GSM521918  
H4K8ac IMR90 fibroblasts Roadmap GSM521919, GSM521921, 
GSM521922, GSM521923 
 
H4K91ac IMR90 fibroblasts Roadmap GSM521924, GSM521925  
 
 
Analysis of repetitive elements enriched in chromatin domains 
The Repeat Masker table for hg19 was downloaded from the UCSC table browser and 
was intersected with BED files listing non-overlapping domains, using Bedtools. For each 
type of repeat, the total number of base pairs falling within domains was computed as a 
percentage of the total genomic coverage of that repeat. This analysis was performed for 
each repeat class, repeat family, and individual repeat name listed in the Repeat Masker 
table. P-values were determined by permutation test, using 1000 simulations of domains 
randomly shuffled across the genome by Bedtools (preserving domain number and size). 
For each repeat, the P-value was the proportion of domain simulations that produced an 
equal or greater overlap with that repeat. To correct for multiple hypothesis testing, P 
values were used to calculate the FDR using the Benjamini-Hochberg procedure. 
Enriched repeats with an FDR < 0.05 were treated as statistically significant. 
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Analysis of DNA methylation in chromatin domains 
Processed whole-genome bisulfite sequencing (WGBS) data for human foreskin 
fibroblasts was downloaded from GSM1127120 (Roadmap Epigenomics Consortium et 
al., 2015). This data file reports the percent methylation per CpG. CpGs were then divided 
into two categories based on whether they fell in annotated CpG islands (UCSC Table 
Browser). Both categories of CpG sites (inside and outside of CpG islands) were 
intersected with chromatin domains of interest, and the distribution of percent-methylation 
values was plotted. 
 
Analysis of datasets for Lamin B1 ChIP-seq, DNase-seq, and MNase sensitivity  
Lamin B1 ChIP-seq reads and input reads for IMR90 fibroblasts (Dou et al., 2015) were 
downloaded from GSE63440, aligned using bowtie2 v2.1.0 (parameters: --very-sensitive), 
and extended to 200 bp. PCR duplicates were collapsed to unique reads. The enrichment 
of Lamin B1 ChIP reads to input reads (after normalizing for sequencing depth) was 
computed over 10-kb genomic windows, with a 500-bp sliding step, using custom scripts. 
Lamin-B1 enrichment values over input were averaged across the two replicates and were 
plotted for all 10-kb windows falling entirely inside a chromatin domain type of interest. 
 ENCODE DNase-seq data for BJ fibroblasts (two replicates) were downloaded as 
aligned reads GSM736518 and GSM736596 (Thurman et al., 2012). The aligned reads 
were binned into 10-kb windows, with a 500-bp sliding step, and normalized based on the 
number of millions of reads sequenced. These normalized pileups were plotted for all 10-
kb windows falling entirely inside a chromatin domain type of interest. 
 MACC scores, which represent sensitivity to MNase from an enzymatic titration, 
were downloaded for human K562 cells from GSE78984 (Mieczkowski et al., 2016). 
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MACC scores were provided at 500-bp resolution, and these scores were converted to 
10-kb sliding window scores (500-bp slide) by averaging the component 500-bp values 
within each 10-kb window. During this averaging, missing values were ignored (rather than 
counting them as zero), and data was not reported for the 10-kb window if fewer than five 
of the constituent 500-bp bins contained data. The 10-kb MACC scores were then plotted 
for chromatin domains, similarly to the Lamin B1 and DNase I data. 
 
Analysis of DNA replication timing data 
ENCODE Repli-seq data for BJ fibroblasts (Pope et al., 2014) were downloaded as 
aligned reads from ENCSR894LZX. These files contain sequencing of newly replicated 
DNA in six cytometry-fractionated cell populations, with two replicates per timepoint. The 
downloaded alignments were intersected with each domain BED file using bedtools, and 
the number of intersecting reads was divided by the number of millions of reads in the 
sequencing file. These normalized intersection scores were then averaged between the 
two sequencing replicates per timepoint, and then they were expressed as a fraction of 
the sum of the intersection scores across the six timepoints. Thus, the final values for each 
domain type sum to 1.0 across the six cell cycle fractions. 
 
Analysis of RNA microarray data for hiHep reprogramming 
Microarray data for human fibroblasts, cultured human hepatocytes, hiHep cells, and 
immortalized hiHeps were downloaded from GSE42643 (Huang et al., 2014). The 
microarray data was quantile-normalized with median polish using the Partek Genomics 
Suite. For Refseq genes with multiple probes, only the probe with the highest variance 
across all samples was used. The full microarray was filtered down to genes expressed 
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significantly higher in normal hepatocytes compared to fibroblasts (P < 0.05, at least 2-
fold). For analyses specifically related to silent genes in fibroblasts (eg, Extended Data 
Figure 1A), the list was further reduced to genes expressed in the bottom 40% among in 
fibroblasts, which corresponded to the lower mode of a biomodal distribution. Log2-
normalized gene expression for hiHep cells was calculated on a relative scale, with 0% 
representing the log2-normalized fibroblast expression, and 100% representing the log2-
normalized hepatocyte expression. Negative values (hepatic genes expressed lower in 
hiHeps than fibroblasts) were rounded up to 0%. Expression values on this scale were 
plotted as violin plots in R using the vioplot package, modified to display multiple colors. 
 
Analysis of RNA microarray data for patient-derived fibroblasts 
Exon microarray data were downloaded from GSE33855 (Highley et al., 2014) and 
quantile-normalized with median polish using the Partek Genomics Suite. This dataset 
includes fibroblasts from patients with Amyotrophic Lateral Sclerosis (ALS), some with 
germline mutations and some with sporadic disease, in addition to healthy controls. To 
extract whole gene-level expression from exon-directed probes (multiple per gene), we 
analyzed the microarray as described in the original publication (Highley et al., 2014): 
exon-specific probes were removed from consideration if their log2-normalized signal 
(averaged across all biological samples) was 3 standard deviations above or 1 standard 
deviation below the average signal for all the probes for that gene. This served to remove 
probes with nonspecific hybridization or affected by alternative splicing, respectively. An 
average was then taken of the remaining probes for each gene, for each patient sample. 
These log2-transformed values were then converted back to a linear scale and averaged 
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across the patients for a given genotype – TARDBP-mutated (n=3), sporadic ALS (n=6), 
or control (n=6) – in order to calculate, for each gene, the fold-change versus control. 
 
Alignment and visualization of mRNA-seq data 
Sequencer output was demultiplexed (bcl2fastq using BaseSpace) to produce FASTQ 
files for individual samples. Sequenced reads were aligned to the hg19 Refseq gene 
model, in a strand-specific manner, using TopHat v2.0.11 (parameters: --b2-very-sensitive 
--library-type fr-firststrand) (Kim et al., 2013). To generate genome coverage tracks, BED 
files were first pooled between biological replicates. Reads aligning to genomic regions 
longer than the sequencing length (75 bp), due to spanning of splice junctions, were 
discarded for genomic visualization purposes. Pooled BED files were then converted to 
BedGraph files using genomeCoverageBed (bedtools v2.20.1) and normalized to the 
number of millions of reads sequenced (rpm), to correct for lane or sample biases. The 
resulting subtracted BedGraph was converted to a bigWig file using bedGraphToBigWig 
(v4). 
 
Gene expression analysis for mRNA-seq data 
Sequenced reads were assigned in a strand-specific manner to genes from the hg19 
Refseq table using HTSeq v0.6.1 (parameters: --stranded=reverse --mode=intersection-
nonempty --type=exon -i gene_id) (Anders et al., 2015), such that all exons for all Refseq 
genes with the same official gene symbol were considered to belong to the same feature. 
The unnormalized HTSeq tables, after removal of lines for unassigned reads, were 
analyzed by the DESeq2 v1.11.45 (Love et al., 2014) package in R to produce normalized 
count tables. All samples for both the “hepatic-TF” and “no-TF” RNA-seq studies were 
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normalized in DESeq2 at the same time. For quantification of fibroblast gene expression 
across chromatin categories, the DESeq2-normalized counts for the control siRNA-
transfected fibroblasts in the no-TF condition were used, after dividing each value by the 
length of that gene’s exon model in kb and averaging the two biological replicates. 
Differentially expressed genes were determined in a pairwise manner using DESeq2, with 
a significance cutoff of p.adjust < 0.05. For analysis of genes upregulated by siRNAs 
compared to control siRNA in the “hepatic TF” condition, genes significantly 
downregulated by hepatic TFs alone (hepatic-TF control siRNA compared to no-TF control 
siRNA) were removed from consideration – 3,487 out of 26,839 total genes. This was to 
ensure that upregulated genes could be interpreted as being truly upregulated by the 
siRNA, rather than the siRNA treatment inhibiting the downregulation of the gene by the 
hepatic TFs. For mRNA-seq sample correlation analyses, a regularized log2-
transformation was performed on the normalized counts using DESeq2, and Euclidean 
distances were calculated using the dist() function in R and visualized as a 
heatmap/dendrogram using the “pheatmap” package. 
 
Defining protein sets enriched in heterochromatin and gradient top 
Intensity-based absolute quantification (iBAQ) values were ranked in order of their iBAQ 
score for each of three biological replicates of each sample, to facilitate comparison 
among samples with very different numbers of identified proteins. Technical replicate MS 
runs were averaged. Proteins with only a single detected peptide were removed from 
consideration, and common contaminants (immunoglobulin chains, skin keratins) were 
filtered out. Protein ranks were compared between samples by two-tailed Student’s T test. 
Proteins with a significantly higher rank (P < 0.05) in the strucHC+H3K9me3 sample 
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(H3K9me3-directed IP using strucHC fraction chromatin) compared to the Gradient Top 
fraction were used to define the “heterochromatin proteins.” Proteins detected in 
strucHC+H3K9me3, but without significant enrichment or depletion compared to the 
Gradient Top sample, were used to define the “shared” proteins. Meanwhile, for the 
strucHC whole fraction sample, proteins with significantly higher rank in the strucHC 
fraction compared to the Gradient Top fraction were defined as “strucHC enriched.” 
Finally, remaining proteins were classified as “Gradient Top” proteins if they were either 
significantly enriched in the Gradient Top fraction over strucHC+H3K9me3, significantly 
enriched in Gradient Top over strucHC, or unique to the Gradient Top fraction. Note that 
proteins not detected in the Gradient Top fraction were assigned a rank equal to the total 
number of proteins detected for that replicate; thus, proteins detected uniquely in 
strucHC+H3K9me3 or the strucHC fraction could still be quantified as significantly 
enriched. Note also that the significance by T-test requires at least two values per sample 
being compared, and thus the “heterochromatin” and “strucHC-enriched” proteins by 
definition had to have been detected in at least two out of three replicates of the 
strucHC+H3K9me3 and strucHC samples, respectively. 
 
 
3.3 Genomic and proteomic dataset availability 
All next-generation sequencing data generated by this study (FASTQ files of sequenced 
reads and bigwig files for browser visualization) were uploaded to GEO accession number 
GSE87041, and they will be made available upon publication. Proteomic raw data files are 
available on the Chorus database under Project ID 1172, Experiment ID 2585.  
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4.1  RESPECTIVE CONTRIBUTIONS 
The majority of the experiments and analyses in this chapter were performed by me alone, 
with guidance from Kenneth S. Zaret.  Simone Sidoli and Shu Lin, with guidance from 
Benjamin A. Garcia, performed the mass spectrometry experiments and the quantitative 
proteomics analysis on peptide samples that I provided.  Kelsey Kaeding prepared and 
sequenced the mRNA-seq libraries for the transcriptome analysis after siRNA treatment, 
using RNA samples that I prepared, and she also validated the efficiency of the 
knockdowns by RT-PCR.  Zhiying He assisted with some of the hiHep reprogramming 
experiments.  Greg Donahue provided custom scripts and advice for computational 
analyses, worked directly with me for alignment of next-generation sequencing data, and 
performed the analysis of whole-genome bisfulfite sequencing data.  Computational 
analyses performed by primarily by me included the mapping and analysis of chromatin 
domains enriched for various features, the differential gene expression analysis for 
mRNA-seq, and the analysis of available microarray data for studying hiHep 
reprogramming or the consequences of TARDBP mutation. The manuscript was written 
by me and Dr. Zaret.  
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4.2  ABSTRACT 
Heterochromatic regions in mammalian cells suppress recombination, silence 
transcription, and are crucial for maintaining cell differentiation. Genomic and biochemical 
characterization of heterochromatin has relied on the associated histone modifications 
H3K9me3 and H3K27me3, yet these marks are also found in euchromatic regions that 
permit transcription. We employed a biophysical method to isolate structurally compact 
heterochromatin from human somatic cells, mapped its genomic organization compared 
to histone modifications, and used proteomics to reveal an extensive number of 
heterochromatin-bound proteins. We discriminate subtypes of H3K9me3- and 
H3K27me3-marked domains, in structural heterochromatin versus euchromatin, and we 
present a resource of hundreds of proteins that preferentially bind heterochromatin, 
revealing an enrichment for RNA-binding proteins and proteins that oppose iPS 
reprogramming. The structural heterochromatin landscape includes repressed genes for 
alternative lineages that are resistant to activation by introduced transcription factors. 
Depletion of identified heterochromatin-associated proteins reduces this barrier, rendering 
alternative-lineage genes more competent for transcriptional activation. 
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4.3  INTRODUCTION 
Cell differentiation is achieved, in part, through the selective repression of transcription of 
a large fraction of the genome. Among such silent domains, regions of heterochromatin 
are distinguished by their high levels of physical compaction, causing intense staining with 
DNA dyes or by electron microscopy (Heitz, 1928; Underwood et al., 2016). The 
condensed structure of heterochromatin restricts the accessibility of DNA to binding by 
transcription factors (Soufi et al., 2012) and allows persistent gene silencing, despite the 
presence of transcriptional activators (Ayyanathan et al., 2003; Hathaway et al., 2012). 
The packaging of DNA into dense chromatin structures also suppresses recombination at 
repeat-rich sequences, promoting genome stability (Peters et al., 2001). But lacking has 
been a direct method to identify genomic domains with high physical compaction while 
allowing recovery and analysis of constituent proteins.  
A hallmark of repeat-rich heterochromatic regions, conserved from fission yeast to 
humans, is the dimethylation and trimethylation of histone 3 lysine 9 (H3K9me2 and 
H3K9me3). In mammals, the methyltransferases SUV39H1/SUV39H2 and SETDB1 are 
responsible for H3K9me2 and H3K9me3 (Peters et al., 2001; Schultz et al., 2002), while 
G9a and GLP catalyze only H3K9me2 (Tachibana et al., 2005). The direct binding of 
H3K9me2/3 by heterochromatin protein 1 (HP1) recruits additional repressive complexes 
(Eissenberg and Elgin, 2014). Human fibroblasts contain broad, megabase-scale domains 
of H3K9me3 that include repressed genes for neural function and adhesion, as well as 
developmental transcription factors (Hawkins et al., 2010; Soufi et al., 2012). H3K9me3 
and HP1 are also deposited over zinc finger (ZNF) genes that contain Krüppel-associated 
box (KRAB) domains, which is dependent on the recruitment of SETDB1 by the KRAB-
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ZNFs themselves and their co-repressor KAP1 (Schultz et al., 2002; Vogel et al., 2006; 
O’Geen et al., 2007). The global pattern of H3K9me3 domains shows partial 
rearrangement across different cell lineages (Soufi et al., 2012; Becker et al., 2016), but 
the protein machinery that mediates the developmental dynamics of large-scale H3K9me3 
domains is largely unknown..  
Repressed genes also can be associated with H3 lysine 27 trimethylation 
(H3K27me3), catalyzed by the Polycomb Repressive Complex 2 (PRC2) (Margueron and 
Reinberg, 2011). This mark is prominent on the inactive X chromosome and at promoters 
for developmental transcription factors (Ezhkova et al., 2009; Hawkins et al., 2010; Xu et 
al., 2014a). However, H3K27me3-marked sites can be accessible to general transcription 
factors and RNA polymerase (Breiling et al., 2001; Dellino et al., 2004) and the literature 
is conflicted on whether the term “heterochromatin” includes H3K27me3-marked regions 
(Trojer and Reinberg, 2007; Beisel and Paro, 2011). 
We previously described megabase-scale, H3K9me3-enriched domains that are 
resistant to binding by the pluripotency transcription factors Oct4, Sox2, Klf4, and cMyc 
(OSKM) in human fibroblasts, but where the factors bind in human embryonic stem (ES) 
cells (Soufi et al., 2012). These Differentially Bound Regions (DBRs) contain pluripotency 
genes whose activation during iPS reprogramming is restricted to rare cells late in the 
reprogramming process (Buganim et al., 2012). Reducing H3K9me3 levels, by depleting 
SUV39H1/H2 methyltransferases, improves the efficiency of iPS reprogramming (Onder 
et al., 2012; Soufi et al., 2012) as well as reprogramming by somatic cell nuclear transfer 
(Matoba et al., 2014). However, the chromatin components that mediate the resistance of 
H3K9me3 heterochromatin to gene activation during reprogramming are poorly 
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understood, and whether H3K9me3 heterochromatin impedes reprogramming between 
differentiated lineages is not clear. 
To discover proteins embedded in heterochromatin, mass spectrometry (MS) has 
been performed after H3K9me3-directed chromatin immunoprecipitation (ChIP) (Soldi and 
Bonaldi, 2013; Engelen et al., 2015; Ji et al., 2015) or pulldown with a H3K9me3 bait 
(Vermeulen et al., 2010; Eberl et al., 2013), but the relationship between H3K9me3-
associated proteins and heterochromatin per se is unclear. In two cases, proteomic 
analysis was performed in mouse pluripotent ES cells (Engelen et al., 2015; Ji et al., 2015), 
a cell type found to lack compacted blocks of heterochromatin by high-resolution imaging 
techniques (Fussner et al., 2011; Underwood et al., 2016). More importantly, H3K9me3 
and HP1 are found outside of heterochromatin, including in the gene bodies of expressed 
genes, and can promote transcriptional elongation (Piacentini et al., 2003; Vakoc et al., 
2005; Riddle et al., 2012). Gene clusters on Drosophila chromosome 4q and human ZNF 
clusters on chromosome 19 contain H3K9me3 and HP1, despite simultaneous 
transcription (Riddle et al., 2012; Vogel et al., 2006; Blahnik et al., 2011). A definitive 
accounting of transcriptionally permissive H3K9me3 domains is currently lacking. 
Although RNA-binding proteins appear abundant after H3K9me3 ChIP (Soldi and Bonaldi, 
2013) or among readers of the H3K9me3 mark (Vermeulen et al., 2010), it is unclear of 
these proteins are specifically associated with the transcriptionally repressed, 
heterochromatic form of H3K9me3-marked chromatin. 
In this study, we find that H3K9me3 domains, more than H3K27me3 domains, 
impede the activation of liver genes during reprogramming of fibroblasts to hepatocytes. 
In our investigation of H3K9me3 domains, we found that such regions are resistant to 
sonication, which causes their underrepresentation in ChIP-seq, and which allowed us to 
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physically isolate heterochromatic domains on sucrose gradients. We performed 
quantitative genomics and proteomics on the isolated heterochromatin, as well as 
functional analysis of selected heterochromatin proteins. The results provide resource 
maps of subsets of H3K9me3 and H3K27me3 domains that are in euchromatin versus 
heterochromatin, and they reveal unexpected complexity in the proteins that are enriched 
in what we define as “structural heterochromatin.” We show that structural 
heterochromatin proteins identified by our approach inhibit the activation of 
developmentally silenced genes, establishing the proteins as functional regulators of 
heterochromatin. 
 
4.4  RESULTS 
Silent genes in H3K9me3 domains are more resistant to reprogramming than silent 
genes in H3K27me3 domains 
Human fibroblasts can be reprogrammed to a hepatocyte-like fate by the ectopic 
expression of liver transcription factors (Huang et al., 2014; Du et al., 2014). The resulting 
human induced hepatocytes (hiHeps) express hepatic markers and recapitulate some 
features of liver metabolism, but expression profiling reveals a failure to fully express all 
hepatocyte genes (Huang et al., 2014; Du et al., 2014). We analyzed a published 
microarray comparing hiHep cells to fibroblasts and cultured human hepatocytes (Huang 
et al., 2014), focusing on genes that are silent in fibroblasts and upregulated in 
hepatocytes. We found that genes marked by H3K9me3 in the starting fibroblasts have a 
profound failure to activate during cell conversion to hiHeps (Supp. Fig. 4-1A), with the 
median barely above 0% induction. By contrast, genes marked by H3K27me3, another 
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mark associated with transcriptional silence (Margueron and Reinberg, 2011), show no 
greater defect in activation than genes lacking either mark (Supp. Fig. 4-1A). The 
H3K9me3-marked genes in fibroblasts that fail to activate include genes that crucial for 
terminal hepatocyte differentiation, including NHR1H4 (encoding the bile acid receptor 
FXR), FOXA2, metabolic enzymes, cytochrome P450 subunits, secreted plasma proteins, 
and epithelial adhesion proteins. We conclude that H3K9me3-marked chromatin is the 
most refractory to gene activation by hepatic factors, similar to that seen at DBRs for 
reprogramming to pluripotency (Soufi et al., 2012; Matoba et al., 2014), leading us to 
further investigate the nature H3K9me3 domains in the human fibroblasts. 
 
Heterochromatic Differentially Bound Regions are resistant to sonication 
Using data from the NIH Epigenomics Roadmap (Bernstein et al., 2010), we find that 
genome mapping tracks for input-subtracted H3K9me3 show pronounced enrichment 
over DBRs (Figure 4-1A, purple track), but raw H3K9me3 signals are only modestly 
elevated in these regions (Figure 4-1A, yellow track). Surprisingly, the input signals alone 
show depletion over most H3K9me3 domains, including DBRs (Figure 4-1A, blue track, 
red arrows). Sequencing of both input and ChIP is typically performed after size-selecting 
short DNA fragments, thereby depleting regions that are more resistant to sonication. A 
study reported that megabase-scale H3K9me3 domains are largely dependent on culture 
conditions, but the ChIP data was analyzed without normalizing to input from the same 
sample (Zhu et al., 2013). Our own input-normalized analysis of the same ChIP-seq 
datasets showed that megabase-scale H3K9me3 domains are present at shared and 
different sites across diverse human cell types (Supp. Fig. 4-1B) (Becker et al., 2016). 
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Sites of high sonication susceptibility map to active promoters (Auerbach et al., 2009), but 
resistance to sonication has not been used to identify heterochromatic regions. 
We prepared crosslinked, sonicated chromatin from human BJ foreskin fibroblasts, 
in which the DBRs were mapped (Soufi et al., 2012) and used sucrose gradient 
ultracentrifugation under conditions that separate chromatin fragments by size (Gilbert et 
al., 2004) (Figure 4-1B).  By qPCR, we compared the migration sites previously shown to 
be functionally euchromatic versus heterochromatic in fibroblasts: euchromatic sites 
outside DBRs that are bound by Oct4/Sox2 in fibroblasts and ES cells, versus 
heterochromatic sites inside DBRs that are bound in ES cells but lack binding in fibroblasts 
(Soufi et al., 2012). DBR sites (Figure 4-1C, red) are significantly depleted from the 
fractions at the top of the gradient, which contain the most highly sheared DNA. 
Meanwhile, fractions from the middle of the gradient, containing longer DNA fragments 
normally excluded from ChIP-seq (Figure 4-1B), were selectively enriched for DBR sites 
(Figure 4-1C). The magnitude of DBR enrichment in middle gradient fractions is 
comparable to that achieved by conventional H3K9me3 ChIP-qPCR (Supp. Fig. 4-1C). 
Thus, gradient-mediated separation of sonication-resistant chromatin provides a 
biophysical readout of chromatin regions of heterochromatic domains. 
 We pooled the fractions of the gradient showing the greatest enrichment of DBR 
sites (fractions #10-17, red box in Figure 4-1B). This material was termed the “structural 
heterochromatin (strucHC) fraction” and was compared to a “euchromatin fraction” from 
the top of the gradient (fraction #2) in all subsequent analyses. Secondary H3K9me3 
ChIP, performed from the strucHC fraction, resulted in additive enrichment of DBR sites 
(Supp. Fig. 4-1C). The chromatin recovery by H3K9me3 IP, as a fraction of input, was 
much greater for the strucHC fraction compared to bulk chromatin or the euchromatin 
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fraction (Supp. Fig. 4-1D), confirming that the gradient step enriches for H3K9me3-marked 
chromatin. 
 
Genomic mapping of the structural heterochromatin landscape 
We sequenced DNA from the strucHC and euchromatin fractions of the gradient 
(“Gradient-seq”) (Figure 4-1D). For samples containing larger DNA fragments, including 
strucHC fractions, IPs off of this fraction, and input to the gradient, the purified DNA was 
sonicated further (Supp. Fig. 4-2A,B). In parallel, we performed conventional input-
normalized H3K9me3 ChIP-seq and mRNA-seq of BJ fibroblast cells. 
We found that of the 258 DBRs (Soufi et al., 2012), 256 are positively enriched in 
strucHC over input chromatin, in contrast to similarly sized regions that flank DBRs (Figure 
4-1E). Browser views show that the strucHC sequencing signals form megabase-scale 
domains that correspond closely to H3K9me3 ChIP-seq domains, including DBRs, while 
the euchromatin fraction exhibits an inverse pattern (Figure 4-1F). Meanwhile, many 
H3K27me3-marked sites overlap with regions of euchromatin signal, while others show 
strong strucHC enrichment even in the absence of H3K9me3 (Figure 4-1F, green arrows). 
To quantitatively compare these samples without imposing numerical thresholds, we 
computed the pair-wise Spearman correlation coefficients among the samples after 
binning the input-normalized data into 10 kb windows. Genome-wide, the strucHC signal 
has a strong correlation with H3K9me3 ChIP-seq from either this study or the Epigenomics 
Roadmap (Figure 4-2A). Meanwhile, strucHC has weaker (but still positive) correlation 
with H3K27me3. Finally, the strucHC fraction and H3K9me3/H3K27me3 ChIP samples all 
anti-correlate with the euchromatin fraction (Figure 4-2A). 
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To identify genomic domains that were enriched in each sample (horizontal colored 
bars above each track in Figure 4-1F), we used a sliding window algorithm to select 10 kb 
intervals that exceeded a threshold for signal divided by input, followed by edge-pruning 
of enriched regions in 500-bp steps (see Chapter 2). The identified domains for strucHC 
cover 997 MB of the hg19 genome assembly and have weighted average length 135 kb. 
Euchromatin domains, which total 1240 MB, were identified using the same procedure, 
except the euchromatin sequencing was compared directly to strucHC, which provided 
greater contrast than input. Finally, mappable regions not in strucHC or euchromatin 
domains, meaning that they had comparable abundance in the two gradient fractions, 
were classified as intermediate domains. 
To assess histone mark levels in strucHC domains, we downloaded ChIP-seq data 
for 27 marks profiled in human fibroblasts by the Roadmap Epigenomics consortium 
(Bernstein et al., 2010) as well as ChIP-seq for H3K9me2 (Chandra et al., 2012). We 
computed the enrichment or depletion of each mark, relative to input, over the width of 
each strucHC domain and plotted the average across all domains (Figure 4-2B). 
H3K9me3 is most strongly enriched in strucHC, while H3K27me3 and H3K9me2 have 
modest levels of enrichment. All other marks tested, including those associated with active 
promoters/enhancers or transcriptional elongation, are strongly depleted (Figure 4-2B). 
Consistent with these associations, 607 MB of the strucHC domains (60.8%) are also 
called as H3K9me3 domains, while 327 MB (32.8%) are H3K27me3 domains (Figure 4-
2C). Interestingly, these two molecular forms of strucHC domains are largely distinct, with 
only 70 MB of overlap (7.0%), reminiscent of ChIP-Seq data (Hawkins et al., 2010; 
Chandra et al., 2012). 
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Genes within strucHC domains are transcriptionally repressed, in comparison to 
genes falling inside euchromatic domains, with the intermediate domains nearly as 
repressed as strucHC (Figure 4-2D). StrucHC is enriched for genes important for non-
fibroblast lineages, including genes for cell surface (neuronal ion channels, G-protein-
coupled receptors, and epithelial adhesion proteins), immune defense proteins, factors for 
endodermal and ectodermal development, keratins, muscle components, and enzymes 
for digestion and hepatic metabolism (Figure 4-2E). As expected, strucHC domains 
contain the majority of satellite repeat sequences and are significantly enriched for LINE 
elements and endogenous retroviruses. Using whole-genome bisulfite sequencing 
(WGBS) data from the Roadmap Epigenomics consortium (Bernstein et al., 2010), we find 
that DNA methylation rates at CpGs islands are highly divergent between the structural 
classes (Figure 4-2F, left). Domains of strucHC have the highest rate of methylation at 
CpG islands (median CpG is methylated at ~75% of copies), while at euchromatic CpG 
islands three-quarters of CpGs have no detectable methylation (Figure 4-2F, left). 
Meanwhile, outside of CpG islands, rates of DNA methylation are high in all three 
categories (Figure 4-2F, right), consistent with methylation being widespread outside of 
islands (Jones, 2012). Non-CpG-island methylation is actually highest in euchromatin 
(Figure 4-2F, right), perhaps because of the DNA methylation associated with transcribed 
gene bodies (Jones, 2012). 
 
Gradient-seq reveals euchromatic subtypes of repressive histone mark domains 
We observed that ZNF gene clusters on chromosome 19 have high levels of H3K9me3, 
despite expression of the genes (Figure 4-3A), as reported previously (Vogel et al., 2006; 
Blahnik et al., 2011). Notably, the expressed ZNF gene clusters are depleted from the 
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strucHC fraction and enriched in the euchromatin fraction (Figure 4-3A). These regions 
are further enriched by H3K9me3 IP off of the euchromatin fraction (Figure 4-3A), 
confirming that a sonication-sensitive chromatin structure can coexist with the H3K9me3 
mark on the same chromatin fragment.  
 To identify similar regions on a genome-wide basis, we selected all 10-kb intervals 
that were enriched in the euchromatin fraction over strucHC fraction and for domains of 
H3K9me3 or H3K27me3. These euchromatic subtypes of these histone mark domains 
occupied 31 MB of sequence for H3K9me3 (3.2% of the total H3K9me3) and 193 MB 
(28.7%) for H3K27me3 (Figure 4-2C). Most of the genes in euchromatic H3K9me3 or 
H3K27me3 domains were expressed, although at lower levels than the euchromatin as a 
whole (Figure 4-3B). Consistent with this, euchromatic H3K9me3 domains, but not other 
H3K9me3 domains, were enriched for H3K36me3 (Supp. Fig. 4-3A), a mark associated 
with transcriptional elongation (Vakoc et al., 2006). At transcribed ZNF genes, H3K9me3 
and H3K36me3 are both observed in the gene bodies, but the H3K9me3 signal is reduced 
or absent over the promoters (Supp. Fig. 4-3B). 
The euchromatic H3K9me3 domains had robust selectivity for gene family clusters, 
with more than half of the genes inside these domains belonging to the KRAB-ZNF family 
(n=150 of 230 InterPro database matches), in addition to the protocadherin gamma cluster 
and certain homeobox (HOX) genes (Figure 4-3C). Genes in Euchromatic H3K9me3 are 
listed in Table 4-1. The 3% of fibroblast H3K9me3 domains that are euchromatic contain 
a majority of sites regulated by the HUSH complex (Tchasovnikarova et al., 2015), an 
enrichment of 39-fold compared to the strucHC subtype (Figure 4-3D). Indeed, the sites 
reported to have the greatest dependence on HUSH/SETDB1 for H3K9me3 levels fall in 
euchromatin (Supp. Fig. 4-3C), consistent with the complex localizing to genes that are 
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“dimmed” but nonetheless expressed (Tchasovnikarova et al., 2015).  Euchromatic 
H3K27me3 domains include all four human HOX gene clusters (Figure 4-3E) and keratin 
type I and protocadherin gamma clusters, in addition to non-clustered genes for basic-
helix-loop-helix and forkhead transcription factors (Figure 4-3C).   
While as expected, the majority of satellite repeats fall in strucHC, the specific 
repeat type HSATII, which due to its constitutive silence might otherwise be classified as 
heterochromatic, is consistently found in euchromatic H3K9me3 domains (Figure 4-3F). 
That HSATII has an accessible structure is corroborated by its enrichment in available 
tracks of DNase-I sensitivity (Supp. Fig. 4-3D). A unique feature of HSATII is its massive 
overexpression in diverse human cancers (Ting et al., 2011) and cellular senescence (De 
Cecco et al., 2013).  Heterochromatic regions have been found to have an elevated rate 
of mutation accumulation across human cancers (Lawrence et al., 2013), and we find that 
this effect is more pronounced in the strucHC and intermediate H3K9me3 subtypes, 
compared to euchromatic H3K9me3 or H3K27me3-marked regions (Supp. Fig. 4-3E). 
Thus, Gradient-seq provides structural insight into different repressed domains associated 
with human disease. 
 
Relationship between strucHC and other markers of heterochromatin 
Our finding that chromatin regions with the same repressive histone marks could be 
partitioned into structural subtypes with markedly different sonication sensitivity as 
measured by Gradient-seq (Figure 4-4A) led us to investigate to what extend to those 
differences are reflected in other properties associated with heterochromatin. The 
structural categories were indeed highly predictive of the levels of CpG methylation at CpG 
islands, as quantified by WGBS (Bernstein et al., 2010) (Figure 4-4B). Both inside and 
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outside H3K9me3 domains, methylation rates were consistently high at strucHC islands 
and low at euchromatic islands, with moderate levels in the intermediate category (Figure 
4-4B), correlating with the levels of gene silencing for these subtypes (Figure 4-3B). 
Interestingly, methylation rates are highest in the 133 MB of strucHC that lack enrichment 
for H3K9me3 or H3K27me3 (Figure 4-4B, far right), confirming that the strucHC domains 
have heterochromatic features even where they diverge from traditional histone mark-
based approaches. By contrast, outside of CpG islands, methylation rates are high in all 
categories (Supp. Fig. 4-4A), and highest in the euchromatin subtypes, similar to that 
observed for the total strucHC and euchromatin domains (Figure 4-2F). 
 We find that association of chromatin with the nuclear lamina, meanwhile, is 
related to both structural classification and the type of histone mark. Levels of Lamin B1 
binding by ChIP-seq (Dou et al., 2015) are generally higher in H3K9me3 domains 
compared to H3K27me3 domains (Figure 4-4C), consistent with previous reports (Guelen 
et al., 2008). However, within H3K9me3 domains, the strucHC and intermediate subtypes 
are much more consistently enriched for Lamin B1 binding (Figure 4-4C) and overlap at a 
higher rate with previously mapped Lamina Associated Domains (Guelen et al., 2008) 
(Supp. Fig. 4-4D), compared to the euchromatic subtype of H3K9me3. Similarly, within 
H3K27me3 domains and regions without enrichment for H3K9me3 or H3K27me3, 
strucHC subtypes have higher levels of lamina association (Figure 4-4C, Supp. Fig. 4-
4D). 
 Sensitivity to nucleases like DNase I or micrococcal nuclease is a classic measure 
of chromatin accessibility. We next compared our chromatin subtypes using ENCODE 
data for sequencing after DNase I digestion (DNase-seq) in BJ fibroblasts (Thurman et 
al., 2012). As expected, 10-kb windows within euchromatin domains are consistently more 
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DNase-sensitive than windows in strucHC or intermediate domains (Figure 4-4D, far left), 
further corroborating that Gradient-seq detects differences in the structural accessibility of 
chromatin. Meanwhile, DNase-seq does not clearly distinguish strucHC from intermediate 
domains, two forms of chromatin that are mostly transcriptional silent (Figure 4-2D) and 
yet are quantifiably different according to Gradient-seq (Figure 4-4A, far left), consistent 
with the specificity of DNase I for open chromatin regions (Thurman et al., 2012). 
Euchromatin domains are highly DNase-sensitive even where they overlapped with 
H3K27me3 (Figure 4-4D, middle right), but interestingly not when they overlap with 
H3K9me3 (Figure 4-4D, middle left), even though both types of regions are 
transcriptionally active (Figure 4-3B). 
 One recent study (Mieczkowski et al., 2016) performed MNase titrations to define 
the MNase accessibility (MACC) of chromatin regions, with a higher MACC score 
indicating sensitivity at lower concentrations of MNase. Similar to the results with DNase-
seq, the MACC signal for human K562 cells (Mieczkowski et al., 2016) is elevated in 
euchromatin domains, both as a whole and in H3K27me3 domains, but not in euchromatin 
overlapping H3K9me3 (Supp. Fig. 4-4B). Although the MACC and Gradient-seq 
experiments were performed in different in different cell types, we confirmed these findings 
at regions with similar H3K9me3 or H3K27me3 patterns in both K562 cells and foreskin 
fibroblasts (Supp. Fig. 4-4C). Indeed, in such regions, the pattern of MNase resistance 
closely mirrors the pattern of strucHC versus euchromatin domains (Supp. Fig. 4-4C, left), 
indicating that there is widespread similarity of sonication-resistance and MNase-
resistance. However, a clear exception occurs at regions bearing both H3K9me3 and 
H3K36me3 in both cell types (Supp. Fig. 4-4C, right), which are classified as euchromatic 
according to Gradient-seq but have negative MACC signals. Thus, in contrast to Gradient-
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seq, nuclease-based methods are unable to distinguish transcriptionally active H3K9me3 
domains from transcriptionally inactive ones, perhaps reflecting an intrinsic property of 
H3K9me3-marked chromatin to resist enzymatic cleavage reactions. 
 Finally, we analyzed replication timing within each chromatin subtype using Repli-
seq data (Pope et al., 2014), in which newly replicated is sequenced in six cytometry-
fractionated cell cycle phases. All forms of H3K9me3 domains, including both strucHC 
and euchromatin, replicate late, while H3K27me3 domains replicate in early-to-mid S 
phase (Figure 4-4E), consistent with previous observations (Chandra et al., 2012). Thus, 
in contrast to gene expression and methylation at CpG islands, late replication is a 
property more closely associated with the H3K9me3 histone mark than chromatin 
structure, and can co-occur with gene transcription. 
 In summary, we have used gradient-sedimentation of sonication-resistant 
chromatin to purify a set of transcriptional silent chromatin domains (strucHC), which 
includes the majority of H3K9me3 domains as well as a subset of DNase-resistant 
H3K27me3 or unmarked regions, but notably excludes the H3K9me3/H3K27me3 regions 
with transcribed genes and hypomethylated CpG islands. 
 
The proteome of H3K9me3-marked structural heterochromatin 
To identify proteins embedded in structural heterochromatin, as distinct from 
transcriptionally active H3K9me3 domains, we performed label-free quantitative proteomic 
studies on three biological replicates of the strucHC fraction, along with H3K9me3 IPs 
performed off of each strucHC fraction (Figure 4-5A). Results were compared to the 
euchromatin-containing fraction, which contains both euchromatic fragments as well as 
soluble proteins from the lysate, and thus for accuracy will be referred to as the “gradient 
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top” fraction. Proteins were decrosslinked, digested with trypsin, and analyzed by nano 
liquid chromatography coupled to tandem mass spectrometry (MS/MS). Protein 
abundance in each sample was determined using intensity-based absolute quantification 
(iBAQ) (Cox and Mann, 2008; Schwanhäusser et al., 2011), and protein ranks were 
compared between samples. In total, across the different samples, we identified 3,097 
proteins with at least two peptides. Of the 1,864 proteins detected in the strucHC fraction, 
217 proteins had a significantly higher rank in strucHC compared to the gradient top 
fraction (T-test, P < 0.05), and these were termed “strucHC-enriched proteins” (red dots 
in Figure 4-5B, left). The strucHC-enriched proteins are listed in Table 4-2. However, we 
cannot exclude the possibility that some non-chromatin-bound proteins may sediment to 
the strucHC fraction and be included among the proteins enriched in this fraction. 
 To specifically identify proteins that crosslink to H3K9me3-marked 
heterochromatin, we focused our proteomic analysis on the H3K9me3-directed IPs 
performed using strucHC chromatin (Figure 4-5A, henceforth “strucHC+H3K9me3”). 
Analysis of the DNA isolated from the same samples reveal a high enrichment for 
heterochromatic regions (Figure 4-1F, Supp. Fig. 4-1C). The strucHC+H3K9me3 
chromatin was eluted after stringent high-salt washes, and thus has comparable specificity 
for chromatin-bound proteins as traditional ChIP-mass spec approaches, but inclusion of 
the gradient sedimentation step allows depletion of transcriptionally active H3K9me3 
domains. Out of 716 proteins detected in the strucHC+H3K9me3 sample, we identified 
172 “heterochromatin proteins” (Table 4-3) that were significantly enriched in 
strucHC+H3K9me3 compared to the gradient top fraction (Figure 4-5B, right, orange 
dots). As expected, there was substantial overlap between the heterochromatin proteins 
and strucHC-enriched proteins (Figure 4-5C). An additional 429 proteins detected in both 
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strucHC+H3K9me3 and the gradient top fraction, but without significantly different ranks 
between the two samples, and hence were classified as “shared” (Figure 4-5B, right, grey 
dots). Finally, among the remaining proteins, 1,474 proteins were classified as belonging 
the gradient top, meaning they were uniquely detected in that sample or were significantly 
enriched by rank in comparison to the strucHC or strucHC+H3K9me3 samples. 
 The 172 identified heterochromatin proteins include several proteins known to 
compose or associate with compacted chromatin (Figure 4-5D), including the linker 
histone (H1.1, H1x, and H1.0), histone variant macroH2A, and lamin B1, as well as the 
repressive histone modifier histone deacetylase 2. Also included among the 
heterochromatin proteins are NONO and SFPQ, proteins that form a co-repressor 
complex (Mathur et al., 2001; Dong et al., 2009) and are known to interact with the 
H3K9me3 mark (Vermeulen et al., 2010), and we find strongly enriched in 
strucHC+H3K9me3 (Figure 4-5D, bottom). Strong enrichment was also observed 
HNRNPK, which is required for silencing and H3K9me3 deposition at genes and repetitive 
elements (Bao et al., 2015; Thompson et al., 2015). Furthermore, the identified 
heterochromatin proteins include proteins that interact directly with HP1 and have been 
linked to gene repression, such as HP1BP3 , THRAP3, and BCLAF1 (Vermeulen et al., 
2010). Meanwhile, HPγ itself was in the category shared between heterochromatin and 
euchromatin, consistent with our genomic data showing that HP1-associated ZNF 
domains (Vogel et al., 2006) are enriched in euchromatin. 
 To our knowledge, only one previous study used proteomics to comprehensively 
identify proteins present in H3K9me3 chromatin in differentiated mammalian cells (Soldi 
and Bonaldi, 2013). The results of this study, using H3K9me3-directed ChIP-MS in HeLa 
cells, agree strongly with our own: 60 (37%) of the 172 heterochromatin proteins identified 
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by our approach were previously found to be enriched by H3K9me3 ChIP (Soldi and 
Bonaldi, 2013) (Figure 4-5E, left orange bar), an enrichment of 27-fold compared to the 
gradient top proteins (Figure 4-5E, blue). Moreover, 124 out of the 208 (60%) proteins 
discovered by H3K9me3 ChIP-MS (Soldi and Bonaldi, 2013) fall into the heterochromatin 
or shared categories from our study. Meanwhile, other studies have used proteomics to 
characterize specific subsets of H3K9me3-related proteins, such as “readers” that interact 
with a H3K9me3 bait (Vermeulen et al., 2010) or proteins associated with pericentromeric 
satellites in mouse ES cells (Saksouk et al., 2014). The heterochromatin protein group 
also has a significantly higher rate of overlap with both of these studies compared to 
gradient top proteins (Figure 4-5E, middle panels), though as expected fewer proteins fall 
into these specific categories. The strucHC-enriched proteins similarly have an elevated 
rate of overlap with all three studies (Figure 4-5E, red bars). Similar to previous studies of 
constitutive heterochromatin (Saksouk et al., 2014), we find nucleolar proteins among the 
heterochromatin proteins, including nucleolin (NCL), BRIX1, NOP2/NOP56/NOP58, 
Pescadillo homolog (PES1), and GTPBP4. This is consistent with role of H3K9me2/3 in 
repressing rDNA arrays (Santoro et al., 2002) and the physical association of 
heterochromatin at the nucleolar periphery (Politz et al., 2013). 
Remarkably, despite the low levels of gene transcription within strucHC domains 
(Figure 4-2D), 119 of the 172 heterochromatin proteins have RNA-binding activity 
according to a published database (Gerstberger et al., 2014), including known co-
repressors HNRNPK, NONO, and SFPQ (Mathur et al., 2001; Dong et al., 2009; 
Thompson et al., 2015). RNA binding by HP1 has long been known to be important for its 
localization to heterochromatin (Muchardt et al., 2002), but RNA binding has not been 
appreciated as a common feature among mammalian heterochromatin proteins. Yet the 
  103 
RNA-binding proteins we find in heterochromatin, compared to the total heterochromatin 
proteins, have an even higher rate of agreement of previously published sets of H3K9me3 
ChIP-MS proteins or H3K9me3 readers (Figure 4-5F). Thus, the association of such 
proteins with H3K9me3-marked chromatin has been demonstrated through multiple 
independent approaches, and our use of gradient sedimentation ensures that such 
proteins are indeed associated with the heterochromatic, transcriptionally repressed 
portion of H3K9me3 domains. 
A major functional property of the H3K9me3 form of heterochromatin is impeding 
reprogramming to pluripotency (Onder et al., 2012; Soufi et al., 2012; Matoba et al., 2014).   
Using data from a genome-wide screen (Toh et al., 2016), we find that heterochromatin 
proteins are enriched for factors that are repressors of iPS reprogramming (siRNAs that 
increase iPS conversion) and depleted for factors that enhance reprogramming (Supp. 
Fig. 4-5A). To our knowledge, across several studies, 22 of the 172 heterochromatin 
proteins have been shown to impede iPS reprogramming (Supp. Fig. 4-5B), several of 
which are RNA binding proteins, including HNRNPK (Thompson et al., 2015) and 
muscleblind-like protein 1 (MNBL1) (Han et al., 2013). 
 Surprisingly, we noted that the heterochromatin proteins included six proteins 
implicated in the neurodegenerative disease amyotrophic lateral sclerosis (ALS), with 
strong quantitative enrichment in strucHC+H3K9me3 (Figure 4-5G). Based on the total 
number of proteins known to be recurrently mutated in ALS (Cirulli et al., 2015), this rate 
of overlap with heterochromatin and strucHC-enriched proteins is significantly higher than 
expected (Figure 4-5E, far right). Among such proteins, TARDBP (also called TDP-43) 
has been well-studied as a biochemical component of the pathological inclusions found in 
ALS neurons and a genetic cause of certain forms of familial ALS (Lee et al., 2012). 
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TARDBP has been shown to oppose iPS reprogramming in two independent genome-
wide screens (Qin et al., 2014; Toh et al., 2016) (Supp. Fig. 4-5B), suggesting that it might 
be important for heterochromatic silencing. Using transcriptome data from fibroblasts 
isolated from ALS patients (Highley et al., 2014), we find that germline mutation of TDP-
43 is associated with a modest but widespread upregulation of genes in strucHC, 
compared to healthy controls (Supp. Fig. 4-5C,D,E). Such upregulation is absent in 
sporadic ALS cases, where the fibroblast copies of TDP-43 are normal. These findings 
help explain overexpression of heterochromatic repeat elements and the altered 
organization of compacted chromatin in ALS disease models (Li et al., 2012; Amlie-Wolf 
et al., 2015). Thus, identification of proteins crosslinked to chromatin in the strucHC 
fraction has revealed new proteins with functional roles in human heterochromatin. 
 
Activation of liver-specific genes is impeded by H3K9me3-marked strucHC and 
associated proteins RBMX/RBMXL1 
We next investigated whether strucHC and its bound proteins, in addition to impeding 
reprogramming to pluripotency, oppose conversion to the hepatic lineage.  Indeed, in 
human fibroblasts, liver genes in H3K9me3 domains in strucHC or intermediate forms, but 
not liver genes in H3K9me3 domains in euchromatin, have a profound failure to activate 
during cell conversion to hiHep cells (Figure 4-6A, median indicated by white circles). 
These include genes for important for hepatic cell fate, metabolism, epithelialization, and 
secretion into the blood plasma (Figure 4-6B; genes listed in Table 4-4). Compared to 
fibroblasts, these genes show a diminution of H3K9me3 in human liver (Figure 4-6C). 
While genes in H3K27me3 in fibroblasts allowed greater levels of hepatic gene induction, 
the strucHC form of H3K27me3 was slightly more refractory than the intermediate or 
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euchromatic forms of this mark (Figure 4-6A). We conclude that H3K9me3-marked 
chromatin, of either the strucHC or intermediate form, is most refractory to gene activation 
by hepatic factors. 
 We reasoned that disruption of heterochromatin might render this class of 
H3K9me3-marked genes more competent for activation by hepatic transcription factors 
(TFs). We used a cocktail of three factors previously shown to produce hiHep cells 
(FOXA3, HNF1A, and HNF4A) (Huang et al., 2014) and confirmed that expression of 
these factors was sufficient to convert foreskin fibroblasts to hepatocyte-like cells 
expressing liver markers (Supp. Fig. 4-6A). We found that two cycles of siRNA against 
SUV39H1, which reduced H3K9me3 levels (Supp. Fig. 4-6B), greatly enhanced the 
activation of a panel of hepatic genes marked by H3K9me3 in fibroblasts (Figure 4-6D). 
SUV39H1 knockdown alone, in the absence of hepatic TFs, did not result in detectable 
expression by RT-qPCR (Figure 4-6D).  
The protein RNA Binding Motif Protein, X-linked (RBMX) had the second highest 
enrichment in strucHC+H3K9me3 among heterochromatin proteins (Figure 4-5D, bottom, 
red dot), and the related protein RBMXL1 was enriched in the strucHC fraction and 
detected in one strucHC+H3K9me3 replicate. RBMX is known to bind chromatin 
independent of its RNA recognition motif (Matsunaga et al., 2012), and its depletion 
causes defects in pericentromeric cohesion (Matsunaga et al., 2012), a phenotype 
reminiscent of SUV39H1 mutants (Peters et al., 2001). However, RBMX is not known to 
function in gene silencing or heterochromatin. We find that siRNAs co-targeting RBMX 
and RBMXL1 (RBMX/L1) (Supp. Fig. 4-6C,D) enable the activation of liver-specific genes 
in strucHC by hepatic TFs, comparable to SUV39H1 knockdown (Figure 4-6D). The 
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enhanced expression persisted in hiHep cells 14 days after induction (Supp. Fig. 4-6E), 
demonstrating gene expression stability substantially later than the RBMX knockdown. 
 
Regulation of diverse genes in strucHC by RBMX/L1 
To understand the role of RBMX/L1 in impeding hepatic TF activity genome-wide, we 
performed mRNA-seq in fibroblasts treated with RBMX/L1 siRNA, compared to control 
siRNA and siRNA against SUV39H1, after 7 days of hepatic TF expression (Figure 4-7A). 
Unsupervised clustering of the mRNA-seq data by Euclidean distance confirmed the 
similarity of biological replicates and showed that the RBMX/L1 siRNA treatment clustered 
with the SUV39H1 knockdown (Supp. Fig. 4-7A, green box). Out of 1333 genes 
upregulated by RBMX/L1 knockdown (compared to non-targeting siRNA) in the presence 
of hepatic TFs, 65% were also upregulated by SUV39H1 (P < 10-200) (Figure 4-7B).   
 Within strucHC, the SUV39H1 knockdown condition revealed 281 genes that are 
responsive to heterochromatin disruption and can be activated by either endogenous 
factors or the hepatic TF cocktail. Among these 281 genes, the effect of SUV39H1 siRNA 
was well correlated with the effect of RBMX/L1 siRNA (Figure 4-7C, left), with upregulation 
by RBMX/L1 siRNA reaching statistical significance for 102 of these genes. Genes 
upregulated by both SUV39H1 and RBMX/L1 siRNA include the liver-specific genes 
encoding C-Reactive Protein (CRP) and the nuclear receptor NR1H4/FXR (Figure 4-7D). 
We note that certain strucHC genes are uniquely regulated by either SUV39H1 or 
RBMX/L1 (Figure 4-7C). A list of strucHC genes upregulated by each siRNA is provided 
in Table 4-5. 
We also performed mRNA-seq in cells treated with SUV39H1, RBMX/L1, and 
control siRNA in the absence of ectopic transcription factors (Figure 4-7A, Supp. Fig. 4-
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7). Fewer genes in strucHC were upregulated in this condition (109 after SUV39H1 
knockdown and 67 for RBMX/L1 knockdown, Supp. Fig. 4-7C), consistent with our qPCR 
studies (Figure 4-6D) and prior studies on SUV39H1 (Bulut-Karslioglu et al., 2014). 
Importantly, in the absence of ectopic TFs, knockdown of RBMX/L1 was sufficient for the 
activation of genes within strucHC and H3K9me3 domains, such as the TMEM178 (Figure 
4-7E) and the imprinted gene Paternally Expressed 3 (PEG3). Thus, the role of RBMX/L1 
in impeding gene activation is not dependent upon ectopic TF expression. Taken together, 
our studies with RBMX/L1 validate the proteomic study of the strucHC gradient fraction as 
a resource for discovering novel regulators of genes within heterochromatin. 
 
4.5  DISCUSSION 
It is becoming clear that silent chromatin adopts diverse structural and functional forms, 
and that understanding the mechanisms of gene silencing provides insight that is crucial 
for being able to reprogram cells by modifying silent chromatin. Genome mapping of 
histone modifications such as H3K9me3 and H3K27me3 has been integral to the study of 
lineage-specific gene repression (Ezhkova et al., 2009; Hawkins et al., 2010; Xu et al., 
2014a), but these marks are also found in transcriptionally active or accessible chromatin 
(Vakoc et al., 2005; Blahnik et al., 2011; Riddle et al., 2012; Breiling et al., 2001). Here we 
show that the recovery of sonication-resistance chromatin fragments using sucrose 
gradients is an effective method of heterochromatin purification, with efficiency 
comparable of conventional ChIP. This approach allows us, for the first time, to distinguish 
heterochromatic forms of H3K9me3 and H3K27me3 domains from those that are 
competent for transcription, and to comprehensively identify proteins that are associated 
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with definitive regions of heterochromatin. Using this dataset, we show that particular 
heterochromatin proteins are required to prevent activation of cell type-inappropriate 
genes, either under homeostatic conditions or in the presence of ectopic transcription 
factors. We also provide diverse resources for future studies on heterochromatin subtypes 
and the genes and repeat elements they contain.  
 Our use of sucrose gradients was inspired by previous studies applying gradient 
sedimentation to MNase I-digested or sonicated chromatin (Gilbert et al., 2004; Ishihara 
et al., 2010), but these approaches focused on fragments that changed buoyancy without 
changing size or resistance to fragmentation. Our method, in addition to its enrichment of 
heterochromatic regions, has the advantage of avoiding an electrophoresis-based size-
selection step, thereby enabling subsequent IP or analysis of protein content. 
 The literature has been conflicted on whether heterochromatin includes 
H3K27me3-marked regions or applies solely to H3K9me3-marked and HP1-bound 
regions (Trojer and Reinberg, 2007; Beisel and Paro, 2011). We find that many 
H3K27me3 domains are enriched in the sonication-resistant strucHC fraction comparable 
to heterochromatic DBRs (Figure 4-1F, green arrows versus purple arrows), with 49% of 
the H3K27me3 domains overlapping with strucHC. Meanwhile, 29% of H3K27me3 
domains are enriched in the euchromatic gradient fraction, correlating with enhanced 
permissiveness to transcription. Thus, H3K27me3-marked chromatin spans a wide range 
of physical states, suggesting that this histone mark alone is insufficient to predict or 
exclude heterochromatin status. This also highlights a potential danger of generalizing 
from model loci to all sites bearing the same histone mark, as we find that all four HOX 
clusters, which have been pivotal to the study of Polycomb biology (Margueron and 
Reinberg, 2011), reside in euchromatin domains. 
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Compared to H3K27me3, H3K9me3 domains have a much stronger tendency to 
be heterochromatic, with only 3.2% being significantly enriched in the euchromatic 
fraction. Although the euchromatic subtype represents a small fraction of the total 
H3K9me3 domains, it contains genes that have been used to normalize H3K9me3 ChIP-
seq data (Zhu et al., 2013) or to study the HUSH complex, KAP1, and SETDB1 
(Tchasovnikarova et al., 2015; Groner et al., 2010), without recognition that these sites 
are euchromatic and atypical for H3K9me3. Although most genes in euchromatic 
H3K9me3 domains are expressed (Figure 4-3B) and are more readily activated by ectopic 
transcription factors (Figure 4-6B), H3K9me3 has a repressive role at these sites in 
dimming gene expression (Tchasovnikarova et al., 2015; Groner et al., 2010). As active 
genes marked by H3K9me3 are still bound by multiple isoforms of HP1 (Vogel et al., 
2006), our data allow new studies on which chromatin components distinguish the 
heterochromatic and euchromatic forms of H3K9me3 domains.  
We find that genes marked by H3K9me3, if in strucHC or intermediate domains, 
are markedly deficient in activation by hepatic transcription factors during hiHep 
reprogramming, with the majority of hepatocyte genes persisting at near-fibroblast levels 
(Figure 4-6A). A comparable defect was not observed for the heterochromatic form of 
H3K27me3 domains, demonstrating a significant distinction between H3K9me3- and 
H3K27me3-marked chromatin. This finding shows, for the first time, that H3K9me3-
marked chromatin impedes direct conversion between two mature lineages.  This agrees 
with prior work showing that such chromatin impedes binding by iPS reprogramming 
factors and reprogramming itself (Soufi et al., 2012; Onder et al., 2012), and it suggests 
that diverse other forms of cell reprogramming might similarly be limited by the extent to 
which strucHC domains can be accessed. 
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The ability to purify heterochromatin physically provided the opportunity to uncover 
the protein composition of repressed chromatin domains, without contaminating 
euchromatin or bias for particular histone modifications. The proteins we find to be 
enriched in H3K9me3-marked heterochromatin include many proteins known to be 
involved in gene repression or associated with H3K9me3 (Figure 4-5D). Beyond specific 
examples corroborated by the literature, we show that this set of heterochromatin proteins 
as a whole is enriched for functional features of heterochromatin, such as impeding 
reprogramming to pluripotency (Supp. Fig. 4-5A,B). Using this dataset, we were able to 
discover that two related proteins, RBMX and RBMX/L1, although not previously 
implicated in transcriptional repression, impede gene activation, with knockdown 
phenotypes comparable in magnitude to a classic heterochromatin regulator (Figure 4-
6D). We find that RBMX/L1 and SUV39H1 inhibit TF-mediated gene induction at many 
sites where they are otherwise dispensable for silencing, suggesting that gene induction 
assays using alternative-lineage TFs may be important to test the functionality of 
heterochromatin proteins. 
Heterochromatin regulation is instrumental to cell fate control in development and 
iPS reprogramming. Our findings support a role for heterochromatin in impeding 
conversion between mature lineages, they define subtypes of heterochromatin that 
contribute differentially to this barrier, and they reveal a large resource of proteins that can 
be investigated in order to overcome it.  Understanding the general and specific aspects 
of heterochromatin, starting with the datasets provided here, could lead to the selective 
opening of silent chromatin domains and more efficient cellular reprogramming to new, 
fully differentiated types of cells. 
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4.6  MAIN FIGURES 
 
Figure 4-1. Heterochromatic regions can be enriched and mapped genomically by 
isolating sonication-resistant chromatin. 
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 (A) The positions of DBRs (black bars; Soufi et al., 2012) compared to H3K9m3 ChIP-
seq for IMR90 fibroblasts (Roadmap Epigenomics consortium, GSE16256) with and 
without normalization to input. Red arrows indicate regions of depletion in the input track 
alone. 
(B) Crosslinked, sonicated chromatin from human BJ fibroblasts was separated on a 
sucrose gradient. Agarose gel shows the size ranges of DNA purified from each fraction. 
Boxes indicate the fractions used as the euchromatin and structural heterochromatin 
(strucHC) samples in subsequent analyses. 
(C) qPCR on DNA isolated from sucrose gradient fractions from BJ fibroblasts. Based on 
prior work (Soufi et al., 2012), all qPCR sites (red and blue) contain binding sites for 
OCT4/SOX2 in ES cells, but red sites fall inside DBR domains and lack OCT4/SOX2 
binding in fibroblasts. An equal DNA mass was loaded per fraction, and results were 
averaged from two biological replicates. Error bars show SEM among tested qPCR sites. 
(D) Plan for ChIP and gradient-purified samples used for DNA sequencing. 
(E) Sequencing signal per domain in strucHC gradient fraction minus input. For each point, 
signal is averaged over an entire domain, which is either a DBR (red) or the flanking 2 MB 
on both sides of a DBR (blue). Black lines show the median and interquartile ranges. P 
value by Wilcoxon rank sum test. 
(F) Browser view of 18 MB segment of chr12 showing physical mapping of chromatin 
structure by Gradient-seq in foreskin fibroblasts compared to ChIP-seq signals for 
repressive histone marks. Horizontal, colored bars above sequencing tracks indicate 
enriched domains called by a sliding window algorithm. The pattern in the strucHC fraction 
has broad similarity to H3K9me3 domains, which include DBRs (purple arrows), and anti-
correlates with the signal in the Euchromatin fraction and gene expression by mRNA-seq. 
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However, some strucHC domains contain chromatin co-marked by H3K9me3 and 
H3K27me3 (red arrows), or H3K27me3 alone (green arrows). “strucHC + K9 IP” indicates 
the H3K9me3 IP performed using the strucHC fraction chromatin. H3K27me3 ChIP data 
was obtained from the Epigenomics Roadmap consortium. 
  114 
 
Figure 4-2. The genomic landscape of structural heterochromatin contains distinct 
histone modification signatures and cell type-inappropriate genes. 
(A) Spearman correlation analysis and unsupervised clustering of ChIP- and Gradient-seq 
datasets. Samples were compared using their input-normalized tag density binned into 10 
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kb sliding windows. Data from the Epigenomics Roadmap is labeled with “(R)”; all other 
samples were sequenced in this study. 
(B) Histone mark levels, normalized for input, over the width of strucHC domains, using 
Roadmap Epigenomics data. The plots show an average of all 28,807 strucHC domains, 
weighted by domain length.  An additional 14 acetyl marks depleted in strucHC are not 
shown. 
(C) Schematic showing the distribution of H3K9me3 and H3K27me3 domains across the 
three structural categories defined by Gradient-seq. In the strucHC category, domains are 
drawn to scale, to indicate the number of megabases (MB) of overlap. 
(D) Expression levels of genes within the three structural categories of chromatin defined 
by Gradient-seq. Boxplots show mRNA-seq tag counts per gene, normalized by DESeq2 
and divided by gene length (whiskers: 5th and 95th percentiles). P values by Wilcoxon rank 
sum test. 
(E) Gene Ontology (GO) analysis of Refseq genes inside strucHC domains. GO terms 
were manually filtered to remove redundant categories. FDR was computed by Benjamini-
Hochberg. Shown are the top 15 most significant terms, sorted by gene count. 
(F) Rates of methylation per CpG were determined by whole-genome bisulfite sequencing 
(Roadmap Epigenomics consortium data for foreskin fibroblasts, GSM1127120). The 
distribution of methylation rates was plotted for each category (whiskers: 10th and 90th 
percentiles). P values by Wilcoxon rank sum test. 
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Figure 4-3. A subset of H3K9me3 and H3K27me3 domains are structurally 
euchromatic and permissive to transcription. 
(A) Browser view of euchromatic H3K9me3 domains over ZNF gene family cluster, which 
is depleted from strucHC. Note the mRNA-seq signal indicating transcription of these 
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genes. The “euchr. + K9 IP” track shows the H3K9me3 ChIP performed off of the 
euchromatic (“Euchr.”) fraction of the gradient. 
(B) Genes in euchromatic H3K9me3 and H3K27me3 domains are largely expressed, in 
contrast to the strucHC or intermediate (“int.”) subtypes, which contain mostly silent genes. 
Boxplots show mRNA-seq tag counts per gene, normalized by DESeq2 and divided by 
gene length (whiskers: 5th and 95th percentiles). The number of genes per category is 
shown in parentheses. P values by Wilcoxon rank sum test. 
(C) Gene annotation for euchromatic subtypes of H3K9me3 and H3K27me3 domains, 
using the InterPro database of protein families. FDR was computed by Benjamini-
Hochberg. Redundant terms were omitted. 
(D) Analysis of genomic sites reported to lose H3K9me3 after depletion of the HUSH 
complex/SETDB1 (Tchasovnikarova et al., 2015). Shown are the number of such sites 
(left) and the frequency of sites per MB (right) per chromatin category. 
 (E) Browser view of euchromatic H3K27me3 (“K27”) domain over HOX-A gene cluster. 
 (F) Fraction of satellite repeat types overlapping with strucHC versus euchromatic 
H3K9me3 domains. Asterisks indicate significantly enrichment (FDR < 0.05) in strucHC 
(red) or euchromatic H3K9me3 (blue) based on 1000 simulations of randomly shuffled 
domains. 
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Figure 4-4. Relationship between structural subtypes of histone mark domains 
and hallmark properties of heterochromatin. 
(A) Genomic windows (10-kb size, 500-bp sliding step) were classified by their association 
with strucHC, intermediate (“int”), or euchromatin (“euchr”) domains, and also by their 
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presence inside or outside H3K9me3 and H3K27me3 domains. Windows were then 
scored for their sequencing signal in the strucHC fraction divided by the euchromatin 
fraction, and the distribution of scores per category is plotted (whiskers: 5th and 95th 
percentiles). 
(B) The frequency of methylation per CpG was determined by whole-genome bisulfite 
sequencing (Roadmap consortium data for foreskin fibroblasts, GSM1127120). For CpGs 
falling within CpG islands, the distribution of methylation frequencies was plotted for each 
chromatin category (whiskers: 10th and 90th percentiles). 
(C) As in Panel A, except that 10-kb windows are scored based on the IMR90 lamin B1 
ChIP-seq signal (reads per million sequenced) divided by the corresponding input signal 
(Dou et al., 2015). 
(D) As in Panel A, except that 10-kb windows are scored based the number of DNase-seq 
reads per million reads mapped, averaged across two replicates, using ENCODE data for 
BJ fibroblasts (Thurman et al., 2012). 
(E) BJ fibroblast Repli-seq reads (Pope et al., 2014) for each cell cycle phase were 
intersected with each domain type, and the number of intersecting reads were normalized 
for sequencing depth and expressed as a fraction of the total signal for that domain type, 
so that each column sums to 1. 
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Figure 4-5. Proteomic analysis of purified H3K9me3-marked heterochromatin. 
(A)  Summary of quantitative proteomics study of 3 purified fractions. 
(B) Proteins were scored by their relative rank between samples (x axis) and the 
significance of the difference between samples (T-test, y-axis). Proteins significantly 
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enriched in the strucHC + H3K9me3 IP compared to gradient top (orange dots) were 
defined as heterochromatin proteins. Proteins detected in strucHC + H3K9me3 IP, but 
without significant difference from gradient top (grey dots) were defined as shared 
proteins. 
(C) Overlap of strucHC-enriched proteins with two groups of proteins (heterochromatin 
and shared) that were detected in the strucHC + H3K9me3 IP. 
(D) Top: List of a selection of heterochromatin proteins that were previously shown to 
contribute to heterochromatin and/or gene repression. Bottom: the 172 heterochromatin 
proteins were sorted and plotted by their fold-enrichment in the strucHC + H3K9me3 
(relative to gradient top), with the selected proteins above indicated by orange dots. 
RBMX, a focus of subsequent studies, is indicated in red. References: 1Thompson et al., 
2015; 2Dong et al., 2009; 3Mathur et al., 2001; 4van Dijk et al., 2010; 5Hayashihara et al., 
2010; 6Vermeulen et al., 2010. 
(E) Percentage of each proteomic category (eg, heterochromatin proteins) that is found in 
each published dataset. The raw number of proteins found in common is listed below the 
bars. Significance were computed relative to the background overlap for the total set of 
3,097 MS-detected proteins: *p<0.05, **p<0.001. 
(F) Percentage of proteins that overlap with each dataset, as in Panel E, plotted for the 
total set of 172 heterochromatins and for the heterochromatin proteins that have RNA-
binding activity according to (Gerstberger et al., 2014). 
(G) As in Panel D (bottom), but proteins recurrently mutated in ALS (Cirulli et al., 2015) 
are indicated in green. 
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Figure 4-6. H3K9me3 domains and heterochromatin proteins impede the activation 
of hepatic genes in fibroblasts. 
(A) Violin plots showing the levels of gene activation during hiHep reprogramming. 
Microarray data (Huang et al., 2014) was curated for genes expressed in cultured 
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hepatocytes over fibroblasts. Expression of these genes in hiHep cells was plotted on a 
relative scale ranging from fibroblast levels (0%) to hepatocyte levels (100%), using log2-
transformed values. Median values indicated by white circles. P values calculated versus 
all hepatic genes by Wilcoxon rank sum test. 
(B) Examples of hepatic genes in fibroblast H3K9me3 domains (strucHC or intermediate 
subtypes) that were analyzed in part (A), grouped according to protein function. 
(C) Browser views comparing fibroblast (“fib.”) and liver chromatin state and expression 
levels at hepatic genes. For both tissues, ChIP-seq data for H3K9me3 and H3K27me3 
and mRNA-seq data were obtained from the Epigenomics Roadmap (Bernstein et al., 
2010). Red arrows indicate liver-specific mRNA-seq signal for the labeled genes. 
(D) RT-PCR for hepatic genes marked by H3K9me3 in fibroblasts, after two cycles of 
siRNA transfection. Knockdowns were performed in fibroblasts expressing the hepatic TFs 
FOXA3, HNF1A, and HNF4A (left) and in fibroblasts without ectopic TF expression (right). 
Error bars show the SEM of two biological replicates. P values by Student’s T test. 
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Figure 4-7. RBMX is required to suppress transcriptional activation at diverse 
genes in strucHC domains. 
(A) Diagram of mRNA-seq experiment, performed under two conditions: with and without 
expression of the hepatic factors FOXA3, HNF1A, and HNF4A for hiHep reprogramming.  
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(B) Genes significantly upregulated by SUV39H1 and RBMX/L1 siRNA, compared to 
control siRNA, in the presence of hiHep factors. Genes downregulated by the hiHep 
factors in the control siRNA condition were removed from consideration. P-value indicates 
the significance of the overlap between gene sets. 
(C) Comparison of fold-changes induced by SUV39H1 siRNA versus RBMX/L1 siRNA, in 
the presence of hihep factors, at genes inside strucHC domains. Genes are color-coded 
based on whether they were upregulated with statistical significance (Padj < 0.05) in one 
sample, the other, or both. The extent of overlap of statistically upregulated strucHC genes 
is shown in the Venn diagram. 
(D) Browser views of genes in strucHC that are upregulated by si-SUV39H1 and si-
RBMX/L1 in the presence of hepatic factors. Note the mRNA-seq signal when either 
siRNA is added in the presence of factors (red arrows), but not in control siRNA samples 
or in the absence of factors. H3K27me3 data was obtained from the Epigenomics 
Roadmap; all other samples were sequenced in this study. 
(E) Browser view of gene in strucHC that is upregulated by si-RBMX/L1 both in the 
presence and absence of hepatic factors. 
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4.7  SUPPLEMENTARY FIGURES 
 
Supplementary Figure 4-1. H3K9me3-marked heterochromatin impedes hiHep 
reprogramming, resists sonication, and is enriched by gradient sedimentation. 
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(A) Violin plots showing the levels of gene activation during hiHep reprogramming. 
Microarray data (Huang et al., 2014) was curated for genes silent in fibroblasts and 
expressed in cultured hepatocytes. Genes were then classified by histone mark in 
fibroblasts (starting cell type) using Roadmap Epigenomics ChIP-seq data. Expression of 
these genes in hiHep cells was plotted on a relative scale ranging from fibroblast levels 
(0%) to hepatocyte levels (100%), using log2-transformed values. Median values indicated 
by white circles. P values calculated by Wilcoxon rank sum test. 
(B) H3K9me3 ChIP-seq profiles for various human cell and tissue types, comparing input-
normalized signal (purple) to unnormalized signal (yellow). Data obtained from the 
Epigenomics Roadmap consortium (Bernstein et al, 2010). Some domains of H3K9me3 
enrichment over input are present constitutively across differentiated tissues (black box), 
whereas others are present in non-fibroblast tissues (blue box) or are specific to fibroblasts 
and similar tissue types (green box). 
(C) qPCR for DBR and non-DBR sites, plotted relative to the average of the non-DBR 
sites. Fraction #14 was the gradient fraction showing greatest DBR enrichment. Error bars 
show SEM of qPCR sites tested. 
(D) Rate of chromatin recovery by H3K9me3-directed IP, comparing IP from gradient 
fractions versus IP from input chromatin (conventional ChIP). DNA yield measured by 
PicoGreen assay. 
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Supplementary Figure 4-2. Preparation of sequencing libraries for Gradient-seq. 
(A) Agarose gel showing sonication of purified DNA for Gradient-seq experiment, to shear 
large fragments down to a ~200 bp size for library preparation and sequencing. 
(B) Number of reads for each DNA sequencing sample, showing the proportion of reads 
that aligned to the genome and passed filtering to remove duplicate reads. “+K9 IP” 
indicates the H3K9me3 IPs performed from the strucHC and euchromatin (“euchr.”) 
fractions. 
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Supplementary Figure 4-3. Characterization of euchromatic subtype of H3K9me3 
domains. 
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(A) Histone mark levels in human fibroblasts, normalized for input, plotted over subtypes 
of H3K9me3 domains: the strucHC/intermediate subtypes (left), and the euchromatic 
subtype (right). All ChIP-seq data was obtained from the Roadmap Epigenomics 
consortium (Bernstein et al, 2010), except for H3K9me2 ChIP-seq data (Chandra et al, 
2012). 
(B) Browser view showing enrichment of H3K36me3 (green arrow) in euchromatic 
H3K9me3 domains containing with transcribed genes. Note that the gaps in H3K9me3 
domains (diminution of H3K9me3 signal) coincide with H3K4me3-marked active gene 
promoters. 
(C) Among genomic sites that depend upon the HUSH complex and SETDB1 for 
H3K9me3 levels, we plotted the fold-change in H3K9me3 upon deletion of HUSH 
components and SETDB1, using data from (Tchasovnikarova et al, 2015). The 12 most 
HUSH-dependent sites (points in blue circle) all fell inside the euchromatic subtype of 
H3K9me3. 
(D) Brower view showing overlap of euchromatic H3K9me3 domains over HSATII repeats, 
which are also Dnase I-hypersensitive (Roadmap Epigenomics track for IMR90 
fibroblasts). View is proximal to the chr7 centromere (coordinates 61,721,000-
61,871,000). 
(E) Structural subtypes of H3K9me3 and H3K27me3 domains were compared for rates of 
noncoding mutations per gene, averaged across all human cancers, using data from 
(Lawrence et al, 2013). P values calculated by Wilcoxon rank sum test. Whiskers: 5th - 95th 
percentiles. 
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Supplementary Figure 4-4. Relationship of chromatin subtypes from Gradient-seq 
to DNA methylation, MNase sensitivity, and lamina association. 
(A) This plot considers only CpG dinucleotides that are not part of CpG islands. Using 
Gradient-seq data, chromatin was classified into strucHC, intermediate (“int”), and 
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euchromatin (“euchr”) categories, for the total mappable genome (“total”), within H3K9me3 
and H3K27me3 domains, or outside of those domains (“neither mark enriched”). Whole-
genome bisulfite sequencing (Roadmap consortium data for foreskin fibroblasts, 
GSM1127120) was used to determine the frequency of methylation per CpG dinucleotide. 
The distribution of methylation frequencies is plotted for non-CpG-island CpGs falling 
within each chromatin subtype (whiskers: 10th and 90th percentiles). 
(B) MACC scores, where higher MACC indicate that chromatin is more sensitive to 
MNase, were determined on a 500-bin basis for K562 cells by Mieczkowski et al., 2016. 
MACC scores were averaged across 10-kb sliding windows, and the distribution of MACC 
scores is plotted for all 10-kb windows falling inside a given chromatin subtype (whiskers: 
5th and 95th percentiles). 
(C) Browser views comparing MACC signal in K562 cells (Mieczkowski et al., 2016) and 
Gradient-seq signal in foreskin fibroblasts, using regions with similar patterns of 
H3K9me3, H3K27me3, and H3K36me3 histone marks between the two cell types. 
Gradient-seq signal is plotted as the euchromatin signal minus the strucHC signal (“euchr 
- strucHC"). Left: Note that the pattern of euchr/strucHC domains is highly similar to the 
pattern of positive/negative MACC signal, in regions where both cell types have similar 
H3K9me3 (without H3K36me3) domains or H3K27me3 domains. Right: Sites bearing 
H3K9me3 and H3K36me3 in both cell types are classified as euchromatin according to 
Gradient-seq, but have negative MACC scores, indicating MNase resistance. All histone 
mark tracks are replicate-pooled and input-subtracted. Foreskin fibroblast H3K27me3 and 
H3K36me3 ChIP-seq data was obtained from the Epigenomics Roadmap (GSE16368); 
H3K9me3 ChIP-seq was from this study. K562 ChIP-seq data was downloaded from 
ENCODE (GSE29611). 
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(D) Rate of overlap between each chromatin subtype and Lamina Associated Domains 
(LADs) mapped in IMR90 fibroblasts (Guelen et al., 2008). The number of megabases of 
overlap divided by the number of megabases total in the chromatin subtype was used to 
calculate the percentage. 
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Supplementary Figure 4-5. Heterochromatin proteins such as TARDBP impede iPS 
reprogramming and contribute to heterochromatic silencing in human cells. 
(A) Proteomic categories were compared to lists of iPS repressors (proteins whose 
knockdown increases reprogramming) and iPS effectors (knockdown inhibits 
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repreogramming) from a genome-wide RNAi screen (Toh et al., 2016). The ratio of 
repressors to effectors is plotted for each category, and the numbers of repressors and 
effectors are listed above the bar. Asterisk indicates P < 0.05 by simulation test. 
(B) Listed are heterochromatin proteins whose knockdown has previously been shown to 
enhance iPS reprogramming efficiency, along with the corresponding reference. Note that 
TARDBP knockdown was found to enhance reprogramming in two genome-wide screens. 
1Han et al., 2013; 2Bao et al., 2015. 
(C) Both scatterplots compare gene expression in fibroblasts from ALS patients to 
fibroblasts from healthy controls, using published microarray data (Highley et al, 2014). 
Left plot: in fibroblasts from TARDBP-mutant ALS patients, there is upregulation of genes 
in strucHC (red dots) compared to controls. Right plot: no upregulation of strucHC genes 
is observed in fibroblasts from sporadic ALS patients, which lack germline TARDBP 
mutation. 
(D) Analysis of microarray data for ALS patient-derived fibroblasts (Highley et al, 2014), 
with expression plotted for genes in the 3 structural chromatin categories defined by 
Gradient-seq. Gene expression is normalized relative to the average of healthy patients 
(n=6). Sporadic ALS cases (no germline TARDBP mutation) serve as a control for 
TARDBP-mutant fibroblasts. P values calculated using Wilcoxon signed rank test (paired), 
comparing TARDBP-mutant samples to sporadic ALS samples for the same chromatin 
category. Whiskers: 5th - 95th percentiles. 
(E) Same as Panel D, but showing gene expression for the subtypes of H3K9me3 and 
H3K27me3 domains. Boxplots are shown for TARDBP mutant fibroblasts (T) and 
fibroblasts from patients with sporadic ALS (S). 
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Supplementary Figure 4-6. Knockdown of SUV39H1 and RBMX/L1 enhances 
hepatic gene activation during hiHep reprogramming. 
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(A) Immunofluorescence imaging confirming induction of hepatic markers after 14 days of 
hiHep reprogramming with FOXA3, HNF1A, and HNF4A, compared to uninfected 
fibroblasts cultured under the same conditions. Scale bars, 50μM. 
(B) Western blots in fibroblasts after two cycles of SUV39H1 siRNA, compared to non-
targeting control siRNA. 
(C) RT-PCR showing that RBMX/L1 siRNAs deplete transcripts for both RBMX and 
RBMXL1, after two cycles of siRNA transfection. Error bars show the SEM of three 
biological replicates. P values by Student’s T test. 
(D) Western blots for RBMX protein in fibroblasts after two cycles of siRNA transfection. 
(E) RT-PCR analysis of fibroblasts treated with two cycles of siRNA, followed by hiHep 
reprogramming for 14 days. Three independent siRNAs were tested for the RBMX/L1 
knockdown condition; all other samples have two biological replicates shown. 
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Supplementary Figure 4-7. RBMX represses select strucHC genes in the absence 
of ectopic transcription factors. 
(A) Comparison of mRNA-seq samples by Euclidean distance, using the normalized gene 
expression scores for each sample. Each sample type has two biological replicates that 
cluster together. The two experimental conditions, “hiHep condition” and “no TF condition”, 
refer to siRNA knockdowns performed in the presence and absence of hiHep transcription 
factors, respectively. The green box highlights the clustering of SUV39H1 siRNA and 
RBMX/L1 siRNA in the hiHep condition. 
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(B) Venn diagram of genes significantly upregulated by SUV39H1 and RBMX/L1 siRNA, 
compared to control siRNA, in the absence of ectopic transcription factors. P-value 
indicates the significance of the overlap between gene sets. 
(C) Among genes inside strucHC domains, comparison of genes upregulated by 
SUV39H1 and RBMX/L1 siRNA in the no TF condition.  
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4.8  TABLES 
 
Table 4-1. List of genes in the euchromatic subtype of fibroblast H3K9me3 
domains. 
Refseq genes with at least 50% overlap with euchromatic H3K9me3 domains were 
identified and collapsed down to 308 unique gene symbols. The amount of overlap is 
reported in the right-most column, as a fraction of the gene body length. (If there were 
multiple Refseq genes for a given symbol, the one with the highest rate of overlap was 
chosen.) 
RefSeq ID gene symbol name fraction of gene 
in domain 
NR_002451 ABCA11P 
ATP binding cassette subfamily A member 11, 
pseudogene 0.94 
NM_000677 ADORA3 adenosine A3 receptor 0.84 
NM_139058 ARX aristaless related homeobox 0.98 
NM_001098169 BSX brain specific homeobox 1 
NM_144645 C4orf36 chromosome 4 open reading frame 36 0.52 
NM_001017978 CT83 cancer/testis antigen 83 1 
NR_033339 CTBP1-AS2 CTBP1 antisense RNA 2 (head to head) 0.5 
NM_001565 CXCL10 C-X-C motif chemokine ligand 10 1 
NM_001029865 DBX1 developing brain homeobox 1 1 
NM_001037499 DEFB114 defensin beta 114 1 
NM_001426 EN1 engrailed homeobox 1 1 
NM_001278182 EOMES eomesodermin 1 
NM_001007253 ERV3-1 endogenous retrovirus group 3 member 1 0.78 
NM_001080458 EVX2 even-skipped homeobox 2 1 
NM_022774 EXO5 exonuclease 5 0.86 
NM_012159 FBXL21 
F-box and leucine rich repeat protein 21 
(gene/pseudogene) 0.88 
NM_005249 FOXG1 forkhead box G1 1 
NR_026718 FOXO3B forkhead box O3B pseudogene 1 
NR_102763 GATA6-AS1 GATA6 antisense RNA 1 (head to head) 1 
NM_001301687 GBX2 gastrulation brain homeobox 2 1 
NM_004821 HAND1 heart and neural crest derivatives expressed 1 1 
NM_001105574 HMX3 H6 family homeobox 3 1 
NR_033205 HOXB-AS3 HOXB cluster antisense RNA 3 0.74 
NM_018952 HOXB6 homeobox B6 0.79 
NM_004502 HOXB7 homeobox B7 1 
NM_024016 HOXB8 homeobox B8 0.88 
NM_017410 HOXC13 homeobox C13 1 
NR_047507 HOXC13-AS HOXC13 antisense RNA 1 
NR_038435 HOXD-AS2 HOXD cluster antisense RNA 2 1 
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NR_023915 IPW 
imprinted in Prader-Willi syndrome (non-protein 
coding) 0.78 
NM_001320334 KIAA1143 KIAA1143 0.58 
NM_152349 KRT222 keratin 222 0.9 
NM_005568 LHX1 LIM homeobox 1 0.87 
NR_038400 LINC00308 long intergenic non-protein coding RNA 308 0.53 
NR_135279 LINC00334 long intergenic non-protein coding RNA 334 0.61 
NR_103734 LINC00342 long intergenic non-protein coding RNA 342 0.84 
NR_104059 LINC00397 long intergenic non-protein coding RNA 397 1 
NR_024383 LINC00461 long intergenic non-protein coding RNA 461 1 
NR_047483 LINC00554 long intergenic non-protein coding RNA 554 0.95 
NR_038914 LINC01349 long intergenic non-protein coding RNA 1349 0.55 
NR_120618 LINC01475 long intergenic non-protein coding RNA 1475 1 
NR_026732 LINC01551 long intergenic non-protein coding RNA 1551 1 
NR_036508 LOC100128398  1 
NR_104179 LOC100289333  0.64 
NR_135129 LOC100505588  1 
NR_134920 LOC101928238  1 
NR_110091 LOC101928597  1 
NR_125869 LOC102723883  0.85 
NR_110544 LOC102724188  0.79 
NR_135110 LOC105376633  0.59 
NM_032517 LYZL1 lysozyme like 1 0.61 
NM_001308244 MAPK9 mitogen-activated protein kinase 9 0.61 
NM_001190787 MCIDAS 
multiciliate differentiation and DNA synthesis 
associated cell cycle protein 1 
NR_036053 MIR1270 microRNA 1270 1 
NR_036235 MIR4273 microRNA 4273 1 
NR_039722 MIR4500 microRNA 4500 1 
NR_030297 MIR571 microRNA 571 1 
NR_030373 MIR643 microRNA 643 1 
NR_106898 MIR6839 microRNA 6839 1 
NR_030741 MIR9-2 microRNA 9-2 1 
NM_145285 NKX2-3 NK2 homeobox 3 1 
NM_030905 OR2J2 olfactory receptor family 2 subfamily J member 2 1 
NM_032109 OTP orthopedia homeobox 1 
NM_001310159 PAX6 paired box 6 0.66 
NR_046636 PCDH9-AS3 PCDH9 antisense RNA 3 0.7 
NM_032009 PCDHGA2 protocadherin gamma subfamily A, 2 1 
NM_032011 PCDHGA3 protocadherin gamma subfamily A, 3 1 
NM_032053 PCDHGA4 protocadherin gamma subfamily A, 4 1 
NM_032054 PCDHGA5 protocadherin gamma subfamily A, 5 1 
NM_032086 PCDHGA6 protocadherin gamma subfamily A, 6 1 
NM_032087 PCDHGA7 protocadherin gamma subfamily A, 7 0.93 
NM_014004 PCDHGA8 protocadherin gamma subfamily A, 8 1 
NM_032089 PCDHGA9 protocadherin gamma subfamily A, 9 1 
NM_032096 PCDHGB2 protocadherin gamma subfamily B, 2 1 
NM_032097 PCDHGB3 protocadherin gamma subfamily B, 3 1 
NM_032098 PCDHGB4 protocadherin gamma subfamily B, 4 1 
NM_032099 PCDHGB5 protocadherin gamma subfamily B, 5 1 
NM_003924 PHOX2B paired like homeobox 2b 1 
NM_021620 PRDM13 PR/SET domain 13 1 
NR_023917 PTENP1 phosphatase and tensin homolog pseudogene 1 1 
NR_103745 PTENP1-AS PTENP1 antisense RNA 0.81 
NM_001080521 RASSF10 Ras association domain family member 10 0.62 
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NM_021163 RBAK RB associated KRAB zinc finger 0.64 
NM_001204513 
RBAK-
RBAKDN RBAK-RBAKDN readthrough 0.55 
NR_125730 RNU6-2 RNA, U6 small nuclear 2 1 
NM_001193307 SAMD9 sterile alpha motif domain containing 9 0.77 
NR_026830 SATB2-AS1 SATB2 antisense RNA 1 1 
NM_152679 SLC10A4 solute carrier family 10 member 4 0.82 
NM_005642 TAF7 TATA-box binding protein associated factor 7 1 
NM_006593 TBR1 T-box, brain 1 0.55 
NM_033208 TIGD7 tigger transposable element derived 7 0.56 
NM_016170 TLX2 T-cell leukemia homeobox 2 1 
NR_037893 TMCC1-AS1 TMCC1 antisense RNA 1 (head to head) 0.55 
NM_020683 TMIGD3 
transmembrane and immunoglobulin domain 
containing 3 0.53 
NR_003148 TPM3P9 tropomyosin 3 pseudogene 9 0.78 
NR_001524 TTTY3 
testis-specific transcript, Y-linked 3 (non-protein 
coding) 1 
NR_002176 TTTY3B 
testis-specific transcript, Y-linked 3B (non-protein 
coding) 1 
NM_020633 VN1R1 vomeronasal 1 receptor 1 1 
NM_175619 ZAR1 zygote arrest 1 0.78 
NM_203303 ZCCHC13 zinc finger CCHC-type containing 13 1 
NM_001318475 ZFP1 ZFP1 zinc finger protein 0.5 
NM_001308440 ZFP28 ZFP28 zinc finger protein 1 
NM_153018 ZFP3 ZFP3 zinc finger protein 0.71 
NM_001320666 ZFP30 ZFP30 zinc finger protein 0.81 
NM_001282515 ZFP37 ZFP37 zinc finger protein 1 
NM_001320178 ZFP69 ZFP69 zinc finger protein 0.68 
NM_023070 ZFP69B ZFP69 zinc finger protein B 0.91 
NM_133466 ZFP82 ZFP82 zinc finger protein 0.96 
NM_001305203 ZFP90 ZFP90 zinc finger protein 0.84 
NM_033132 ZIC5 Zic family member 5 0.69 
NM_001010879 ZIK1 zinc finger protein interacting with K protein 1 0.77 
NM_173531 ZNF100 zinc finger protein 100 0.61 
NM_033204 ZNF101 zinc finger protein 101 0.75 
NM_001013746 ZNF107 zinc finger protein 107 0.6 
NM_015852 ZNF117 zinc finger protein 117 1 
NM_006956 ZNF12 zinc finger protein 12 0.81 
NM_001008727 ZNF121 zinc finger protein 121 0.78 
NM_001297568 ZNF124 zinc finger protein 124 0.81 
NM_003433 ZNF132 zinc finger protein 132 1 
NM_003435 ZNF134 zinc finger protein 134 1 
NR_023311 ZNF137P zinc finger protein 137, pseudogene 0.59 
NM_021030 ZNF14 zinc finger protein 14 1 
NM_001300776 ZNF140 zinc finger protein 140 1 
NM_003441 ZNF141 zinc finger protein 141 0.93 
NM_001029976 ZNF16 zinc finger protein 16 0.63 
NM_003450 ZNF174 zinc finger protein 174 0.84 
NM_007147 ZNF175 zinc finger protein 175 0.51 
NM_001172651 ZNF177 zinc finger protein 177 1 
NM_001278508 ZNF180 zinc finger protein 180 0.67 
NM_001029997 ZNF181 zinc finger protein 181 0.64 
NM_001007088 ZNF182 zinc finger protein 182 0.53 
NM_001318892 ZNF184 zinc finger protein 184 0.79 
NM_001130519 ZNF195 zinc finger protein 195 0.84 
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NM_006991 ZNF197 zinc finger protein 197 0.51 
NM_001203250 ZNF20 zinc finger protein 20 0.75 
NM_001145447 ZNF200 zinc finger protein 200 0.64 
NM_001265597 ZNF211 zinc finger protein 211 0.85 
NM_013359 ZNF221 zinc finger protein 221 0.54 
NM_001129996 ZNF222 zinc finger protein 222 0.68 
NM_001032372 ZNF226 zinc finger protein 226 0.75 
NM_014518 ZNF229 zinc finger protein 229 0.93 
NM_145911 ZNF23 zinc finger protein 23 0.79 
NM_001320952 ZNF232 zinc finger protein 232 0.84 
NM_005674 ZNF239 zinc finger protein 239 0.51 
NR_023392 ZNF252P zinc finger protein 252, pseudogene 0.63 
NM_021047 ZNF253 zinc finger protein 253 0.94 
NM_005773 ZNF256 zinc finger protein 256 0.55 
NM_001256279 ZNF26 zinc finger protein 26 0.94 
NM_001012756 ZNF260 zinc finger protein 260 0.87 
NM_005741 ZNF263 zinc finger protein 263 0.56 
NM_001265588 ZNF267 zinc finger protein 267 0.65 
NM_001165881 ZNF268 zinc finger protein 268 1 
NR_024565 ZNF271P zinc finger protein 271, pseudogene 0.69 
NM_021148 ZNF273 zinc finger protein 273 0.65 
NM_001278734 ZNF274 zinc finger protein 274 0.77 
NM_006969 ZNF28 zinc finger protein 28 0.51 
NM_001297752 ZNF283 zinc finger protein 283 0.88 
NM_001130842 ZNF286A zinc finger protein 286A 0.78 
NM_001145045 ZNF286B zinc finger protein 286B 0.89 
NM_020653 ZNF287 zinc finger protein 287 0.81 
NM_001172831 ZNF300 zinc finger protein 300 1 
NR_026867 ZNF300P1 zinc finger protein 300 pseudogene 1 1 
NM_001012320 ZNF302 zinc finger protein 302 0.74 
NM_001190791 ZNF317 zinc finger protein 317 0.63 
NM_001005368 ZNF32 zinc finger protein 32 0.66 
NR_047557 ZNF32-AS1 ZNF32 antisense RNA 1 1 
NR_047558 ZNF32-AS2 ZNF32 antisense RNA 2 0.53 
NM_207333 ZNF320 zinc finger protein 320 0.76 
NM_001242797 ZNF322 zinc finger protein 322 0.65 
NM_024620 ZNF329 zinc finger protein 329 0.72 
NM_001242475 ZNF345 zinc finger protein 345 0.97 
NM_001172674 ZNF347 zinc finger protein 347 0.74 
NM_021632 ZNF350 zinc finger protein 350 1 
NR_103847 ZNF350-AS1 ZNF350 antisense RNA 1 0.77 
NM_014594 ZNF354C zinc finger protein 354C 0.95 
NM_001007094 ZNF37A zinc finger protein 37A 0.89 
NR_026777 ZNF37BP zinc finger protein 37B, pseudogene 0.78 
NM_001256838 ZNF382 zinc finger protein 382 0.84 
NM_152604 ZNF383 zinc finger protein 383 1 
NM_032347 ZNF397 zinc finger protein 397 0.88 
NM_001033719 ZNF404 zinc finger protein 404 1 
NM_017879 ZNF416 zinc finger protein 416 1 
NM_001297734 ZNF417 zinc finger protein 417 0.86 
NM_144689 ZNF420 zinc finger protein 420 0.74 
NM_001300883 ZNF426 zinc finger protein 426 1 
NM_001001415 ZNF429 zinc finger protein 429 0.97 
NM_001256654 ZNF43 zinc finger protein 43 0.95 
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NM_014650 ZNF432 zinc finger protein 432 0.83 
NM_001080411 ZNF433 zinc finger protein 433 0.93 
NM_030634 ZNF436 zinc finger protein 436 0.85 
NM_152262 ZNF439 zinc finger protein 439 1 
NM_001164276 ZNF44 zinc finger protein 44 0.71 
NM_152357 ZNF440 zinc finger protein 440 0.53 
NM_152355 ZNF441 zinc finger protein 441 0.81 
NM_030824 ZNF442 zinc finger protein 442 0.51 
NM_005815 ZNF443 zinc finger protein 443 0.66 
NM_001297623 ZNF461 zinc finger protein 461 0.94 
NM_001008801 ZNF468 zinc finger protein 468 0.69 
NM_001001668 ZNF470 zinc finger protein 470 1 
NM_020813 ZNF471 zinc finger protein 471 0.87 
NM_001297624 ZNF480 zinc finger protein 480 0.91 
NM_133464 ZNF483 zinc finger protein 483 0.61 
NM_152356 ZNF491 zinc finger protein 491 0.79 
NM_001076678 ZNF493 zinc finger protein 493 0.95 
NM_001258280 ZNF501 zinc finger protein 501 1 
NM_001134440 ZNF502 zinc finger protein 502 1 
NM_001099269 ZNF506 zinc finger protein 506 1 
NM_001314059 ZNF510 zinc finger protein 510 0.79 
NM_001318005 ZNF514 zinc finger protein 514 0.94 
NM_145287 ZNF519 zinc finger protein 519 0.51 
NR_003699 ZNF525 zinc finger protein 525 0.54 
NM_032453 ZNF527 zinc finger protein 527 0.66 
NR_125345 ZNF528-AS1 ZNF528 antisense RNA 1 1 
NR_027239 ZNF529 zinc finger protein 529 0.93 
NR_110703 ZNF529-AS1 ZNF529 antisense RNA 1 0.88 
NM_152606 ZNF540 zinc finger protein 540 0.61 
NR_003127 ZNF542P zinc finger protein 542, pseudogene 0.91 
NM_001297763 ZNF546 zinc finger protein 546 0.56 
NM_001199295 ZNF549 zinc finger protein 549 0.9 
NM_001277090 ZNF550 zinc finger protein 550 0.63 
NM_001270938 ZNF551 zinc finger protein 551 1 
NM_001172775 ZNF555 zinc finger protein 555 0.74 
NM_001044387 ZNF557 zinc finger protein 557 0.81 
NM_001304350 ZNF558 zinc finger protein 558 0.62 
NM_001202406 ZNF559 zinc finger protein 559 1 
NM_001172650 
ZNF559-
ZNF177 ZNF559-ZNF177 readthrough 0.85 
NM_152289 ZNF561 zinc finger protein 561 0.75 
NM_001130031 ZNF562 zinc finger protein 562 0.91 
NM_145276 ZNF563 zinc finger protein 563 0.69 
NM_144976 ZNF564 zinc finger protein 564 0.72 
NM_152603 ZNF567 zinc finger protein 567 0.96 
NM_152484 ZNF569 zinc finger protein 569 0.81 
NM_144694 ZNF570 zinc finger protein 570 0.94 
NM_001290314 ZNF571 zinc finger protein 571 0.93 
NR_038249 ZNF571-AS1 ZNF571 antisense RNA 1 0.91 
NM_152412 ZNF572 zinc finger protein 572 1 
NR_037159 ZNF582-AS1 ZNF582 antisense RNA 1 (head to head) 0.55 
NM_001159860 ZNF583 zinc finger protein 583 1 
NR_110152 ZNF585A zinc finger protein 585A 1 
NM_152279 ZNF585B zinc finger protein 585B 0.57 
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NM_001077426 ZNF586 zinc finger protein 586 0.86 
NM_001204817 ZNF587 zinc finger protein 587 0.65 
NM_032530 ZNF594 zinc finger protein 594 0.95 
NM_001286052 ZNF595 zinc finger protein 595 0.66 
NM_001042415 ZNF596 zinc finger protein 596 0.73 
NM_001007248 ZNF599 zinc finger protein 599 0.89 
NM_001164715 ZNF605 zinc finger protein 605 0.83 
NM_025027 ZNF606 zinc finger protein 606 0.9 
NM_001031721 ZNF613 zinc finger protein 613 0.57 
NM_025040 ZNF614 zinc finger protein 614 0.92 
NM_001199324 ZNF615 zinc finger protein 615 0.91 
NM_178523 ZNF616 zinc finger protein 616 0.91 
NM_014789 ZNF623 zinc finger protein 623 0.77 
NM_145233 ZNF625 zinc finger protein 625 0.74 
NR_037802 ZNF625-ZNF20 ZNF625-ZNF20 readthrough (NMD candidate) 0.68 
NM_145297 ZNF626 zinc finger protein 626 1 
NM_173658 ZNF660 zinc finger protein 660 0.55 
NR_036521 ZNF667-AS1 ZNF667 antisense RNA 1 (head to head) 0.9 
NM_001142572 ZNF669 zinc finger protein 669 0.51 
NM_001317998 ZNF677 zinc finger protein 677 1 
NM_138286 ZNF681 zinc finger protein 681 0.79 
NM_021915 ZNF69 zinc finger protein 69 0.74 
NM_020394 ZNF695 zinc finger protein 695 0.54 
NM_198535 ZNF699 zinc finger protein 699 0.82 
NM_001282796 ZNF7 zinc finger protein 7 0.77 
NM_001271848 ZNF700 zinc finger protein 700 0.9 
NM_001172655 ZNF701 zinc finger protein 701 0.7 
NM_001290210 ZNF717 zinc finger protein 717 0.53 
NM_001289930 ZNF718 zinc finger protein 718 0.95 
NM_001130913 ZNF720 zinc finger protein 720 0.57 
NM_133474 ZNF721 zinc finger protein 721 0.88 
NR_045525 ZNF724P  0.94 
NM_001170905 ZNF736 zinc finger protein 736 0.8 
NM_001159293 ZNF737 zinc finger protein 737 0.96 
NR_027130 ZNF738 zinc finger protein 738 0.74 
NR_126069 ZNF75A zinc finger protein 75a 1 
NM_001185063 ZNF75D zinc finger protein 75D 1 
NM_001289952 ZNF761 zinc finger protein 761 1 
NM_001012753 ZNF763 zinc finger protein 763 0.53 
NM_001040185 ZNF765 zinc finger protein 765 0.79 
NM_001010851 ZNF766 zinc finger protein 766 0.75 
NM_001024596 ZNF772 zinc finger protein 772 1 
NR_130705 ZNF773 zinc finger protein 773 0.71 
NM_173632 ZNF776 zinc finger protein 776 0.93 
NM_001005851 ZNF780B zinc finger protein 780B 0.85 
NM_001242802 ZNF790 zinc finger protein 790 0.88 
NR_040027 ZNF790-AS1 ZNF790 antisense RNA 1 1 
NM_153358 ZNF791 zinc finger protein 791 0.59 
NM_001080821 ZNF799 zinc finger protein 799 0.59 
NM_001031665 ZNF816 zinc finger protein 816 0.91 
NR_073396 ZNF818P zinc finger protein 818, pseudogene 0.73 
NM_001080493 ZNF823 zinc finger protein 823 0.59 
NM_001171979 ZNF829 zinc finger protein 829 0.9 
NM_001102657 ZNF836 zinc finger protein 836 0.65 
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NM_001127372 ZNF84 zinc finger protein 84 1 
NM_001136499 ZNF841 zinc finger protein 841 1 
NM_001136501 ZNF844 zinc finger protein 844 0.92 
NM_138374 ZNF845 zinc finger protein 845 0.62 
NM_001077624 ZNF846 zinc finger protein 846 0.79 
NM_001193552 ZNF850 zinc finger protein 850 0.94 
NM_001287349 ZNF852 zinc finger protein 852 0.77 
NM_001136116 ZNF879 zinc finger protein 879 0.92 
NM_001145434 ZNF880 zinc finger protein 880 1 
NM_001277291 ZNF891 zinc finger protein 891 0.9 
NM_001300951 ZNF91 zinc finger protein 91 0.94 
NM_031218 ZNF93 zinc finger protein 93 0.72 
NM_152455 ZSCAN29 zinc finger and SCAN domain containing 29 0.94 
NM_001112734 ZSCAN30 zinc finger and SCAN domain containing 30 0.56 
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Table 4-2. List of strucHC-enriched proteins. 
Shown are the 217 proteins enriched in the strucHC fraction compared to the euchromatin 
fraction. The fold-enrichement column is computed by the relative change in protein rank 
between the samples. The right-most column indicates “Y” (yes) if the protein was also 
one of the 172 heterochromatin proteins (enriched in the strucHC + H3K9me3 IP sample). 
gene symbol protein fold-enrichment 
in strucHC vs 
euchromatin 
t-test het 
protein? 
EBNA1BP2 Probable rRNA-processing protein EBP2 18.2 0.0398 Y 
SRSF10 Serine/arginine-rich splicing factor 10 17.1 0.0221 Y 
RBMX RNA-binding motif protein, X chromosome 15.8 0.0047 Y 
SRSF9 Serine/arginine-rich splicing factor 9 13.4 0.0369 Y 
HNRNPA2B1 Heterogeneous nuclear ribonucleoproteins 
A2/B1 
13.0 0.0199 Y 
BRIX1 Ribosome biogenesis protein BRX1 homolog 12.5 0.0152 Y 
RRS1 Ribosome biogenesis regulatory protein homolog 12.2 0.0401 Y 
LLPH Protein LLP homolog 11.2 0.0430  
HNRNPC Heterogeneous nuclear ribonucleoproteins 
C1/C2 
10.8 0.0285 Y 
KHDRBS3 KH domain-containing, RNA-binding, signal 
transduction-associated protein 3 
10.7 0.0426 Y 
POLDIP3 Polymerase delta-interacting protein 3 10.5 0.0170 Y 
HNRNPM Heterogeneous nuclear ribonucleoprotein M 10.4 0.0004 Y 
RPF2 Ribosome production factor 2 homolog 9.9 0.0215 Y 
TRA2B Transformer-2 protein homolog beta 8.9 0.0013 Y 
ELN Elastin 8.4 0.0450  
RBM14 RNA-binding protein 14 8.1 0.0213 Y 
FTSJ3 pre-rRNA processing protein FTSJ3 8.1 0.0442 Y 
SRSF1 Serine/arginine-rich splicing factor 1 8.0 0.0039 Y 
NCOA5 Nuclear receptor coactivator 5 8.0 0.0416 Y 
HIST1H1A Histone H1.1 8.0 0.0096 Y 
GNL3 Guanine nucleotide-binding protein-like 3 7.8 0.0137 Y 
DDX27 Probable ATP-dependent RNA helicase DDX27 7.7 0.0325 Y 
DDX17 Probable ATP-dependent RNA helicase DDX17 7.7 0.0319 Y 
HNRNPK Heterogeneous nuclear ribonucleoprotein K 7.5 0.0057 Y 
GTPBP4 Nucleolar GTP-binding protein 1 7.4 0.0001 Y 
MATR3 Matrin-3 7.4 0.0143 Y 
FYTTD1 UAP56-interacting factor 7.1 0.0438 Y 
TAF15 TATA-binding protein-associated factor 2N 7.1 0.0086 Y 
ZNF326 DBIRD complex subunit ZNF326 7.1 0.0405 Y 
DDX5 Probable ATP-dependent RNA helicase DDX5 7.0 0.0383 Y 
RPL4 60S ribosomal protein L4 6.9 0.0021  
DCD Dermcidin 6.7 0.0047 Y 
HNRNPA0 Heterogeneous nuclear ribonucleoprotein A0 6.7 0.0017 Y 
HNRNPU Heterogeneous nuclear ribonucleoprotein U 6.5 0.0117 Y 
NOP2 Probable 28S rRNA (cytosine(4447)-C(5))-
methyltransferase 
6.4 0.0188 Y 
HNRNPR Heterogeneous nuclear ribonucleoprotein R 6.4 0.0385 Y 
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HNRNPH3 Heterogeneous nuclear ribonucleoprotein H3 6.4 0.0003 Y 
DDX54 ATP-dependent RNA helicase DDX54 6.3 0.0374 Y 
HNRNPF Heterogeneous nuclear ribonucleoprotein F 6.3 0.0044 Y 
NOP16 Nucleolar protein 16 6.3 0.0489  
TRA2A Transformer-2 protein homolog alpha 6.2 0.0002 Y 
HNRNPH1 Heterogeneous nuclear ribonucleoprotein H 6.2 0.0005 Y 
WDR46 WD repeat-containing protein 46 6.1 0.0500 Y 
NSA2 Ribosome biogenesis protein NSA2 homolog 6.0 0.0378  
H1F0 Histone H1.0 6.0 0.0048 Y 
CHTOP Chromatin target of PRMT1 protein 6.0 0.0015 Y 
SRSF7 Serine/arginine-rich splicing factor 7 6.0 0.0125 Y 
PPAN Suppressor of SWI4 1 homolog 6.0 0.0472 Y 
NOC3L Nucleolar complex protein 3 homolog 5.9 0.0351 Y 
ALYREF THO complex subunit 4 5.9 0.0039 Y 
KHDRBS1 KH domain-containing, RNA-binding, signal 
transduction-associated protein 1 
5.7 0.0076 Y 
HNRNPL Heterogeneous nuclear ribonucleoprotein L 5.7 0.0024 Y 
HNRNPDL Heterogeneous nuclear ribonucleoprotein D-like 5.7 0.0129 Y 
CCDC137 Coiled-coil domain-containing protein 137 5.6 0.0422  
BOP1 Ribosome biogenesis protein BOP1 5.6 0.0438  
EWSR1 RNA-binding protein EWS 5.5 0.0008 Y 
MAK16 Protein MAK16 homolog 5.3 0.0443  
SLTM SAFB-like transcription modulator 5.3 0.0294  
RALY RNA-binding protein Raly 5.3 0.0009 Y 
FUS RNA-binding protein FUS 5.2 0.0482 Y 
DDX56 Probable ATP-dependent RNA helicase DDX56 5.1 0.0484  
NONO Non-POU domain-containing octamer-binding 
protein 
5.0 0.0079 Y 
FN1 Fibronectin 5.0 0.0298  
PES1 Pescadillo homolog 4.9 0.0005 Y 
UTP14A U3 small nucleolar RNA-associated protein 14 
homolog A 
4.9 0.0500  
RBMXL1 RNA binding motif protein, X-linked-like-1 4.8 0.0480  
CCDC86 Coiled-coil domain-containing protein 86 4.7 0.0483  
RRP15 RRP15-like protein 4.6 0.0254  
RNPS1 RNA-binding protein with serine-rich domain 1 4.6 0.0362  
TRIM4 Tripartite motif-containing protein 4 4.6 0.0351  
NIFK MKI67 FHA domain-interacting nucleolar 
phosphoprotein 
4.5 0.0168  
RBFOX2 RNA binding protein fox-1 homolog 2 4.5 0.0083  
RBM28 RNA-binding protein 28 4.4 0.0412 Y 
S100A9 Protein S100-A9 4.4 0.0414 Y 
SAFB Scaffold attachment factor B1 4.4 0.0203 Y 
S100A8 Protein S100-A8 4.4 0.0439 Y 
SFPQ Splicing factor, proline- and glutamine-rich 4.2 0.0037 Y 
YTHDC1 YTH domain-containing protein 1 4.2 0.0401  
AKAP8 A-kinase anchor protein 8 4.2 0.0472 Y 
SRSF4 Serine/arginine-rich splicing factor 4 4.2 0.0354  
PWP2 Periodic tryptophan protein 2 homolog 4.1 0.0385 Y 
SAFB2 Scaffold attachment factor B2 4.1 0.0394  
NOL7 Nucleolar protein 7 4.1 0.0103  
GLTSCR2 Glioma tumor suppressor candidate region gene 
2 protein 
4.1 0.0401 Y 
MYEF2 Myelin expression factor 2 4.1 0.0496 Y 
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HNRNPUL1 Heterogeneous nuclear ribonucleoprotein U-like 
protein 1 
4.1 0.0029 Y 
FBN1 Fibrillin-1 4.0 0.0459  
HNRNPLL Heterogeneous nuclear ribonucleoprotein L-like 3.9 0.0261 Y 
CALML5 Calmodulin-like protein 5 3.9 0.0490  
RPL17 60S ribosomal protein L17 3.9 0.0066  
PUM3 Pumilio domain-containing protein KIAA0020 3.8 0.0397  
HNRNPUL2 Heterogeneous nuclear ribonucleoprotein U-like 
protein 2 
3.8 0.0244 Y 
HNRNPAB Heterogeneous nuclear ribonucleoprotein A/B 3.8 0.0456 Y 
DDX50 ATP-dependent RNA helicase DDX50 3.7 0.0307 Y 
SRSF6 Serine/arginine-rich splicing factor 6 3.7 0.0211 Y 
SRSF5 Serine/arginine-rich splicing factor 5 3.6 0.0221 Y 
RRP9 U3 small nucleolar RNA-interacting protein 2 3.6 0.0083  
DDX18 ATP-dependent RNA helicase DDX18 3.5 0.0203  
DIMT1 Probable dimethyladenosine transferase 3.4 0.0153  
HNRNPD Heterogeneous nuclear ribonucleoprotein D0 3.4 0.0043 Y 
H1FX Histone H1x 3.3 0.0381 Y 
ZNF438 Zinc finger protein 438 3.3 0.0273 Y 
RAVER1 Ribonucleoprotein PTB-binding 1 3.3 0.0228 Y 
YLPM1 YLP motif-containing protein 1 3.3 0.0500 Y 
RPL14 60S ribosomal protein L14 3.3 0.0329 Y 
TBL3 Transducin beta-like protein 3 3.3 0.0139 Y 
DDX21 Nucleolar RNA helicase 2 3.3 0.0151 Y 
SAP18 Histone deacetylase complex subunit SAP18 3.3 0.0198  
NAT10 N-acetyltransferase 10 3.2 0.0007  
RRP1 Ribosomal RNA processing protein 1 homolog A 3.2 0.0391  
KIAA2026 Uncharacterized protein KIAA2026 3.2 0.0109  
NOC2L Nucleolar complex protein 2 homolog 3.2 0.0388  
RBM15 Putative RNA-binding protein 15 3.1 0.0496 Y 
FBLN5 Fibulin-5 3.1 0.0480  
DDX47 Probable ATP-dependent RNA helicase DDX47 3.1 0.0291  
RSL1D1 Ribosomal L1 domain-containing protein 1 3.1 0.0027 Y 
LUC7L3 Luc7-like protein 3 3.0 0.0174  
XRN2 5-3 exoribonuclease 2 3.0 0.0030 Y 
WDR43 WD repeat-containing protein 43 3.0 0.0192 Y 
PSPC1 Paraspeckle component 1 3.0 0.0086 Y 
HSPG2 Basement membrane-specific heparan sulfate 
proteoglycan core protein 
2.9 0.0252  
DES Desmin 2.9 0.0155  
RPL24 60S ribosomal protein L24 2.9 0.0074 Y 
RPS6 40S ribosomal protein S6 2.8 0.0483  
RBM4 RNA-binding protein 4 2.8 0.0145 Y 
RPL21 60S ribosomal protein L21 2.8 0.0141  
MBNL1 Muscleblind-like protein 1 2.8 0.0001 Y 
ALKBH5 RNA demethylase ALKBH5 2.8 0.0411  
H2AFY Core histone macro-H2A.1 2.8 0.0050 Y 
ZFR Zinc finger RNA-binding protein 2.8 0.0263  
SHROOM3 Protein Shroom3 2.8 0.0250 Y 
NOP58 Nucleolar protein 58 2.7 0.0009 Y 
LUC7L2 Putative RNA-binding protein Luc7-like 2 2.7 0.0297  
CPSF7 Cleavage and polyadenylation specificity factor 
subunit 7 
2.7 0.0252 Y 
FBL rRNA 2-O-methyltransferase fibrillarin 2.7 0.0205 Y 
U2AF1 Splicing factor U2AF 35 kDa subunit 2.7 0.0069 Y 
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INTS7 Integrator complex subunit 7 2.7 0.0134  
KHSRP Far upstream element-binding protein 2 2.6 0.0075 Y 
ELAVL1 ELAV-like protein 1 2.6 0.0500 Y 
IMP3 U3 small nucleolar ribonucleoprotein protein 
IMP3 
2.6 0.0067  
PTDSS1 Phosphatidylserine synthase 1 2.6 0.0126 Y 
FUBP3 Far upstream element-binding protein 3 2.6 0.0127 Y 
RPS4Y1 40S ribosomal protein S4, Y isoform 1 2.6 0.0024 Y 
GAR1 H/ACA ribonucleoprotein complex subunit 1 2.5 0.0021 Y 
WDR12 Ribosome biogenesis protein WDR12 2.5 0.0142  
CTBP1 C-terminal-binding protein 1 2.5 0.0046  
FUBP1 Far upstream element-binding protein 1 2.5 0.0183 Y 
AAAS Aladin 2.4 0.0295  
PRPSAP2 Phosphoribosyl pyrophosphate synthase-
associated protein 2 
2.4 0.0246  
EIF6 Eukaryotic translation initiation factor 6 2.4 0.0234  
NOL11 Nucleolar protein 11 2.4 0.0480  
NLE1 Notchless protein homolog 1 2.4 0.0430  
HEATR1 HEAT repeat-containing protein 1 2.3 0.0468  
U2AF2 Splicing factor U2AF 65 kDa subunit 2.3 0.0342 Y 
CIRBP Cold-inducible RNA-binding protein 2.3 0.0231  
RPL18A 60S ribosomal protein L18a 2.3 0.0346  
PNO1 RNA-binding protein PNO1 2.3 0.0079  
CPSF6 Cleavage and polyadenylation specificity factor 
subunit 6 
2.3 0.0404 Y 
LYAR Cell growth-regulating nucleolar protein 2.2 0.0350  
MYBBP1A Myb-binding protein 1A 2.2 0.0235 Y 
RCC2 Protein RCC2 2.2 0.0025 Y 
CYR61 Protein CYR61 2.2 0.0109  
TARDBP TAR DNA-binding protein 43 2.2 0.0036 Y 
PWP1 Periodic tryptophan protein 1 homolog 2.2 0.0020  
NOP56 Nucleolar protein 56 2.2 0.0347 Y 
EMILIN1 EMILIN-1 2.1 0.0172  
CCAR2 Cell cycle and apoptosis regulator protein 2 2.1 0.0072  
SKIV2L2 Superkiller viralicidic activity 2-like 2 2.1 0.0156 Y 
LUC7L Putative RNA-binding protein Luc7-like 1 2.0 0.0295  
NEXN Nexilin 2.0 0.0437  
TIA1 Nucleolysin TIA-1 isoform p40 2.0 0.0147 Y 
MRTO4 mRNA turnover protein 4 homolog 2.0 0.0028  
SRRT Serrate RNA effector molecule homolog 2.0 0.0397  
NOL9 Polynucleotide 5-hydroxyl-kinase NOL9 1.9 0.0465  
TSPO Translocator protein 1.9 0.0383  
RBM22 Pre-mRNA-splicing factor RBM22 1.9 0.0494  
PTBP1 Polypyrimidine tract-binding protein 1 1.9 0.0283 Y 
EXOSC3 Exosome complex component RRP40 1.9 0.0029  
TGFBI Transforming growth factor-beta-induced protein 
ig-h3 
1.9 0.0144  
PRPF40A Pre-mRNA-processing factor 40 homolog A 1.9 0.0165  
SRI Sorcin 1.9 0.0179  
RBM12 RNA-binding protein 12 1.9 0.0232  
RCC1 Regulator of chromosome condensation 1.8 0.0080 Y 
ZNF207 BUB3-interacting and GLEBS motif-containing 
protein ZNF207 
1.8 0.0202  
EXOSC9 Exosome complex component RRP45 1.8 0.0008  
TRIP6 Thyroid receptor-interacting protein 6 1.7 0.0374  
  151 
DHX15 Putative pre-mRNA-splicing factor ATP-
dependent RNA helicase DHX15 
1.7 0.0377 Y 
NUP160 Nuclear pore complex protein Nup160 1.7 0.0318  
ELOVL5 Elongation of very long chain fatty acids protein 
5 
1.7 0.0391  
CTGF Connective tissue growth factor 1.7 0.0124  
ZC3H18 Zinc finger CCCH domain-containing protein 18 1.6 0.0077  
DNAJC8 DnaJ homolog subfamily C member 8 1.6 0.0204  
NHP2 H/ACA ribonucleoprotein complex subunit 2 1.6 0.0399  
EDF1 Endothelial differentiation-related factor 1 1.6 0.0398  
PRMT1 Protein arginine N-methyltransferase 1 1.6 0.0197 Y 
TOP1 DNA topoisomerase 1 1.6 0.0064 Y 
WDR18 WD repeat-containing protein 18 1.6 0.0394  
DDX3Y ATP-dependent RNA helicase DDX3Y 1.6 0.0374  
DKC1 H/ACA ribonucleoprotein complex subunit 4 1.6 0.0223 Y 
RRP12 RRP12-like protein 1.5 0.0448  
VPS26B Vacuolar protein sorting-associated protein 26B 1.5 0.0366  
EXOSC6 Exosome complex component MTR3 1.5 0.0025  
SPARC SPARC 1.5 0.0113  
CCDC50 Coiled-coil domain-containing protein 50 1.5 0.0178  
PLRG1 Pleiotropic regulator 1 1.5 0.0492  
SUPT16H FACT complex subunit SPT16 1.4 0.0171 Y 
LIMS1 LIM and senescent cell antigen-like-containing 
domain protein 1 
1.4 0.0001  
SPATS2L SPATS2-like protein 1.4 0.0411  
DHCR24 Delta(24)-sterol reductase 1.4 0.0111  
EXOSC2 Exosome complex component RRP4 1.3 0.0238  
METAP1 Methionine aminopeptidase 1 1.3 0.0136  
GATAD2A Transcriptional repressor p66-alpha 1.3 0.0347  
CROCC Rootletin 1.3 0.0206  
CCAR1 Cell division cycle and apoptosis regulator 
protein 1 
1.3 0.0144  
SART1 U4/U6.U5 tri-snRNP-associated protein 1 1.3 0.0168  
RPA1 Replication protein A 70 kDa DNA-binding 
subunit 
1.2 0.0151  
DDX1 ATP-dependent RNA helicase DDX1 1.2 0.0189  
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Table 4-3. List of heterochromatin proteins. 
Shown are the 172 proteins enriched in the strucHC + H3K9me3 IP sample, compared to 
the euchromatin fraction. The fold-enrichement column is computed by the relative change 
in protein rank between the samples. 
gene symbol protein 
fold-enrichment in 
strucHC + K9me3 
vs euchromatin t-test 
RBM14 RNA-binding protein 14 28.9 0.0273 
RBMX RNA-binding motif protein, X chromosome 19.6 0.0082 
KHDRBS3 
KH domain-containing, RNA-binding, signal 
transduction-associated protein 3 19.3 0.0399 
VCAN Versican core protein 18.7 0.0366 
KHDRBS1 
KH domain-containing, RNA-binding, signal 
transduction-associated protein 1 18.6 0.0000 
NONO Non-POU domain-containing octamer-binding protein 15.8 0.0143 
DDX5 Probable ATP-dependent RNA helicase DDX5 15.5 0.0347 
DCD Dermcidin 15.1 0.0002 
SFPQ Splicing factor, proline- and glutamine-rich 14.8 0.0037 
S100A9 Protein S100-A9 14.1 0.0406 
DDX17 Probable ATP-dependent RNA helicase DDX17 14.0 0.0288 
EWSR1 RNA-binding protein EWS 13.6 0.0005 
HIST1H1A Histone H1.1 13.4 0.0060 
SRSF9 Serine/arginine-rich splicing factor 9 13.1 0.0371 
FUS RNA-binding protein FUS 12.8 0.0402 
FYTTD1 UAP56-interacting factor 12.8 0.0420 
TAF15 TATA-binding protein-associated factor 2N 12.2 0.0108 
S100A8 Protein S100-A8 12.1 0.0406 
SHROOM3 Protein Shroom3 11.9 0.0113 
ZNF326 DBIRD complex subunit ZNF326 11.4 0.0429 
PVRL2 Nectin-2 11.3 0.0430 
HNRNPM Heterogeneous nuclear ribonucleoprotein M 11.0 0.0013 
HNRNPH3 Heterogeneous nuclear ribonucleoprotein H3 10.9 0.0004 
POLDIP3 Polymerase delta-interacting protein 3 10.8 0.0158 
JUP Junction plakoglobin 10.3 0.0475 
DSG1 Desmoglein-1 10.2 0.0436 
NCOA5 Nuclear receptor coactivator 5 10.0 0.0438 
HNRNPK Heterogeneous nuclear ribonucleoprotein K 9.9 0.0108 
BRIX1 Ribosome biogenesis protein BRX1 homolog 9.5 0.0165 
EBNA1BP2 Probable rRNA-processing protein EBP2 9.5 0.0406 
RPF2 Ribosome production factor 2 homolog 9.5 0.0213 
HNRNPH2 Heterogeneous nuclear ribonucleoprotein H2 9.3 0.0471 
SERPINB12 Serpin B12 9.2 0.0442 
H1FX Histone H1x 9.2 0.0370 
HNRNPH1 Heterogeneous nuclear ribonucleoprotein H 9.1 0.0009 
ZNF438 Zinc finger protein 438 9.0 0.0272 
KPRP Keratinocyte proline-rich protein 9.0 0.0447 
HNRNPR Heterogeneous nuclear ribonucleoprotein R 9.0 0.0322 
PPAN Suppressor of SWI4 1 homolog 8.3 0.0456 
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NOP2 
Probable 28S rRNA (cytosine(4447)-C(5))-
methyltransferase 8.3 0.0200 
HNRNPL Heterogeneous nuclear ribonucleoprotein L 8.2 0.0035 
HNRNPUL1 
Heterogeneous nuclear ribonucleoprotein U-like 
protein 1 8.2 0.0012 
H1F0 Histone H1.0 8.2 0.0031 
HNRNPA2B1 Heterogeneous nuclear ribonucleoproteins A2/B1 7.8 0.0242 
SRSF10 Serine/arginine-rich splicing factor 10 7.6 0.0206 
RRS1 Ribosome biogenesis regulatory protein homolog 7.6 0.0390 
BLMH Bleomycin hydrolase 7.5 0.0423 
GNL3 Guanine nucleotide-binding protein-like 3 7.5 0.0152 
MATR3 Matrin-3 7.4 0.0130 
DDX54 ATP-dependent RNA helicase DDX54 7.4 0.0409 
SAFB Scaffold attachment factor B1 7.4 0.0200 
PSPC1 Paraspeckle component 1 7.3 0.0089 
RAVER1 Ribonucleoprotein PTB-binding 1 7.2 0.0219 
GLTSCR2 
Glioma tumor suppressor candidate region gene 2 
protein 7.2 0.0458 
GTPBP4 Nucleolar GTP-binding protein 1 7.1 0.0001 
WDR46 WD repeat-containing protein 46 7.1 0.0479 
RB1CC1 RB1-inducible coiled-coil protein 1 7.1 0.0480 
SBSN Suprabasin 7.0 0.0474 
FTSJ3 pre-rRNA processing protein FTSJ3 7.0 0.0478 
CASP14 Caspase-14 6.9 0.0465 
YLPM1 YLP motif-containing protein 1 6.9 0.0411 
HNRNPDL Heterogeneous nuclear ribonucleoprotein D-like 6.9 0.0106 
RALY RNA-binding protein Raly 6.9 0.0001 
HNRNPF Heterogeneous nuclear ribonucleoprotein F 6.8 0.0041 
TGM3 Protein-glutamine gamma-glutamyltransferase E 6.8 0.0484 
RBM12B RNA-binding protein 12B 6.6 0.0475 
H2AFY Core histone macro-H2A.1 6.6 0.0058 
C3 Complement C3 6.5 0.0489 
CMAS N-acylneuraminate cytidylyltransferase 6.5 0.0181 
SERPINB6 Serpin B6 6.4 0.0210 
AKAP8 A-kinase anchor protein 8 6.4 0.0490 
MYEF2 Myelin expression factor 2 6.4 0.0492 
DDX27 Probable ATP-dependent RNA helicase DDX27 6.4 0.0313 
WDR36 WD repeat-containing protein 36 6.4 0.0489 
HNRNPU Heterogeneous nuclear ribonucleoprotein U 6.2 0.0089 
ZC3H14 Zinc finger CCCH domain-containing protein 14 6.1 0.0486 
NOC3L Nucleolar complex protein 3 homolog 6.1 0.0366 
TRA2A Transformer-2 protein homolog alpha 6.1 0.0014 
CPSF7 
Cleavage and polyadenylation specificity factor 
subunit 7 6.1 0.0211 
RBM28 RNA-binding protein 28 6.0 0.0429 
SRSF1 Serine/arginine-rich splicing factor 1 6.0 0.0048 
KHSRP Far upstream element-binding protein 2 6.0 0.0068 
ZNF638 Zinc finger protein 638 5.9 0.0500 
PWP2 Periodic tryptophan protein 2 homolog 5.9 0.0325 
PGM5 Phosphoglucomutase-like protein 5 5.8 0.0338 
TRA2B Transformer-2 protein homolog beta 5.7 0.0008 
DST Dystonin 5.7 0.0143 
HNRNPLL Heterogeneous nuclear ribonucleoprotein L-like 5.5 0.0238 
PTDSS1 Phosphatidylserine synthase 1 5.5 0.0139 
DDX50 ATP-dependent RNA helicase DDX50 5.3 0.0233 
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CHTOP Chromatin target of PRMT1 protein 5.2 0.0037 
XRN2 5-3 exoribonuclease 2 5.2 0.0291 
SRSF5 Serine/arginine-rich splicing factor 5 5.1 0.0218 
SYNE1 Nesprin-1 5.1 0.0262 
PES1 Pescadillo homolog 5.1 0.0005 
RPL14 60S ribosomal protein L14 5.0 0.0195 
HNRNPA0 Heterogeneous nuclear ribonucleoprotein A0 5.0 0.0012 
HNRNPC Heterogeneous nuclear ribonucleoproteins C1/C2 5.0 0.0262 
HP1BP3 Heterochromatin protein 1-binding protein 3 5.0 0.0213 
MBNL1 Muscleblind-like protein 1 4.8 0.0011 
RBM15 Putative RNA-binding protein 15 4.8 0.0478 
WDR43 WD repeat-containing protein 43 4.7 0.0165 
RCC1 Regulator of chromosome condensation 4.6 0.0020 
FUBP1 Far upstream element-binding protein 1 4.6 0.0181 
GAR1 H/ACA ribonucleoprotein complex subunit 1 4.6 0.0001 
HNRNPUL2 
Heterogeneous nuclear ribonucleoprotein U-like 
protein 2 4.5 0.0279 
TBL3 Transducin beta-like protein 3 4.4 0.0082 
RBM4 RNA-binding protein 4 4.3 0.0025 
DEK Protein DEK 4.3 0.0292 
RCC2 Protein RCC2 4.3 0.0001 
RPS4Y1 40S ribosomal protein S4, Y isoform 1 4.1 0.0030 
SRSF6 Serine/arginine-rich splicing factor 6 4.0 0.0228 
SRSF7 Serine/arginine-rich splicing factor 7 4.0 0.0166 
CPSF6 
Cleavage and polyadenylation specificity factor 
subunit 6 4.0 0.0218 
SUN1 SUN domain-containing protein 1 3.9 0.0187 
ELAVL1 ELAV-like protein 1 3.8 0.0288 
ALYREF THO complex subunit 4 3.8 0.0026 
TOR1AIP1 Torsin-1A-interacting protein 1 3.8 0.0062 
DSP Desmoplakin 3.7 0.0064 
NEMF Nuclear export mediator factor NEMF 3.7 0.0050 
DDX21 Nucleolar RNA helicase 2 3.7 0.0094 
HNRNPAB Heterogeneous nuclear ribonucleoprotein A/B 3.4 0.0469 
NOP58 Nucleolar protein 58 3.3 0.0045 
TIA1 Nucleolysin TIA-1 isoform p40 3.3 0.0007 
FUBP3 Far upstream element-binding protein 3 3.3 0.0064 
TOP1 DNA topoisomerase 1 3.1 0.0007 
RBM39 RNA-binding protein 39 3.0 0.0333 
SKIV2L2 Superkiller viralicidic activity 2-like 2 3.0 0.0001 
MAP1A Microtubule-associated protein 1A 2.9 0.0170 
LMNB1 Lamin-B1 2.9 0.0193 
RSL1D1 Ribosomal L1 domain-containing protein 1 2.9 0.0022 
ILF3 Interleukin enhancer-binding factor 3 2.9 0.0139 
MYBBP1A Myb-binding protein 1A 2.8 0.0258 
ARG1 Arginase-1 2.8 0.0389 
STT3B 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit STT3B 2.8 0.0033 
U2AF2 Splicing factor U2AF 65 kDa subunit 2.7 0.0171 
U2AF1 Splicing factor U2AF 35 kDa subunit 2.7 0.0019 
PARP1 Poly [ADP-ribose] polymerase 1 2.7 0.0009 
SYNCRIP Heterogeneous nuclear ribonucleoprotein Q 2.7 0.0151 
NMT1 Glycylpeptide N-tetradecanoyltransferase 1 2.6 0.0053 
NOP56 Nucleolar protein 56 2.6 0.0212 
SF1 Splicing factor 1 2.6 0.0099 
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SUPT16H FACT complex subunit SPT16 2.6 0.0011 
NUMA1 Nuclear mitotic apparatus protein 1 2.5 0.0199 
HNRNPD Heterogeneous nuclear ribonucleoprotein D0 2.5 0.0224 
DHX15 
Putative pre-mRNA-splicing factor ATP-dependent 
RNA helicase DHX15 2.5 0.0092 
RPL24 60S ribosomal protein L24 2.5 0.0019 
FBL rRNA 2-O-methyltransferase fibrillarin 2.5 0.0408 
MYH14 Myosin-14 2.4 0.0261 
PTBP1 Polypyrimidine tract-binding protein 1 2.4 0.0318 
RECQL ATP-dependent DNA helicase Q1 2.4 0.0025 
TARDBP TAR DNA-binding protein 43 2.4 0.0022 
PRPF8 Pre-mRNA-processing-splicing factor 8 2.3 0.0287 
ADAR Double-stranded RNA-specific adenosine deaminase 2.3 0.0175 
HACD3 
Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 
3 2.3 0.0094 
BCLAF1 Bcl-2-associated transcription factor 1 2.3 0.0406 
ABCF1 ATP-binding cassette sub-family F member 1 2.2 0.0265 
DKC1 H/ACA ribonucleoprotein complex subunit 4 2.1 0.0157 
NUDT21 
Cleavage and polyadenylation specificity factor 
subunit 5 2.0 0.0171 
FAM120A Constitutive coactivator of PPAR-gamma-like protein 1 2.0 0.0028 
HIST1H4A Histone H4 2.0 0.0474 
HIST1H2BC Histone H2B type 1-C/E/F/G/I 1.9 0.0031 
THRAP3 Thyroid hormone receptor-associated protein 3 1.9 0.0284 
PHB2 Prohibitin-2 1.8 0.0028 
PRMT1 Protein arginine N-methyltransferase 1 1.7 0.0404 
APEX1 DNA-(apurinic or apyrimidinic site) lyase 1.7 0.0433 
IFI16 Gamma-interferon-inducible protein 16 1.7 0.0108 
FXR1 
Fragile X mental retardation syndrome-related protein 
1 1.5 0.0495 
NCL Nucleolin 1.4 0.0265 
RRBP1 Ribosome-binding protein 1 1.4 0.0489 
RPS13 40S ribosomal protein S13 1.3 0.0348 
HDAC2 Histone deacetylase 2 1.3 0.0200 
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Table 4-4. Hepatic genes in repressive fibroblast H3K9me3 domains. 
List of 221 hg19 Refseq genes in repressive H3K9me3 domains (strucHC or intermediate 
subtypes) that are expressed in human hepatocytes over fibroblasts, based on available 
microarray data (Huang et al., 2014). The right-most column indicates how much the gene 
overlaps with the domains (union of the strucHC and intermediate subtypes of H3K9me3). 
Genes with at least 50% overlap qualified for this list. Select genes from this list are shown 
in Figure 4-6B. 
RefSeq ID gene symbol name fraction of gene 
in domain 
NM_000014 A2M alpha-2-macroglobulin 0.77 
NM_003742 ABCB11 ATP binding cassette subfamily B member 11 0.50 
NM_178559 ABCB5 ATP binding cassette subfamily B member 5 0.87 
NR_003087 ABCC13 ATP binding cassette subfamily C member 13 
(pseudogene) 
0.92 
NM_001097 ACR acrosin 1.00 
NM_052956 ACSM1 acyl-CoA synthetase medium-chain family member 
1 
0.92 
NM_182617 ACSM2B acyl-CoA synthetase medium-chain family member 
2B 
1.00 
NM_017888 ACSM5 acyl-CoA synthetase medium-chain family member 
5 
1.00 
NM_139057 ADAMTS17 ADAM metallopeptidase with thrombospondin type 
1 motif 17 
1.00 
NM_207517 ADAMTSL3 ADAMTS like 3 0.98 
NM_153838 ADGRF4 adhesion G protein-coupled receptor F4 0.80 
NM_005989 AKR1D1 aldo-keto reductase family 1 member D1 0.79 
NM_000032 ALAS2 5'-aminolevulinate synthase 2 0.77 
NM_001012421 ANKRD20A2 ankyrin repeat domain 20 family member A2 0.99 
NM_213599 ANO5 anoctamin 5 1.00 
NM_001639 APCS amyloid P component, serum 1.00 
NM_015230 ARAP2 ArfGAP with RhoGAP domain, ankyrin repeat and 
PH domain 2 
1.00 
NM_001185 AZGP1 alpha-2-glycoprotein 1, zinc-binding 0.92 
NM_054025 B3GAT1 beta-1,3-glucuronyltransferase 1 0.98 
NM_000055 BCHE butyrylcholinesterase 1.00 
NM_001012978 BEX5 brain expressed X-linked 5 1.00 
NM_001721 BMX BMX non-receptor tyrosine kinase 0.56 
NM_001002760 BPY2B basic charge, Y-linked, 2B 1.00 
NM_001104629 C4orf19 chromosome 4 open reading frame 19 0.78 
NM_000065 C6 complement component 6 0.93 
NM_002984 CCL4 C-C motif chemokine ligand 4 1.00 
NM_033031 CCNB3 cyclin B3 1.00 
NM_001766 CD1D CD1d molecule 0.57 
NM_001772 CD33 CD33 molecule 1.00 
NM_001778 CD48 CD48 molecule 0.56 
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NM_003874 CD84 CD84 molecule 0.97 
NM_001768 CD8A CD8a molecule 0.61 
NR_003595 CDC14C cell division cycle 14C, pseuodgene 1.00 
NM_145024 CES5A carboxylesterase 5A 0.52 
NM_000744 CHRNA4 cholinergic receptor nicotinic alpha 4 subunit 0.64 
NM_031422 CHST9 carbohydrate sulfotransferase 9 1.00 
NM_001289 CLIC2 chloride intracellular channel 2 0.91 
NM_024734 CLMN calmin 0.51 
NM_152311 CLRN3 clarin 3 0.52 
NM_014141 CNTNAP2 contactin associated protein-like 2 0.95 
NM_006651 CPLX1 complexin 1 0.59 
NM_153634 CPNE8 copine 8 1.00 
NM_000567 CRP C-reactive protein, pentraxin-related 1.00 
NM_172249 CSF2RA colony stimulating factor 2 receptor alpha subunit 0.76 
NR_024387 CXADRP2 coxsackie virus and adenovirus receptor 
pseudogene 2 
1.00 
NR_024076 CXADRP3 coxsackie virus and adenovirus receptor 
pseudogene 3 
1.00 
NM_000767 CYP2B6 cytochrome P450 family 2 subfamily B member 6 0.63 
NM_000772 CYP2C18 cytochrome P450 family 2 subfamily C member 18 1.00 
NM_000769 CYP2C19 cytochrome P450 family 2 subfamily C member 19 1.00 
NM_000770 CYP2C8 cytochrome P450 family 2 subfamily C member 8 1.00 
NM_000771 CYP2C9 cytochrome P450 family 2 subfamily C member 9 1.00 
NM_000778 CYP4A11 cytochrome P450 family 4 subfamily A member 11 1.00 
NM_021187 CYP4F11 cytochrome P450 family 4 subfamily F member 11 1.00 
NM_023944 CYP4F12 cytochrome P450 family 4 subfamily F member 12 1.00 
NM_001082 CYP4F2 cytochrome P450 family 4 subfamily F member 2 1.00 
NM_007253 CYP4F8 cytochrome P450 family 4 subfamily F member 8 0.83 
NM_178033 CYP4X1 cytochrome P450 family 4 subfamily X member 1 1.00 
NM_178134 CYP4Z1 cytochrome P450 family 4 subfamily Z member 1 0.75 
NM_005218 DEFB1 defensin beta 1 1.00 
NM_001364 DLG2 discs large MAGUK scaffold protein 2 0.63 
NM_004010 DMD dystrophin 0.70 
NM_138815 DPPA2 developmental pluripotency associated 2 1.00 
NM_024422 DSC2 desmocollin 2 0.59 
NM_022785 EFCAB6 EF-hand calcium binding domain 6 0.60 
NM_014800 ELMO1 engulfment and cell motility 1 0.65 
NM_000128 F11 coagulation factor XI 0.81 
NM_174912 FAAH2 fatty acid amide hydrolase 2 1.00 
NM_001077710 FAM110C family with sequence similarity 110 member C 1.00 
NM_015381 FAM19A5 family with sequence similarity 19 member A5, C-C 
motif chemokine like 
0.97 
NM_030764 FCRL2 Fc receptor like 2 1.00 
NM_022970 FGFR2 fibroblast growth factor receptor 2 1.00 
NM_002012 FHIT fragile histidine triad 0.84 
NM_001014986 FOLH1 folate hydrolase 1 1.00 
NM_004476 FOLH1 folate hydrolase 1 1.00 
NM_153696 FOLH1B folate hydrolase 1B 0.91 
NM_000814 GABRB3 gamma-aminobutyric acid type A receptor beta3 
subunit 
1.00 
NM_021123 GAGE7 G antigen 7 1.00 
NM_005256 GAS2 growth arrest specific 2 0.60 
NM_020973 GBA3 glucosylceramidase beta 3 (gene/pseudogene) 0.75 
NM_000583 GC GC, vitamin D binding protein 0.80 
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NM_001491 GCNT2 glucosaminyl (N-acetyl) transferase 2, I-branching 
enzyme (I blood group) 
0.90 
NR_003267 GGT3P gamma-glutamyltransferase 3 pseudogene 1.00 
NR_003503 GGT8P gamma-glutamyltransferase 8 pseudogene 0.69 
NM_004122 GHSR growth hormone secretagogue receptor 1.00 
NM_130759 GIMAP1 GTPase, IMAP family member 1 1.00 
NM_015660 GIMAP2 GTPase, IMAP family member 2 1.00 
NM_018326 GIMAP4 GTPase, IMAP family member 4 1.00 
NM_018384 GIMAP5 GTPase, IMAP family member 5 1.00 
NM_024711 GIMAP6 GTPase, IMAP family member 6 1.00 
NM_153236 GIMAP7 GTPase, IMAP family member 7 1.00 
NM_175571 GIMAP8 GTPase, IMAP family member 8 0.82 
NM_144669 GLT1D1 glycosyltransferase 1 domain containing 1 1.00 
NM_001001413 GOLGA6L1 golgin A6 family-like 1 1.00 
NM_022036 GPRC5C G protein-coupled receptor class C group 5 
member C 
1.00 
NM_000831 GRIK3 glutamate ionotropic receptor kainate type subunit 
3 
1.00 
NM_000845 GRM8 glutamate metabotropic receptor 8 0.98 
NM_001080476 GRXCR1 glutaredoxin and cysteine rich domain containing 1 1.00 
NM_033423 GZMH granzyme H 1.00 
NM_004133 HNF4G hepatocyte nuclear factor 4 gamma 1.00 
NM_000860 HPGD hydroxyprostaglandin dehydrogenase 15-(NAD) 0.72 
NM_000415 IAPP islet amyloid polypeptide 0.62 
NM_001002915 IGFL2 IGF like family member 2 0.88 
NM_017416 IL1RAPL2 interleukin 1 receptor accessory protein like 2 0.84 
NM_173178 IL36B interleukin 36, beta 0.71 
NM_000632 ITGAM integrin subunit alpha M 0.71 
NM_138693 KLF14 Kruppel like factor 14 1.00 
NM_057162 KLHL4 kelch like family member 4 0.97 
NM_000892 KLKB1 kallikrein B1 0.87 
NM_152643 KNDC1 kinase non-catalytic C-lobe domain containing 1 0.74 
NM_000226 KRT9 keratin 9 0.85 
NM_173464 L3MBTL4 l(3)mbt-like 4 (Drosophila) 0.50 
NM_033277 LACRT lacritin 0.84 
NR_003061 LILRP2 leukocyte immunoglobulin-like receptor 
pseudogene 2 
1.00 
NR_024090 LINC00320 long intergenic non-protein coding RNA 320 0.63 
NR_024160 LINC00626 long intergenic non-protein coding RNA 626 0.95 
NM_005577 LPA lipoprotein(a) 0.94 
NM_052886 MAL2 mal, T-cell differentiation protein 2 
(gene/pseudogene) 
0.88 
NM_006770 MARCO macrophage receptor with collagenous structure 0.87 
NM_004994 MMP9 matrix metallopeptidase 9 1.00 
NM_001044370 MPPED1 metallophosphoesterase domain containing 1 0.65 
NM_005797 MPZL2 myelin protein zero like 2 0.92 
NM_144765 MPZL2 myelin protein zero like 2 1.00 
NM_024021 MS4A4A membrane spanning 4-domains A4A 1.00 
NM_021201 MS4A7 membrane spanning 4-domains A7 1.00 
NM_001033602 MTUS2 microtubule associated tumor suppressor 
candidate 2 
0.59 
NM_152423 MUM1L1 MUM1 like 1 0.96 
NM_003970 MYOM2 myomesin 2 0.81 
NM_021963 NAP1L2 nucleosome assembly protein 1 like 2 1.00 
NM_002500 NEUROD1 neuronal differentiation 1 1.00 
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NM_145007 NLRP11 NLR family pyrin domain containing 11 1.00 
NM_005123 NR1H4 nuclear receptor subfamily 1 group H member 4 0.58 
NM_001105663 NUDT7 nudix hydrolase 7 0.64 
NM_002534 OAS1 2'-5'-oligoadenylate synthetase 1 1.00 
NM_003553 OR1E1 olfactory receptor family 1 subfamily E member 1 1.00 
NM_001004739 OR5L2 olfactory receptor family 5 subfamily L member 2 1.00 
NR_002171 OR7E156P olfactory receptor family 7 subfamily E member 156 
pseudogene 
1.00 
NM_001079935 OR7E24 olfactory receptor family 7 subfamily E member 24 1.00 
NM_207320 OTUD6A OTU deubiquitinase 6A 1.00 
NM_178129 P2RY8 purinergic receptor P2Y8 0.64 
NM_130467 PAGE5 PAGE family member 5 1.00 
NM_000277 PAH phenylalanine hydroxylase 0.88 
NM_022843 PCDH20 protocadherin 20 1.00 
NM_031856 PCDHA8 protocadherin alpha 8 1.00 
NM_031882 PCDHAC1 protocadherin alpha subfamily C, 1 0.75 
NM_001077358 PDE11A phosphodiesterase 11A 0.54 
NM_016953 PDE11A phosphodiesterase 11A 0.60 
NM_006210 PEG3 paternally expressed 3 1.00 
NM_002625 PFKFB1 6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 1 
0.54 
NM_016112 PKD2L1 polycystin 2 like 1, transient receptor potential 
cation channel 
0.66 
NM_004572 PKP2 plakophilin 2 0.89 
NM_005084 PLA2G7 phospholipase A2 group VII 0.65 
NM_024829 PLBD1 phospholipase B domain containing 1 0.67 
NM_000301 PLG plasminogen 1.00 
NM_002763 PROX1 prospero homeobox 1 0.76 
NM_002864 PZP PZP, alpha-2-macroglobulin like 0.90 
NM_138453 RAB3C RAB3C, member RAS oncogene family 0.72 
NM_006744 RBP4 retinol binding protein 4 0.79 
NM_021026 RFPL1 ret finger protein like 1 1.00 
NM_005615 RNASE6 ribonuclease A family member k6 1.00 
NM_198085 RNF148 ring finger protein 148 1.00 
NM_025236 RNF39 ring finger protein 39 0.65 
NM_005621 S100A12 S100 calcium binding protein A12 0.57 
NM_022136 SAMSN1 SAM domain, SH3 domain and nuclear localization 
signals 1 
1.00 
NM_145168 SDR42E1 short chain dehydrogenase/reductase family 42E, 
member 1 
0.66 
NM_001080451 SERPINA11 serpin family A member 11 1.00 
NM_001085 SERPINA3 serpin family A member 3 0.89 
NM_006215 SERPINA4 serpin family A member 4 1.00 
NM_000354 SERPINA7 serpin family A member 7 1.00 
NM_012435 SHC2 SHC adaptor protein 2 0.89 
NM_001010846 SHE Src homology 2 domain containing E 0.71 
NM_001040153 SLAIN1 SLAIN motif family member 1 0.60 
NM_003037 SLAMF1 signaling lymphocytic activation molecule family 
member 1 
0.76 
NM_021181 SLAMF7 SLAM family member 7 1.00 
NM_005835 SLC17A2 solute carrier family 17 member 2 0.67 
NM_001039752 SLC22A10 solute carrier family 22 member 10 0.91 
NM_021977 SLC22A3 solute carrier family 22 member 3 0.52 
NM_016615 SLC6A13 solute carrier family 6 member 13 0.60 
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NM_006446 SLCO1B1 solute carrier organic anion transporter family 
member 1B1 
0.92 
NM_019844 SLCO1B3 solute carrier organic anion transporter family 
member 1B3 
0.91 
NM_180991 SLCO4C1 solute carrier organic anion transporter family 
member 4C1 
1.00 
NM_001034852 SMOC1 SPARC related modular calcium binding 1 0.85 
NM_152989 SOX5 SRY-box 5 0.97 
NM_153189 SPAM1 sperm adhesion molecule 1 1.00 
NM_003122 SPINK1 serine peptidase inhibitor, Kazal type 1 0.94 
NM_021015 SSX5 SSX family member 5 0.51 
NM_020225 STOX2 storkhead box 2 0.85 
NM_014465 SULT1B1 sulfotransferase family 1B member 1 0.78 
NM_016524 SYT17 synaptotagmin 17 0.77 
NM_016945 TAS2R16 taste 2 receptor member 16 1.00 
NM_003225 TFF1 trefoil factor 1 1.00 
NM_138379 TIMD4 T-cell immunoglobulin and mucin domain 
containing 4 
1.00 
NM_018487 TMEM176A transmembrane protein 176A 1.00 
NM_014020 TMEM176B transmembrane protein 176B 0.89 
NM_001123376 TMEM72 transmembrane protein 72 0.55 
NM_003701 TNFSF11 tumor necrosis factor superfamily member 11 0.55 
NM_001080430 TOX3 TOX high mobility group box family member 3 0.97 
NM_022445 TPK1 thiamin pyrophosphokinase 1 0.95 
NM_012471 TRPC5 transient receptor potential cation channel 
subfamily C member 5 
0.92 
NM_173485 TSHZ2 teashirt zinc finger homeobox 2 0.63 
NM_178562 TSPAN33 tetraspanin 33 0.80 
NM_004616 TSPAN8 tetraspanin 8 0.95 
NR_026547 TSPEAR-AS2 TSPEAR antisense RNA 2 1.00 
NM_000371 TTR transthyretin 1.00 
NM_006001 TUBA3C tubulin alpha 3c 1.00 
NM_019076 UGT1A8 UDP glucuronosyltransferase family 1 member A8 0.61 
NM_001075 UGT2B10 UDP glucuronosyltransferase family 2 member B10 0.87 
NM_001073 UGT2B11 UDP glucuronosyltransferase family 2 member B11 1.00 
NM_001076 UGT2B15 UDP glucuronosyltransferase family 2 member B15 1.00 
NM_001077 UGT2B17 UDP glucuronosyltransferase family 2 member B17 1.00 
NM_053039 UGT2B28 UDP glucuronosyltransferase family 2 member B28 1.00 
NM_021139 UGT2B4 UDP glucuronosyltransferase family 2 member B4 1.00 
NM_001074 UGT2B7 UDP glucuronosyltransferase family 2 member B7 0.75 
NM_018974 UNC93A unc-93 homolog A (C. elegans) 1.00 
NM_206933 USH2A usherin 0.77 
NM_013452 VCX variable charge, X-linked 1.00 
NM_022479 WBSCR17 Williams-Beuren syndrome chromosome region 17 1.00 
NM_182758 WDR72 WD repeat domain 72 1.00 
NM_016373 WWOX WW domain containing oxidoreductase 0.89 
NM_052898 XKR4 XK related 4 0.99 
NM_003446 ZNF157 zinc finger protein 157 0.51 
NM_001037735 ZNF630 zinc finger protein 630 0.69 
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Table 4-5. Heterochromatic genes with enhanced activation after siRNA against 
SUV39H1 or RBMX/L1. 
List of 364 genes in strucHC domains that are significantly upregulated (adjusted p < 0.05) 
by SUV39H1 siRNA and/or RBMX/L1 siRNA, in the presence of hiHep factors. Fold-
changes relative to control siRNA are shown. The data here are used in Figure 4-7C. 
gene symbol Significantly 
upregulated in 
si-SUV39H1? 
Significantly 
upregulated in 
si-RBMX/L1? 
Fold-change: 
si-SUV39H1 vs 
control 
Fold-change: 
si-RBMX/L1 vs 
control 
NR1H4 signif in si-SUV39H1 signif in si-RBMX/L1 17.1 15.2 
SPINK1 signif in si-SUV39H1 signif in si-RBMX/L1 14.2 11.9 
PKIB signif in si-SUV39H1 signif in si-RBMX/L1 11.2 26.0 
TSPAN8 signif in si-SUV39H1 signif in si-RBMX/L1 8.8 6.0 
MYO3B signif in si-SUV39H1 signif in si-RBMX/L1 8.2 10.0 
SLAMF7 signif in si-SUV39H1 signif in si-RBMX/L1 7.6 12.6 
CRP signif in si-SUV39H1 signif in si-RBMX/L1 7.5 18.3 
CLIC5 signif in si-SUV39H1 signif in si-RBMX/L1 6.4 5.6 
LOC101930452 signif in si-SUV39H1 signif in si-RBMX/L1 5.8 7.3 
COL6A5 signif in si-SUV39H1 signif in si-RBMX/L1 5.8 3.5 
SMIM10L2A signif in si-SUV39H1 signif in si-RBMX/L1 5.5 7.2 
UPP2 signif in si-SUV39H1 signif in si-RBMX/L1 5.0 6.0 
FAT2 signif in si-SUV39H1 signif in si-RBMX/L1 5.0 2.4 
BEND4 signif in si-SUV39H1 signif in si-RBMX/L1 4.7 3.9 
DSG2 signif in si-SUV39H1 signif in si-RBMX/L1 4.7 5.8 
GLP2R signif in si-SUV39H1 signif in si-RBMX/L1 4.6 3.7 
FAM134B signif in si-SUV39H1 signif in si-RBMX/L1 4.2 3.7 
IGSF1 signif in si-SUV39H1 signif in si-RBMX/L1 4.2 4.0 
MAFB signif in si-SUV39H1 signif in si-RBMX/L1 4.1 3.4 
SLC17A3 signif in si-SUV39H1 signif in si-RBMX/L1 4.1 4.3 
CNGA3 signif in si-SUV39H1 signif in si-RBMX/L1 4.0 1.7 
GCNT2 signif in si-SUV39H1 signif in si-RBMX/L1 4.0 1.6 
ACMSD signif in si-SUV39H1 signif in si-RBMX/L1 4.0 7.8 
NOX1 signif in si-SUV39H1 signif in si-RBMX/L1 3.9 3.4 
NUGGC signif in si-SUV39H1 signif in si-RBMX/L1 3.8 2.4 
UCA1 signif in si-SUV39H1 signif in si-RBMX/L1 3.6 4.9 
BRINP2 signif in si-SUV39H1 signif in si-RBMX/L1 3.3 3.7 
MOB3B signif in si-SUV39H1 signif in si-RBMX/L1 3.3 4.2 
PADI2 signif in si-SUV39H1 signif in si-RBMX/L1 3.3 3.9 
MIR3945HG signif in si-SUV39H1 signif in si-RBMX/L1 3.1 3.3 
DOCK8 signif in si-SUV39H1 signif in si-RBMX/L1 3.0 2.2 
SERPINI1 signif in si-SUV39H1 signif in si-RBMX/L1 3.0 1.6 
RAPGEF5 signif in si-SUV39H1 signif in si-RBMX/L1 3.0 1.8 
NEBL signif in si-SUV39H1 signif in si-RBMX/L1 3.0 3.9 
VNN1 signif in si-SUV39H1 signif in si-RBMX/L1 2.9 3.8 
GCNT3 signif in si-SUV39H1 signif in si-RBMX/L1 2.9 2.4 
CCND2 signif in si-SUV39H1 signif in si-RBMX/L1 2.8 5.4 
CHD7 signif in si-SUV39H1 signif in si-RBMX/L1 2.8 2.2 
PIK3AP1 signif in si-SUV39H1 signif in si-RBMX/L1 2.8 2.6 
ANO2 signif in si-SUV39H1 signif in si-RBMX/L1 2.8 2.3 
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AKR1C3 signif in si-SUV39H1 signif in si-RBMX/L1 2.8 1.7 
LOC286297 signif in si-SUV39H1 signif in si-RBMX/L1 2.7 2.7 
LIPH signif in si-SUV39H1 signif in si-RBMX/L1 2.7 1.8 
MPZL3 signif in si-SUV39H1 signif in si-RBMX/L1 2.7 3.3 
LOC100133920 signif in si-SUV39H1 signif in si-RBMX/L1 2.7 2.8 
PDZD2 signif in si-SUV39H1 signif in si-RBMX/L1 2.6 1.7 
ELOVL7 signif in si-SUV39H1 signif in si-RBMX/L1 2.6 3.4 
PLA1A signif in si-SUV39H1 signif in si-RBMX/L1 2.6 2.0 
GOLGA8M signif in si-SUV39H1 signif in si-RBMX/L1 2.6 1.6 
UGT1A7 signif in si-SUV39H1 signif in si-RBMX/L1 2.6 1.8 
IQGAP2 signif in si-SUV39H1 signif in si-RBMX/L1 2.6 3.2 
DDX11L16 signif in si-SUV39H1 signif in si-RBMX/L1 2.6 3.8 
TMEM27 signif in si-SUV39H1 signif in si-RBMX/L1 2.6 2.4 
FAM3D signif in si-SUV39H1 signif in si-RBMX/L1 2.5 2.3 
HRG signif in si-SUV39H1 signif in si-RBMX/L1 2.5 2.9 
ULBP3 signif in si-SUV39H1 signif in si-RBMX/L1 2.5 1.8 
SORBS1 signif in si-SUV39H1 signif in si-RBMX/L1 2.5 2.5 
WIPF3 signif in si-SUV39H1 signif in si-RBMX/L1 2.4 3.1 
DCX signif in si-SUV39H1 signif in si-RBMX/L1 2.4 18.5 
FER1L6 signif in si-SUV39H1 signif in si-RBMX/L1 2.4 1.8 
EFHD1 signif in si-SUV39H1 signif in si-RBMX/L1 2.4 1.7 
UGT1A8 signif in si-SUV39H1 signif in si-RBMX/L1 2.4 1.8 
UGT1A9 signif in si-SUV39H1 signif in si-RBMX/L1 2.4 1.8 
DDX11L2 signif in si-SUV39H1 signif in si-RBMX/L1 2.3 3.1 
TEKT4P2 signif in si-SUV39H1 signif in si-RBMX/L1 2.3 2.7 
NLRC4 signif in si-SUV39H1 signif in si-RBMX/L1 2.3 2.3 
GOLGA8J signif in si-SUV39H1 signif in si-RBMX/L1 2.3 1.6 
GOLGA8K signif in si-SUV39H1 signif in si-RBMX/L1 2.3 1.7 
SPTBN2 signif in si-SUV39H1 signif in si-RBMX/L1 2.2 1.9 
PTGFRN signif in si-SUV39H1 signif in si-RBMX/L1 2.2 2.1 
ZFAND2A signif in si-SUV39H1 signif in si-RBMX/L1 2.2 1.4 
ABCC11 signif in si-SUV39H1 signif in si-RBMX/L1 2.2 2.1 
PCSK5 signif in si-SUV39H1 signif in si-RBMX/L1 2.1 2.0 
KLHL4 signif in si-SUV39H1 signif in si-RBMX/L1 2.1 3.0 
TGM5 signif in si-SUV39H1 signif in si-RBMX/L1 2.1 2.5 
PROS1 signif in si-SUV39H1 signif in si-RBMX/L1 2.0 1.7 
APOD signif in si-SUV39H1 signif in si-RBMX/L1 2.0 2.3 
ALDOB signif in si-SUV39H1 signif in si-RBMX/L1 2.0 1.3 
HNF4A signif in si-SUV39H1 signif in si-RBMX/L1 2.0 1.4 
SULT1C2 signif in si-SUV39H1 signif in si-RBMX/L1 1.9 1.7 
KIAA1161 signif in si-SUV39H1 signif in si-RBMX/L1 1.9 1.7 
RNF44 signif in si-SUV39H1 signif in si-RBMX/L1 1.9 1.4 
MFAP3L signif in si-SUV39H1 signif in si-RBMX/L1 1.9 1.5 
RAB6B signif in si-SUV39H1 signif in si-RBMX/L1 1.8 1.8 
FOXA3 signif in si-SUV39H1 signif in si-RBMX/L1 1.8 1.4 
RASGRF2 signif in si-SUV39H1 signif in si-RBMX/L1 1.8 1.5 
AQP7P1 signif in si-SUV39H1 signif in si-RBMX/L1 1.8 1.6 
ACAA1 signif in si-SUV39H1 signif in si-RBMX/L1 1.7 1.2 
HNF1A signif in si-SUV39H1 signif in si-RBMX/L1 1.7 1.4 
GLIDR signif in si-SUV39H1 signif in si-RBMX/L1 1.6 1.6 
PCDH1 signif in si-SUV39H1 signif in si-RBMX/L1 1.6 2.4 
FUT6 signif in si-SUV39H1 signif in si-RBMX/L1 1.6 2.0 
SLC6A20 signif in si-SUV39H1 signif in si-RBMX/L1 1.6 2.1 
GOLGA8S signif in si-SUV39H1 signif in si-RBMX/L1 1.6 1.6 
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ZNF578 signif in si-SUV39H1 signif in si-RBMX/L1 1.6 1.5 
NATD1 signif in si-SUV39H1 signif in si-RBMX/L1 1.5 1.5 
PRODH2 signif in si-SUV39H1 signif in si-RBMX/L1 1.5 1.6 
SERPINC1 signif in si-SUV39H1 signif in si-RBMX/L1 1.5 1.6 
DYSF signif in si-SUV39H1 signif in si-RBMX/L1 1.4 2.1 
ZBTB7B signif in si-SUV39H1 signif in si-RBMX/L1 1.4 1.5 
GPR108 signif in si-SUV39H1 signif in si-RBMX/L1 1.3 1.4 
LINC00504 signif in si-SUV39H1 signif in si-RBMX/L1 1.3 1.3 
TREML3P signif in si-SUV39H1  28.2 1.0 
STOX2 signif in si-SUV39H1  10.1 7.4 
TESPA1 signif in si-SUV39H1  9.9 24.5 
SYT3 signif in si-SUV39H1  9.0 1.2 
TMEM71 signif in si-SUV39H1  8.2 2.5 
TNMD signif in si-SUV39H1  8.1 3.7 
MYH16 signif in si-SUV39H1  7.5 2.8 
LOC102723769 signif in si-SUV39H1  7.1 6.7 
SLC30A2 signif in si-SUV39H1  6.9 5.1 
RRAGD signif in si-SUV39H1  6.4 3.3 
NPPB signif in si-SUV39H1  6.0 1.2 
FATE1 signif in si-SUV39H1  5.9 2.3 
FPR3 signif in si-SUV39H1  5.6 3.0 
TRIM67 signif in si-SUV39H1  5.6 2.5 
TNFRSF11A signif in si-SUV39H1  5.2 4.8 
PADI3 signif in si-SUV39H1  5.0 2.3 
DHRS2 signif in si-SUV39H1  4.9 0.5 
DRGX signif in si-SUV39H1  4.8 3.2 
LINC01234 signif in si-SUV39H1  4.7 2.8 
CLSTN2 signif in si-SUV39H1  4.6 4.2 
COBL signif in si-SUV39H1  4.6 1.9 
LRRC31 signif in si-SUV39H1  4.5 1.6 
ATP8A1 signif in si-SUV39H1  4.4 2.0 
ASPA signif in si-SUV39H1  4.2 1.3 
LYPD1 signif in si-SUV39H1  3.9 1.5 
CYP2B6 signif in si-SUV39H1  3.8 1.2 
CLMN signif in si-SUV39H1  3.8 1.3 
KLHL6 signif in si-SUV39H1  3.8 2.8 
CHDH signif in si-SUV39H1  3.7 1.3 
ERICH2 signif in si-SUV39H1  3.6 2.2 
AMN signif in si-SUV39H1  3.6 1.5 
CPEB1 signif in si-SUV39H1  3.6 1.9 
AKR1C4 signif in si-SUV39H1  3.4 2.5 
TBXAS1 signif in si-SUV39H1  3.4 1.1 
HABP2 signif in si-SUV39H1  3.4 1.2 
FGF14 signif in si-SUV39H1  3.3 1.2 
PDGFB signif in si-SUV39H1  3.3 1.1 
CYP4F3 signif in si-SUV39H1  3.2 1.6 
G6PC signif in si-SUV39H1  3.2 1.0 
LAMP3 signif in si-SUV39H1  3.2 1.2 
GBA3 signif in si-SUV39H1  3.1 1.5 
MYO1H signif in si-SUV39H1  3.1 2.5 
IL18R1 signif in si-SUV39H1  3.1 2.1 
UNC13D signif in si-SUV39H1  3.0 1.1 
ACVR1C signif in si-SUV39H1  3.0 2.3 
AOC3 signif in si-SUV39H1  3.0 1.4 
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CRCT1 signif in si-SUV39H1  3.0 2.3 
TSPAN33 signif in si-SUV39H1  2.9 1.9 
ALDH1L1 signif in si-SUV39H1  2.9 0.5 
CDH26 signif in si-SUV39H1  2.9 1.2 
IFITM10 signif in si-SUV39H1  2.9 1.2 
ATP1A2 signif in si-SUV39H1  2.9 1.5 
KEL signif in si-SUV39H1  2.8 0.3 
SPIRE2 signif in si-SUV39H1  2.8 1.1 
SLC7A9 signif in si-SUV39H1  2.8 2.7 
PANX2 signif in si-SUV39H1  2.8 0.4 
SDK1 signif in si-SUV39H1  2.8 1.1 
NKAIN1 signif in si-SUV39H1  2.7 1.5 
C1orf106 signif in si-SUV39H1  2.6 1.6 
BMP8B signif in si-SUV39H1  2.6 1.5 
GOLGA8IP signif in si-SUV39H1  2.6 1.5 
NR1I3 signif in si-SUV39H1  2.5 1.9 
BMP8A signif in si-SUV39H1  2.5 2.0 
MOGAT3 signif in si-SUV39H1  2.5 1.5 
MTSS1 signif in si-SUV39H1  2.5 1.6 
ZNF208 signif in si-SUV39H1  2.5 1.2 
CYP4F12 signif in si-SUV39H1  2.5 1.9 
PMEPA1 signif in si-SUV39H1  2.5 1.4 
ZMYND15 signif in si-SUV39H1  2.5 1.0 
RAET1K signif in si-SUV39H1  2.4 1.3 
IL17RB signif in si-SUV39H1  2.4 0.7 
CCDC64 signif in si-SUV39H1  2.4 1.9 
DISP2 signif in si-SUV39H1  2.4 1.5 
CACFD1 signif in si-SUV39H1  2.4 1.2 
SERPINA6 signif in si-SUV39H1  2.4 0.9 
GPX3 signif in si-SUV39H1  2.4 1.0 
SPINT1 signif in si-SUV39H1  2.3 1.0 
KIAA0040 signif in si-SUV39H1  2.3 1.2 
AZGP1 signif in si-SUV39H1  2.3 1.4 
URAHP signif in si-SUV39H1  2.3 1.6 
PAPPA2 signif in si-SUV39H1  2.3 1.3 
TMEM37 signif in si-SUV39H1  2.3 1.0 
ZBTB46 signif in si-SUV39H1  2.3 1.3 
UGT1A6 signif in si-SUV39H1  2.2 1.2 
GOLGA8T signif in si-SUV39H1  2.2 1.6 
SERPINA1 signif in si-SUV39H1  2.2 1.1 
ADCK3 signif in si-SUV39H1  2.2 1.3 
TRAPPC6A signif in si-SUV39H1  2.1 1.6 
CLU signif in si-SUV39H1  2.1 1.2 
ALS2CL signif in si-SUV39H1  2.1 1.6 
SLC6A13 signif in si-SUV39H1  2.1 1.3 
GOLGA8H signif in si-SUV39H1  2.1 1.4 
PCSK6 signif in si-SUV39H1  2.1 1.4 
TM6SF2 signif in si-SUV39H1  2.1 1.1 
CTSD signif in si-SUV39H1  2.1 1.3 
SLC26A11 signif in si-SUV39H1  2.1 1.1 
GLYAT signif in si-SUV39H1  2.0 2.0 
NEU1 signif in si-SUV39H1  2.0 1.4 
TMEM133 signif in si-SUV39H1  2.0 1.4 
GOLGA2P5 signif in si-SUV39H1  2.0 0.7 
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DNAH5 signif in si-SUV39H1  2.0 1.0 
FBP1 signif in si-SUV39H1  2.0 1.8 
BCL2 signif in si-SUV39H1  2.0 1.3 
CAPN8 signif in si-SUV39H1  1.9 0.6 
GOLGA8R signif in si-SUV39H1  1.9 1.3 
CTSF signif in si-SUV39H1  1.9 1.2 
LAD1 signif in si-SUV39H1  1.9 1.4 
ZNF469 signif in si-SUV39H1  1.9 1.1 
SH2D5 signif in si-SUV39H1  1.9 1.5 
ABTB1 signif in si-SUV39H1  1.9 1.0 
MELTF signif in si-SUV39H1  1.9 1.1 
SLC13A2 signif in si-SUV39H1  1.9 1.4 
DAGLA signif in si-SUV39H1  1.9 1.2 
GOLGA8O signif in si-SUV39H1  1.9 1.3 
CAPN3 signif in si-SUV39H1  1.8 0.7 
LONRF3 signif in si-SUV39H1  1.8 1.6 
SULF2 signif in si-SUV39H1  1.8 1.3 
LOC101928841 signif in si-SUV39H1  1.8 1.7 
GOLGA8N signif in si-SUV39H1  1.8 1.3 
GSTZ1 signif in si-SUV39H1  1.8 1.1 
AQP7P3 signif in si-SUV39H1  1.8 1.2 
GALNT18 signif in si-SUV39H1  1.8 1.0 
PDE11A signif in si-SUV39H1  1.8 1.1 
C1orf115 signif in si-SUV39H1  1.8 1.5 
HAGH signif in si-SUV39H1  1.8 1.0 
CAMTA1 signif in si-SUV39H1  1.8 1.3 
C12orf56 signif in si-SUV39H1  1.7 1.4 
TBKBP1 signif in si-SUV39H1  1.7 1.4 
ULBP1 signif in si-SUV39H1  1.7 1.3 
FAM195B signif in si-SUV39H1  1.7 1.0 
RBPMS2 signif in si-SUV39H1  1.7 1.2 
SERPINA3 signif in si-SUV39H1  1.7 1.0 
IDUA signif in si-SUV39H1  1.7 0.9 
STARD8 signif in si-SUV39H1  1.7 1.4 
SLC22A18 signif in si-SUV39H1  1.7 1.1 
FGFR4 signif in si-SUV39H1  1.7 1.4 
POMGNT2 signif in si-SUV39H1  1.7 1.5 
OVGP1 signif in si-SUV39H1  1.6 1.0 
HS1BP3 signif in si-SUV39H1  1.6 1.3 
NAPRT signif in si-SUV39H1  1.6 1.0 
CLN3 signif in si-SUV39H1  1.6 1.4 
PLEKHA7 signif in si-SUV39H1  1.6 1.1 
GRN signif in si-SUV39H1  1.6 1.2 
PQLC2 signif in si-SUV39H1  1.6 1.4 
FAM213A signif in si-SUV39H1  1.5 1.3 
ZNF512B signif in si-SUV39H1  1.5 1.1 
PRADC1 signif in si-SUV39H1  1.5 1.0 
TRPV1 signif in si-SUV39H1  1.5 0.8 
TMEM63B signif in si-SUV39H1  1.5 1.2 
GNPTG signif in si-SUV39H1  1.5 0.9 
UVSSA signif in si-SUV39H1  1.5 1.1 
CNNM3 signif in si-SUV39H1  1.5 1.1 
PCK1 signif in si-SUV39H1  1.5 0.5 
OSBPL2 signif in si-SUV39H1  1.5 1.1 
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ECI1 signif in si-SUV39H1  1.5 1.2 
GAA signif in si-SUV39H1  1.5 1.0 
AGT signif in si-SUV39H1  1.5 1.3 
TOLLIP signif in si-SUV39H1  1.5 1.1 
TEX264 signif in si-SUV39H1  1.4 1.1 
OTUB2 signif in si-SUV39H1  1.4 1.0 
GET4 signif in si-SUV39H1  1.4 1.0 
CLCN7 signif in si-SUV39H1  1.4 1.0 
CLPTM1L signif in si-SUV39H1  1.4 1.0 
GOLGA6L5P signif in si-SUV39H1  1.4 1.0 
SLC26A6 signif in si-SUV39H1  1.4 1.1 
CALCOCO1 signif in si-SUV39H1  1.4 1.1 
RNF220 signif in si-SUV39H1  1.3 1.1 
PLOD3 signif in si-SUV39H1  1.3 1.0 
SLC38A10 signif in si-SUV39H1  1.3 1.1 
LMAN2 signif in si-SUV39H1  1.3 0.9 
WWP2 signif in si-SUV39H1  1.3 1.0 
HECTD3 signif in si-SUV39H1  1.3 1.0 
LRPAP1 signif in si-SUV39H1  1.3 0.9 
IL17RA signif in si-SUV39H1  1.3 1.2 
TSPAN9 signif in si-SUV39H1  1.3 1.0 
HDAC6 signif in si-SUV39H1  1.3 1.1 
IQSEC1 signif in si-SUV39H1  1.3 1.0 
TBC1D13 signif in si-SUV39H1  1.2 1.1 
DLGAP4 signif in si-SUV39H1  1.2 0.9 
S100A9  signif in si-RBMX/L1 1.1 24.3 
LINC01559  signif in si-RBMX/L1 4.5 17.2 
ADRA2C  signif in si-RBMX/L1 2.4 11.0 
SPANXN3  signif in si-RBMX/L1 3.9 10.9 
PRSS8  signif in si-RBMX/L1 4.0 8.8 
DUOX1  signif in si-RBMX/L1 0.7 8.3 
NEFL  signif in si-RBMX/L1 2.3 8.2 
CES1  signif in si-RBMX/L1 1.5 7.2 
PRODH  signif in si-RBMX/L1 3.3 6.9 
SLC16A14  signif in si-RBMX/L1 2.6 6.1 
SMIM2-AS1  signif in si-RBMX/L1 1.6 5.5 
XIRP1  signif in si-RBMX/L1 1.4 5.2 
GJA5  signif in si-RBMX/L1 2.0 5.1 
ABCG1  signif in si-RBMX/L1 0.8 5.1 
LRP2  signif in si-RBMX/L1 1.6 5.0 
KSR2  signif in si-RBMX/L1 1.6 5.0 
C2orf72  signif in si-RBMX/L1 1.8 4.8 
DDX11L5  signif in si-RBMX/L1 3.3 4.5 
ADGRG4  signif in si-RBMX/L1 1.9 4.5 
KLHDC7A  signif in si-RBMX/L1 3.4 4.2 
CALCA  signif in si-RBMX/L1 1.4 4.1 
EBI3  signif in si-RBMX/L1 2.0 3.9 
VSTM2L  signif in si-RBMX/L1 0.9 3.9 
KCNQ3  signif in si-RBMX/L1 1.7 3.9 
PEG3  signif in si-RBMX/L1 1.5 3.8 
DNER  signif in si-RBMX/L1 1.8 3.8 
AQP7  signif in si-RBMX/L1 2.9 3.8 
MRO  signif in si-RBMX/L1 1.5 3.6 
CLRN3  signif in si-RBMX/L1 1.8 3.6 
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MYH14  signif in si-RBMX/L1 1.6 3.4 
TNFSF9  signif in si-RBMX/L1 2.1 3.3 
RNF125  signif in si-RBMX/L1 1.8 3.1 
FAM84B  signif in si-RBMX/L1 2.1 3.0 
MYO5B  signif in si-RBMX/L1 1.8 2.9 
TFCP2L1  signif in si-RBMX/L1 1.8 2.9 
SCN3B  signif in si-RBMX/L1 1.6 2.8 
SERPINF2  signif in si-RBMX/L1 1.0 2.8 
TMEM178B  signif in si-RBMX/L1 1.5 2.7 
SLC7A2  signif in si-RBMX/L1 1.0 2.6 
FGB  signif in si-RBMX/L1 0.4 2.4 
LAMB3  signif in si-RBMX/L1 1.3 2.4 
NEB  signif in si-RBMX/L1 1.6 2.4 
FRMD3  signif in si-RBMX/L1 0.8 2.3 
FLVCR2  signif in si-RBMX/L1 1.2 2.3 
TAT  signif in si-RBMX/L1 1.3 2.2 
PRSS3  signif in si-RBMX/L1 0.8 2.2 
PTPRH  signif in si-RBMX/L1 1.4 2.2 
APOB  signif in si-RBMX/L1 1.1 2.1 
GOLGA8DP  signif in si-RBMX/L1 1.3 2.1 
GOLGA8EP  signif in si-RBMX/L1 1.3 2.1 
PTPRD  signif in si-RBMX/L1 1.2 2.1 
OLFM4  signif in si-RBMX/L1 0.5 2.1 
GOLGA8CP  signif in si-RBMX/L1 1.2 2.0 
AIF1L  signif in si-RBMX/L1 0.5 2.0 
RBP4  signif in si-RBMX/L1 0.8 2.0 
STMN3  signif in si-RBMX/L1 0.4 2.0 
B3GNT5  signif in si-RBMX/L1 1.2 2.0 
MUC17  signif in si-RBMX/L1 0.6 1.9 
ZNF560  signif in si-RBMX/L1 1.1 1.9 
TMEM86A  signif in si-RBMX/L1 1.1 1.8 
GPR39  signif in si-RBMX/L1 1.5 1.8 
EFNB1  signif in si-RBMX/L1 1.2 1.8 
HSD3B7  signif in si-RBMX/L1 1.4 1.7 
FGA  signif in si-RBMX/L1 0.3 1.7 
MAPK13  signif in si-RBMX/L1 1.5 1.7 
DGAT2  signif in si-RBMX/L1 1.1 1.7 
SLC29A3  signif in si-RBMX/L1 1.3 1.7 
ADCK2  signif in si-RBMX/L1 1.4 1.6 
KIAA1671  signif in si-RBMX/L1 1.5 1.6 
GGT1  signif in si-RBMX/L1 1.1 1.6 
PTPRF  signif in si-RBMX/L1 1.2 1.5 
ITPR1  signif in si-RBMX/L1 1.0 1.5 
KIAA1217  signif in si-RBMX/L1 1.3 1.5 
LOC101927374  signif in si-RBMX/L1 1.3 1.5 
PNKD  signif in si-RBMX/L1 1.1 1.5 
XPNPEP2  signif in si-RBMX/L1 1.2 1.4 
APOA4  signif in si-RBMX/L1 0.7 1.4 
FAM212B  signif in si-RBMX/L1 1.1 1.4 
HDHD3  signif in si-RBMX/L1 1.4 1.4 
SLC6A8  signif in si-RBMX/L1 0.9 1.4 
LOC101929567  signif in si-RBMX/L1 1.3 1.4 
H6PD  signif in si-RBMX/L1 1.2 1.4 
ATP11A  signif in si-RBMX/L1 1.2 1.3 
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CHAPTER 5. PERSPECTIVES AND FUTURE DIRECTIONS 
The packaging of DNA into repressive heterochromatin is a crucial process for the 
maintenance of genome stability (Peng and Karpen, 2008) and for lineage commitment in 
the early embryo (Fadloun et al., 2013a), and it has emerged as a major barrier to the 
reprogramming of differentiated cell identity (Soufi et al., 2012; Becker et al., 2016). 
Classically, heterochromatic structures were discerned on the basis of their physical 
compaction, such as by the density of DNA under the microscope (Heitz, 1928; Brown, 
1966), and early biophysical studies reported that heterochromatin is resistant to 
mechanical shearing and sediments more rapidly during centrifugation (Frenster et al., 
1963; Doenecke and McCarthy, 1975). Modern genome-wide mapping of histone 
modifications such as H3K9me3 and H3K27me3, which are enriched over known well-
characterized heterochromatic regions such as pericentromeric repeats (Nakayama et al., 
2001; Lehnertz et al., 2003) and the inactive X chromosome (Plath et al., 2003), have 
allowed global assessment of heterochromatic domain positions in the genome and their 
dynamics across development lineages (Hawkins et al., 2010; Zhu et al., 2013; Xu et al., 
2014a). However, emerging evidence of H3K9me3 and H3K27me3 in active chromatin 
regions (Piacentini et al., 2003; Vakoc et al., 2005; Blahnik et al., 2011; Riddle et al., 2012) 
suggests that these marks may lack sufficient sensitivity and specificity to reveal domains 
that are physically condensed and transcriptionally silent. I developed a method, called 
Gradient-seq, to allow genome-wide mapping of heterochromatic domains on the basis of 
their compacted structure, as reflected in their resistance to fragmentation. This approach 
involves isolation of heterochromatic regions as intact chromatin, enabling our team to 
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characterize the proteins physically associated with these regions, including novel 
heterochromatin proteins we show to be functional regulators of gene silencing. 
 
5.1 Gradient-seq as a method to map the human heterochromatin landscape 
I observed that H3K9me3-marked DBR domains, previously mapped on the basis of an 
impediment to reprogramming factor binding (Soufi et al., 2012), were consistently 
depleted in input sequencing tracks for ChIP-seq experiments (Figure 4-1A), which 
suggested that resistance to sonication may be a widespread feature of heterochromatic 
regions. This agreed with previous work showing that heterochromatin is resistant to 
mechanical shearing (Frenster et al., 1963) and that highly sonication-sensitive regions 
map to active gene promoters (Auerbach et al., 2009), but the genome-wide 
correspondence between sonication resistance and heterochromatin was not initially 
clear. I found that isolation of sonication-resistant chromatin fragments was sufficient to 
enrich heterochromatic sequences in DBRs over euchromatic sequences by a magnitude 
comparable to conventional H3K9me3 ChIP (Supp. Fig. 4-1C). Using next-generation 
sequencing, I measured the relative representation of genomic sequences in the 
sonication-resistant material versus the sonication-sensitive material, a method that I 
termed Gradient-seq. The domains of sonication-resistant chromatin, which I refer to as 
structural heterochromatin (strucHC), show striking overlap with most H3K9me3 ChIP-seq 
domains (Figure 4-1F), contain genes with very low levels of gene expression by mRNA-
seq (Figure 4-2D), cover nearly 100% of most heterochromatic satellite repeat elements 
(Figure 4-3F), show high rates of DNA methylation at CpG islands (Figure 4-2F), and are 
globally resistant to DNase I digestion (Figure 4-4D). Thus, the regions of the genome 
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purified by gradient sedimentation meet a variety of criteria traditionally associated with 
heterochromatin (Richards and Elgin, 2002). 
   This technique for physically enriching heterochromatin was informed by previous 
work using sucrose gradients to investigate chromatin structure (Gilbert et al., 2004; 
Ghirlando and Felsenfeld, 2008; Ishihara et al., 2010). Bickmore and colleagues, whose 
ultracentrifugation conditions were the basis for my own studies, showed gene-poor 
regions tend to sediment more rapidly after MNase digestion (Gilbert et al., 2004). 
Subsequent work showed that transcription of an inducible gene was inversely correlated 
with sedimentation rate for crosslinked, sonicated chromatin fragments (Ishihara et al., 
2010). However, these studies detected DNA sequences using 1 MB interval microarrays 
(Gilbert et al., 2004) or quantitative PCR (Ishihara et al., 2010), or compared specific 
fragments excised by nucleases (Ghirlando and Felsenfeld, 2008), and thus rapidly 
sedimenting regions of chromatin have never been mapped with genomic resolution. More 
importantly, these studies all isolated fragments of the same size in order to investigate 
changes in chromatin buoyancy (Gilbert et al., 2004; Ghirlando and Felsenfeld, 2008; 
Ishihara et al., 2010), and thus their findings were unrelated to fragmentation resistance. 
Meanwhile, my observations using input tracks for ChIP-seq suggest that sonication 
resistance alone is a reliable indicator of heterochromatic regions. Furthermore, since our 
method for detecting heterochromatin avoids an electrophoresis-based size-selection step 
(Gilbert et al., 2004; Ishihara et al., 2010), it is compatible with subsequent analysis of 
proteins co-purifying with heterochromatin (Figure 4-5). For the purposes of genomic 
mapping of heterochromatin, however, future work should investigate whether isolation of 
large sonicated DNA fragments (by gel electrophoresis or bead selection), and thereby 
eliminating the effects of differential buoyancy related to chromatin shape, is sufficient to 
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produce genome-wide maps comparable to Gradient-seq. Such an adapted DNA-focused 
method might facilitate the generation of heterochromatin maps for diverse cell and tissue 
types, to gain insight into heterochromatin dynamics across development. 
 The finding that heterochromatic regions are depleted from highly sonicated 
chromatin highlights an important bias in some ChIP-seq studies. All ChIP-seq data 
presented here was normalized to a corresponding input sample on a bin-by-bin basis or 
per-basepair basis for track generation. However, normalization by input-subtraction or 
input-division is not a routine part of the bioinformatics workflow for public consortia such 
as Roadmap Epigenomics (Zhu et al., 2013; Roadmap Epigenomics Consortium et al., 
2015) or ENCODE (ENCODE Project Consortium, 2012), which make ChIP-seq signal 
tracks available in unnormalized form. Studies based on these public resources, without 
normalizing for input, have claimed that large H3K9me3 domains in human cells are 
dependent upon serum used for cell culture (Zhu et al., 2013). However, my re-analysis 
of the same datasets revealed that H3K9me3 domains can be detected with comparable 
abundance across a range of cell and tissue types, in vitro and in vivo, but this detection 
requires input normalization (Supp. Fig. 4-1B). Thus, although it is possible that serum 
affects the magnitude of the H3K9me3 ChIP signal, neither the existence of large 
H3K9me3 domains nor the sonication resistance of those domains are culture artifacts. 
Recently, the Roadmap consortium published a chromatin state segmentation that 
consistently assigned small fractions of the genome to the “Heterochromatin” state 
(Roadmap Epigenomics Consortium et al., 2015). The algorithm used in this analysis did 
account for local enrichments in input but assumed a minimum background signal based 
on the genome average (Roadmap Epigenomics Consortium et al., 2015). My results 
suggest that these widely used genomic tools might warrant revision to account for regions 
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consistently depleted from input chromatin. Furthermore, in light of other recent studies 
mapping domains domains resistant to MNase digestion (Mieczkowski et al., 2016), which 
generally agree with the sonication-resistant strucHC domains (Supp. Fig. 4-4B,C) 
(exceptions discussed below), local normalization to input should be applied to ChIP-seq 
datasets produced by sonication and MNase digestion alike. 
 
5.2 Heterochromatic versus euchromatic subtypes of H3K9me3 domains 
Overall, the strucHC domains enriched by Gradient-seq show a high rate of agreement 
with conventional H3K9me3 ChIP-seq (Figure 4-1F, 4-2A), and 96.8% of the H3K9me3 
domain coverage falls into either the strucHC or intermediate domain categories (Figure 
4-2C), which have low rates of gene transcription (Figure 4-3B). However, the remaining 
31 MB of H3K9me3-marked chromatin overlaps with structurally euchromatic domains, 
defined by a depletion of sequencing signal in the strucHC fraction compared to the 
euchromatin fraction (see plot in Figure 4-4A). This euchromatic subtype of H3K9me3 
domains has remarkable selectivity for specific gene classes (Table 4-1), in particular 
KRAB-ZNF genes (Figure 4-3A,C), which form large gene clusters on chromosome 19 
(Vogel et al., 2006). Earlier work shows that these genes are expressed from both alleles 
and are co-marked by H3K9me3 and the elongation-associated mark H3K36me3 (Blahnik 
et al., 2011), and similarly I find that the euchromatic H3K9me3 domains as a whole 
contain mostly active genes (Figure 4-3B) and are enriched for H3K36me3 (Supp. Fig. 4-
3A). The fact that KRAB-ZNF gene clusters also form large domains of HP1 binding (Vogel 
et al., 2006) rules out the possibility that H3K9me3 detection in these regions is an artifact 
of poor antibody specificity. The sonication-sensitive structure of these regions, combined 
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with the fact that more than three-quarters of the genes they contain have mRNA-seq 
signal (Figure 4-3B), is arguably sufficient to justify labeling such regions of H3K9me3 as 
“euchromatic.” However, I note that the classification of these regions as distinct from 
heterochromatin is further supported by the hypomethylation of CpG islands in these 
regions (in stark contrast to strucHC, see Figure 4-4B), as well as the reduction in contact 
with the nuclear lamina (Figure 4-4C, Supp. Fig. 4-4D), which is a conserved property of 
heterochromatic regions (Towbin et al., 2013). 
A previous analysis of three-dimensional genome contacts by Hi-C found that 
KRAB-ZNF genes have a unique pattern of interactions compared to other H3K9me3-
marked regions, warranting their separate classification as subcompartment B4 (Rao et 
al., 2014) and supporting the idea that these regions are structurally distinct. However, 
this analysis was performed at low resolution (100-kb), and there was only sufficient 
sensitivity to detect subcompartment B4 when the analysis was performed on 
chromosome 19 alone (Rao et al., 2014), meaning that it was not possible to detect similar 
regions elsewhere in the genome. I have generated the first genome-wide map of 
H3K9me3 domains with these euchromatic properities, which can be found on all 24 
chromosomes and have three-times more genomic coverage than was mapped for 
subcompartment B4 (Rao et al., 2014). I find that genes other than KRAB-ZNFs, such as 
the transcribed protocadherin gamma cluster that is involved in intercellular 
communication (Chen and Maniatis, 2013), are also found in this chromatin subtype 
(Figure 4-3C). It is notable that H3K9me3 overlapping euchromatin appears so selective 
for genes that exist as reiterated gene clusters, including HOX genes (Figure 4-3C). It is 
tempting to speculate H3K9me3 is recruited to these gene bodies, despite the fact that 
they are transcribed in this cell type, in order to prevent illicit recombination between the 
  174 
similar sequences of these nearby genes, as has previously been suggested (Blahnik et 
al., 2011). Indeed, it was shown that an isolated 3’ ZNF exon, a unit shared by many ZNF 
genes, is sufficient to recruit H3K9me3 when integrated elsewhere in the genome (Blahnik 
et al., 2011). However, this model should be further tested by investigating whether 
depletion of H3K9me3, HP1, or other heterochromatin components leads to increased 
recombination or mutagenesis at genes in euchromatic H3K9me3 domains. It will also be 
informative to compare genes and repeat classes in humans euchromatic H3K9me3 
domains to those on Drosophila chromosome 4, which was also shown to have 
transcriptionally permissive H3K9me3 domains (Riddle et al., 2012), to see if any 
overarching principles can be discerned. 
 Although the H3K9me3 domains overlapping euchromatin represent a small 
fraction the total fibroblast H3K9me3 domains in the genome (31 of 968 MB), these 
regions have been instrumental to the study of H3K9me3 regulation, without widespread 
recognition of their unique properties. KRAB-ZNF gene clusters are the major sites where 
chromatin binding by KAP1/TRIM28 depends on its recruitment by KRAB-ZNF proteins 
(Iyengar et al., 2011), as part of a potential autoregulatory mechanism (O’Green et al., 
2007; Frietze et al., 2010). In light of my findings, KAP1 recruitment by KRAB-ZNFs, which 
previously has been suggested as a model for heterochromatin domain formation (Groner 
et al., 2010), is compatible with both gene transcription and a sonication-sensitive 
chromatin structure, and is therefore not sufficient for heterochromatin establishment. The 
H3K9me3 signal over ZNF genes is in fact so prominent that a major study associated 
with the Roadmap Epigenomics consortium (Zhu et al., 2013) used these sites to 
standardize their H3K9me3 ChIP-seq datasets across cell types. The fact that sonication-
sensitive H3K9me3 sites were used to define positive signal, combined with the lack of 
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normalization to an input control, may have suppressed the detection of sonication-
resistant heterochromatic domains in this study (Zhu et al., 2013). 
In addition to KAP1, our finding of H3K9me3 domains with euchromatic structure 
is also important for study of the three-protein HUSH complex, which regulates SETDB1 
recruitment and H3K9me3 deposition (Tchasovnikarova et al., 2015). Although 
euchromatic H3K9me3 domains are comparatively rare, they account for a majority of 
reported HUSH-regulated sites in fibroblast H3K9me3 domains (Figure 4-3D), including 
the strongest sites (Supp. Fig. 4-3C) and sites highlighted in the original report 
(Tchasovnikarova et al., 2015) at ZNF and non-ZNF genes. My data suggest that HUSH 
complex binding promotes H3K9me3 deposition without significant chromatin compaction, 
challenging the use of the term “heterochromatin” to describe such sites (Timms et al., 
2016). Nonetheless, my observations are compatible with published model that the HUSH 
complex “dims” the expression of transcribed genes but does not silence them fully 
(Tchasovnikarova et al., 2015; Timms et al., 2016). Future work should investigate the 
contribution of HUSH binding to chromatin accessibility as opposed to merely the readout 
of the H3K9me3 mark. 
A major outstanding question is what chromatin components or mechanisms 
distinguish euchromatic from heterochromatic H3K9me3 domains. Although the HUSH 
complex seems to preferentially act in the euchromatic subtype (Figure 4-3D), the loss of 
this complex leads to increased gene expression and reduced H3K9me3 in these regions 
(Tchasovnikarova et al., 2015), meaning that HUSH is not converting regions that would 
otherwise be heterochromatic H3K9me3 to euchromatin. An attractive experimental 
strategy would be to perform H3K9me3-directed IP from of the euchromatic gradient 
fraction, followed by mass spectrometry, to identify more proteins associated with these 
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regions. I indeed performed such IPs using the euchromatin fraction (analysis of DNA in 
Supp. Fig. 4-1D, sequencing track in Figure 4-3A); however, I found that the amount of 
chromatin obtained was too low to yield informative proteomic data (data not shown). An 
additional challenge of such a purification strategy is that the second step, the H3K9me3 
IP, also re-enriches the heterochromatic H3K9me3 domains (which are depleted <2-fold, 
but still present, in the euchromatic fraction – see Figure 4-1C), and the much greater 
genomic abundance of the heterochromatic regions would presumably cause them to 
overwhelm the signal from the rarer euchromatic regions. A more viable strategy might be 
to perform careful proteomic comparisons between a traditional H3K9me3 ChIP-MS and 
H3K9me3 ChIP from the strucHC fraction, seeking to identify proteins enriched in the 
former compared to the latter, which would be candidates for binders of euchromatic 
H3K9me3 chromatin. Alternatively, to directly purify regions of euchromatic H3K9me3, 
future work could use a protocol called “proteomics of isolated chromatin segments” 
(PICh) (Déjardin and Kingston, 2009), which uses nucleic acid probes to pull down specific 
loci in chromatin and has been used to identify major satellite-associated proteins 
(Saksouk et al., 2014), perhaps directed at an H3K9me3-marked KRAB-ZNF exon. 
Identifying proteins that preferentially promote a euchromatic or heterochromatic structure 
within H3K9me3 domains would be useful for efforts to increase chromatin accessibility 
during cell reprogramming. Such findings may also prove relevant to the chromatin state 
of pluripotent cells, which have H3K9me3-marked regions but lack compacted 
heterochromatin structures by electron spectroscopic imaging and electron microscopy 
(Meshorer and Misteli, 2006; Ahmed et al., 2010; Fussner et al., 2011; Underwood et al., 
2016). 
 
  177 
5.3 Diversity of chromatin structure among H3K27me3 domains 
The literature has been conflicted about whether the term “heterochromatin” includes 
H3K27me3-marked regions, with some authors using the term synonymously with 
H3K9me3-marked and HP1-bound domains (Beisel and Paro, 2011). Indeed, analysis of 
select H3K27me3-marked sites reveals accessibility to binding by general transcription 
machinery (Breiling et al., 2001; Dellino et al., 2004), suggesting that such regions may 
constitute a “lesser” form of heterochromatin. Meanwhile, paradigmatic examples of 
facultative heterochromatin, such as Barr body of the inactive chromosome, are marked 
by H3K27me3 (Plath et al., 2003; Heard, 2005) and also have condensed ultrastructure 
(Rego et al., 2008). Yet H3K9me3-marked chromatin too is dynamic in development 
(Hawkins et al., 2010; Soufi et al., 2012; Becker et al., 2016; Figure 2-1), and thus the 
functional descriptor “facultative” is inadequate to distinguish between the chromatin 
states associated with H3K27me3 versus H3K9me3. Clearly, greater understanding is 
needed on the relationship between H3K27me3-marked domains and structurally 
compact heterochromatin. 
 I find that 49% of the H3K27me3 domains in human fibroblasts (327 of 672 MB; 
Figure 4-2C) fall into domains we map as strucHC by Gradient-seq. The quantitative 
enrichment of these regions in the strucHC fraction compared to the euchromatin fraction 
is actually similar to the H3K9me3-marked strucHC domains (Figure 4-4A, compare red 
plots between H3K9me3 and H3K27me3 subtypes). Thus, H3K9me3- and H3K27me3-
marked forms of strucHC have a chromatin structure that is comparably resistant to 
sonication, supporting the notion that H3K27me3 is a bona fide heterochromatin mark 
(Trojer and Reinberg, 2007). However, compared to H3K9me3, H3K27me3 was less 
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predictive of a heterochromatic or intermediate state, as 29% of H3K27me3 domains (193 
MB; Figure 4-2C) preferentially migrated to the euchromatin fraction (versus 3.2% or 31 
MB of H3K9me3). The euchromatic nature of this H3K27me3 subtype is supported by a 
variety of metrics, including increased gene expression (Figure 4-3B), decreased DNA 
methylation at CpG islands (Figure 4-4B), and marked sensitivity to DNase I digestion 
(Figure 4-4D). The euchromatic subtype of H3K27me3 includes all four major HOX gene 
clusters (Figure 4-3C,E), which have been model loci for the study of Polycomb-regulated 
regions over decades (Lewis, 1978; Duncan, 1982; Xu et al., 2014b), without widespread 
acknowledgement that these regions have an atypical chromatin structure compared to 
more heterochromatic H3K27me3 regions. These findings highlight the challenges of 
generalizing from specific H3K27me3-marked loci to all PRC targets. Future work might 
investigate whether the accessibility of H3K27me3-marked chromatin to transcription 
factor binding (Breiling et al., 2001; Dellino et al., 2004) is different between the strucHC 
and euchromatic subtypes mapped in this study. 
 
5.4 Relationship between chromatin subtypes and hallmark properties of repressive 
chromatin 
A variety of proprieties have been associated with H3K9me3-marked chromatin or 
repressive regions of the genome–such as DNA methylation (Lehnertz et al., 2003), 
localization with the nuclear periphery (Csink and Henikoff, 1996; Guelen et al., 2008; 
Poleshko et al., 2013; Towbin et al., 2013), late replication (O’Keefe et al., 1992; Chandra 
et al., 2012), and resistance to nuclease digestion (Gottesfeld et al., 1975; Wallrath and 
Elgin, 1995; Hamid et al., 1996)—and they have generally have been studied separately. 
It has been unclear whether these properties are directly associated with H3K9me3 
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deposition, compacted chromatin structure, or both, and our identification of H3K9me3 
domains inside and outside of strucHC (as well as strucHC regions lacking H3K9me3 or 
H3K27me3 enrichment) provided an opportunity to test these questions. We find that, 
within CpG islands, the frequency of DNA methylation per CpG shows remarkable 
correlation with the structural classifications from Gradient-seq (Figure 4-4B). Island CpGs 
are consistently methylated in strucHC, regardless of histone mark, and are consistently 
hypomethylated in euchromatin, with and without H3K9me3 or H3K27me3. The highest 
rates of methylation are, in fact, seen at strucHC domains with neither mark enriched. The 
nature of this “third” heterochromatin state, distinct from H3K9me3 and H3K27me3 
domains, remains mysterious at present. Performing gradient sedimentation before and 
after 5-azacytosine treatment, to inhibit DNA methyltransferases, would allow 
determination of whether the observed hypermethylated state is required for 
heterochromatic compaction in these regions. Overall, the patterns of CpG island 
methylation, similar to gene transcription (Figure 4-3B), show a direct relationship with 
genome structure as measured by Gradient-seq. However, since, outside of CpG islands, 
DNA methylation is high in all chromatin categories (Supp. Fig. 4-4A), bisulfite sequencing 
cannot be used to map the full territory of heterochromatin regions. 
 In contrast to CpG island methylation, DNA replication timing is most accurately 
predicted by histone mark rather than extent of chromatin compaction. The strucHC and 
euchromatic subtypes of H3K9me3 replicate similarly late in S phase, while all forms of 
H3K27me3 replicate much earlier (Figure 4-4E). These striking associations for 
H3K9me3- and H3K27me3-marked chromatin were described in some previous studies 
(Chandra et al., 2012), while other groups report weak associations between replication 
timing and histone marks based on genome segmentation models (Dileep et al., 2015), 
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perhaps related to issues of input-normalization discussed above. My data suggest that 
late replication might be conferred by chromatin complexes that localize to H3K9me3-
marked domains, rather than being a direct byproduct of a compacted chromatin structure, 
and that late replication and active gene transcription can co-occur (at euchromatic 
subtypes of H3K9me3). Meanwhile, association of chromatin with the nuclear lamina is 
predicted by specific combinations of structural and histone mark classifications (Figure 
4-4C, Supp. Fig. 4-4D). H3K9me3 domains generally have higher levels of lamin B1 
binding compared to H3K27me3 domains, but within both histone mark categories, 
strucHC and intermediate subtypes showed greater lamin association than euchromatic 
subtypes. 
 Resistance to nucleases like DNase I and MNase is typically interpreted as a 
measure of chromatin structure (Wallrath and Elgin, 1995; Hamid et al., 1996; Thurman 
et al., 2012). It is reassuring that that there is a strong overall concordance between the 
classifications from Gradient-seq and nuclease-based datasets, with euchromatin regions 
showing higher rates of DNase I cleavage (Figure 4-4D) and sensitivity to MNase (Supp. 
Fig. 4-4B). In particular, fibroblast strucHC domains overlap strikingly with domains of 
increased resistance to MNase, determined based on MNase titration in K562 leukemia 
cells (Mieczkowski et al., 2016), particularly among regions with similar H3K9me3 and 
H3K27me3 signals in both cell types. Thus, my findings can be generally corroborated by 
independent approaches not involving sonication or gradient sedimentation. However, a 
key distinction between these methods occurs at the regions of H3K9me3 that are 
euchromatic by Gradient-seq, but remain largely resistant to DNase I (Figure 4-4D) and 
MNase (Supp. Fig. 4-4B,C). Inspection of regions co-marked by H3K9me3 and 
H3K36me3 in both fibroblasts and K562 cells reveals a highly sonication-sensitive 
  181 
chromatin structure by Gradient-seq but resistance to MNase (Supp. Fig. 4-4C). Since 
these two “structural” approaches are discordant regarding the accessibility of such 
regions, independent methods should be used to adjudicate the discrepancy, such as this 
late breaking paper (Risca et al., 2016) that uses correlations in radiation-induced DNA 
cleavage to investigate chromatin structure. However, in the meantime, given that 
euchromatic H3K9me3 domains (according to Gradient-seq) are permissive to gene 
transcription (Figure 4-3B) and DNA hypomethylation (Figure 4-4B), it is likely that there 
is at least some increased chromatin accessibility in these regions compared to other 
types of H3K9me3-marked chromatin. It is possible that something about the local 
environment of H3K9me3-marked chromatin or the chromatin complexes bound to these 
sites that inhibits DNA cleavage reactions, including at more euchromatic sites, and that 
the structure of such regions is better probed by a non-enzymatic method involving sound 
waves/cavitation. Although it remains to be established whether Gradient-seq is a superior 
readout of chromatin structure compared to nuclease-based methods, we note that only 
Gradient-seq allows separation of transcriptionally silent H3K9me3 domains from 
transcriptionally active ones prior to proteomics, which was a principal goal of our study. 
 
5.5 Heterochromatin impedes direct conversion between differentiated 
lineages 
The impediment of genes to be activated during reprogramming is a property, like lamin 
B1 binding, that also appears to be related to both structural state of chromatin and histone 
mark enrichment. Previous transcriptomic analysis showed that, after fibroblasts are 
converted to human induced hepatocytes (hiHeps), large numbers of genes expressed in 
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native liver cells remain aberrantly repressed in the reprogrammed hiHep cells (Huang et 
al., 2014). However, properties of chromatin that predict whether a hepatic gene will be 
properly induced were not identified. I found that, among hepatic genes that are initially 
silent in fibroblasts, H3K9me3-marked genes have a profound defect in activation (Supp. 
Fig. 4-1A), with the majority of genes showing little to no activation above fibroblast levels 
at the conclusion of hiHep reprogramming. This defect was not apparent in H3K27me3-
marked chromatin (Supp. Fig. 4-1A). These findings are consistent with prior evidence 
that H3K9me3-marked chromatin, in particular, presents an impediment to reprogramming 
to pluripotency (Soufi et al., 2012; Matoba et al., 2014). Moreover, these results suggest 
that H3K9me3-marked chromatin poses a general barrier to cell fate reprogramming that 
is not contingent on specific factor combinations (such as OSKM) (Soufi et al., 2012, 2015) 
or the reprogramming being towards a state like pluripotency that has more limited 
heterochromatin (Meshorer and Misteli, 2006; Ahmed et al., 2010; Fussner et al., 2011; 
Underwood et al., 2016). 
 The differential effects of H3K9me3 versus H3K27me3 on hepatic gene activation 
during reprogramming persist even when the comparison is restricted to within strucHC 
(red plots in Figure 4-6A). Thus, even among regions with a similarly sonication-resistant 
chromatin structure, H3K9me3-marked chromatin is uniquely refractory to gene activation, 
revealing an important functional difference between these two heterochromatic marks. 
Moreover, this finding further justifies the study of H3K9me3-associated heterochromatin 
proteins as a means to understand barriers to cell conversion (Becker et al., 2016). 
However, among H3K27me3-marked regions, the strucHC subtype has the lowest levels 
of hepatic gene induction (Figure 4-6A), suggesting that sonication-resistant 
heterochromatic structure also impedes reprogramming independent from the H3K9me3 
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mark. Moreover, whereas the strucHC and intermediate subtypes of H3K9me3 domains 
are refractory to gene activation by hiHep factors, the euchromatic subtype of H3K9me3 
is not (Figure 4-6A). Consequently, the depletion of such sonication-sensitive regions by 
gradient sedimentation is an important step in order to purify only H3K9me3-associated 
proteins that are relevant to reprogramming resistance. 
 In contrast to human iPS reprogramming, which proceeds at low efficiency (Hanna 
et al., 2009; Vierbuchen and Wernig, 2012; Papp and Plath, 2013), a high fraction of cells 
(10-15%) at the conclusion of hiHep reprogramming process express the hepatocyte 
marker genes albumin and alpha-1-antitrypsin (Huang et al., 2014) (Supp. Fig. 4-6A), 
which represents as much of half the cells infected with all three lentiviruses at MOI ~1 
per virus. Thus, there is limited dynamic range to observe improvements of the efficiency 
of hiHep reprogramming, whereas the main concern is the low fidelity of the conversion. 
We show that knockdown of SUV39H1 or RBMX/L1 enhances the induction of a variety 
of hepatic genes, marked by H3K9me3 in the starting fibroblasts, both early in 
reprogramming (Figure 4-6D) and at the conclusion of the process (Supp. Fig. 4-6E). 
These findings confirm, first, that the resistance of these heterochromatic H3K9me3 
regions to hiHep reprogramming is dependent on the H3K9me3 methyltransferase 
SUV39H1, similar to the impediment to iPS factor activity (Soufi et al., 2012). Second, this 
shows that siRNA against SUV39H1 or RBMX/L1 enhances the fidelity of conversion at 
the genes most refractory to reprogramming. Ongoing work in the laboratory is 
investigating whether these perturbations also enhance hiHep reprogramming fidelity from 
a functional standpoint, by testing whether the reprogrammed cells have a greater ability 
to engraft in and repopulate the livers of FAH-deficient mice (Azuma et al., 2007). 
Alternatively, one might consider testing whether the siRNA treatments affect the 
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performance of the reprogrammed cells in in-vitro assays of hepatocyte function, such as 
P450 drug metabolism, considering that such activity is typically limited in programmed 
hepatocytes (Vallier, 2014) and given that CYP450 genes are repressed in fibroblast 
H3K9me3 domains (Figure 4-6B). 
We note that the activation of these heterochromatinized hepatocyte genes after 
SUV39H1 or RBMX/L1 knockdown is generally modest in comparison to native 
hepatocytes. This suggests that these regions of chromatin are still refractory to activation 
even in the presence of these perturbations, and it may be useful to try enhancing the 
extent of heterochromatin disruption. One strategy might be to use CRISPR-mediated 
gene deletion instead of RNAi, to produce cells with complete loss of these 
heterochromatin proteins. Alternatively, combinations of heterochromatin perturbations 
should be tested, such as RNAi/CRISPR against multiple H3K9me3-associated proteins, 
or combining SUV39H1 knockdown with HDAC inhibitions in order to simultaneously 
disrupt multiple mechanisms of chromatin compaction.  
 
5.6 Proteomics reveals functional regulators of H3K9me3-marked 
heterochromatin 
Our identification of 172 heterochromatin proteins by quantitative proteomics (Figure 4-
5B) was based on analysis of H3K9me3 IPs performed using the strucHC fraction, 
compared to the euchromatin fraction (Figure 4-5A). Thus, our strategy resembles 
traditional ChIP-MS approaches in terms of its specificity for components of H3K9me3-
marked chromatin (Soldi and Bonaldi, 2013; Engelen et al., 2015; Ji et al., 2015), but has 
the advantage of first depleting transcriptionally active H3K9me3 domains during the 
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gradient sedimentation step. As expected, the list of identified heterochromatin proteins 
includes known structural components of heterochromatin, such as linker histone and 
lamin B1, as well as a variety of known mediators of gene silencing (Figure 4-5D). Our 
results also overlap significantly, but not completely, with the only previous H3K9me3 
ChIP-MS dataset performed for differentiated cells (Soldi and Bonaldi, 2013) (Figure 4-
5E). Furthermore, the strong agreement between proteins enriched in the strucHC fraction 
and those enriched in the H3K9me3 IP off of the strucHC fraction (Figure 4-5C) is 
consistent with H3K9me3-marked chromatin being the major component of the strucHC 
fraction. The fact that 22 of the heterochromatin proteins have previously been shown to 
impede iPS reprogramming (Supp. Fig. 4-5B) suggests that this should be a rich dataset 
for revealing new factors involved in restricting cell fate conversion. 
 A surprising finding is the large number of heterochromatin proteins with RNA 
binding activity (119 of 172). However, this subset of heterochromatin proteins actually 
has an improved rate of overlap with other H3K9me3-related proteomic studies (Figure 4-
5F) (Vermeulen et al., 2010; Soldi and Bonaldi, 2013), indicating that this observation is 
not particular to our approach or method of analysis. The presence of RNA-binding 
proteins in heterochromatin is consistent with previous evidence that RNA-binding by HP1 
is required for its heterochromatin localization (Muchardt et al., 2002), that some 
constitutive heterochromatin regions generate RNA (Saksouk et al., 2015), and that 
particular noncoding RNAs are important for heterochromatic compaction after escape 
from pluripotency (Savić et al., 2014). Specific RNA-binding proteins like HNRNPK, which 
we also find in heterochromatin, have been shown to regulate H3K9me3 
methyltransferases and reprogramming (Bao et al., 2015; Thompson et al., 2015). 
Nonetheless, the role of RNA in mammalian heterochromatin remains controversial, as 
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RNAi-dependent mechanisms for heterochromatin establishment discovered in yeast 
have not been verified in mammals (Saksouk et al., 2015). Since our two-step method for 
heterochromatin purification (gradient sedimentation followed by H3K9me3 IP) achieves 
high purity for heterochromatic regions (Supp. Fig. 4-1C), a major outstanding question is 
which RNAs are present in this sample. Indeed, we have performed RNA-seq from these 
samples, in collaboration with Roberto Bonasio’s laboratory, and analysis of this data is in 
process.  
 We show that two RNA-binding proteins have functional roles in heterochromatic 
gene silencing. First, we show that TARDBP (also known as TDP-43), which is the least 
enriched among six ALS-related proteins in heterochromatin (Figure 4-5G) but the most 
comprehensively studied (Lee et al., 2012), suppresses expression of genes in strucHC 
domains (Supp. Fig. 4-5C,D), using microarray data form human patient-derived 
fibroblasts. This large number of strucHC genes shows modest but widespread 
upregulation in fibroblasts from TARDBP-mutant ALS patients, compared to healthy 
controls, but not in sporadic ALS cases with wild-type TARDBP (Supp. Fig. 4-5C,D). 
Second, we studied the role of RBMX (together with the related protein RBMXL1) in 
regulating gene expression genome-wide, with and without the presence of hiHep 
reprogramming factors. Indeed, RBMX/L1 knockdown led to significant upregulation of 67 
strucHC genes in the absence of exogenous factors (Figure 4-7E, Supp. Fig. 4-7C). 
However, the most striking result was observed in the context of hiHep reprogramming, 
where the effects of SUV39H1 siRNA in enhancing activation of strucHC genes were 
closely mirrored by RBMX/L1 siRNA (Figure 4-7C; Table 4-5). Thus, RBMX/L1 contributes 
to the observed impediment in activating heterochromatic liver genes during hiHep 
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reprogramming, consistent with what was observed at candidate transcripts by RT-PCR 
(Figure 4-6D). 
 The mechanisms by which RBMX/L1 and TARDBP function in heterochromatic 
silencing is currently unclear. A crucial question is whether the RNA-binding activity of 
these proteins is required for the localization to or activity in strucHC. Previous work shows 
that the RNA-recognition motif (RRM) of RBMX is dispensable for both its binding to 
chromatin and its role in regulating centromeric cohesion (Matsunaga et al., 2012), a 
function that has been shown for other heterochromatin proteins like SUV39H1 (Peters et 
al., 2001). Thus, RBMX’s role in strucHC may not require RNA interaction at all. This 
question should be investigated by testing if an RRM-deletion mutant of RBMX 
phenocopies RBMX deletion in terms of enhancing the activation of H3K9me3-marked 
hepatic genes during reprogramming. A similar strategy can be pursued for TARDBP and 
other RNA-binding proteins in our heterochromatin dataset, to investigate the wider 
functional relevance of the observed enrichment for RNA-binding domains among these 
proteins. In addition, to gain insight into the mechanism of RBMX function, it will be useful 
to identify RBMX-interacting proteins by IP and mass spectrometry, to see if RBMX binds 
HP1 or H3K9me3 methyltransferases, as was previously shown for HNRNPK  (Bao et al., 
2015; Thompson et al., 2015). 
 
5.7 Monitoring reprogramming impediments to screen heterochromatin 
proteins 
Our studies with the canonical H3K9me3 regulator SUV39H1 as well as RBMX illustrate 
that perturbation of heterochromatin does not immediately induce widespread de-
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repression of silenced genes. This agrees with previous genetic studies of SUV39H1/H2 
(Bulut-Karslioglu et al., 2014), it may indicate the existence of redundant silencing 
mechanisms or simply the requirement for targeted transcriptional activators to upregulate 
these cell-type specific genes (Figure 4-6D). In light of this data, testing putative 
heterochromatin regulators for whether they are directly required for gene silencing may 
be an inappropriate criterion for establishing functionality. The key functional property of 
heterochromatin is not merely transcriptional repression but dominance over 
transcriptional activating mechanisms, as seen for classic studies of position effect 
variegation (Wallrath and Elgin, 1995; Elgin and Reuter, 2013), as well as, more recently, 
resistance to reprogramming (Soufi et al., 2012). Our experiments in the context of hiHep 
conversion (Figure 4-6D) show that monitoring activation of sentinel heterochromatinized 
genes following ectopic addition of alternative-lineage transcription factors is a powerful 
assay for revealing the action of novel heterochromatin regulators. 
Given that we’ve identified multiple hepatic genes that show an H3K9me3-
dependent impediment to activation during hiHep reprogramming (Figure 4-7C,D), it is 
possible to leverage such sites in order to screen a wider set of proteins for functional 
roles in heterochromatin. Specifically, we are conducting an siRNA screen of 
approximately 100 heterochromatin proteins, from our proteomic analysis as well as select 
candidates from the literature. Similar to the experimental design in Figure 4-7A (top), we 
have transduced cells with hiHep transcription factors followed by independent siRNAs 
against each candidate heterochromatin protein. The endpoint of the assay is RT-PCR for 
hepatic genes in strucHC, such as DSC2, CRP and NR1H4 (Figure 4-6D, 4-7D), with the 
goal of identifying proteins whose knockdown enhances the reprogramming of these 
genes, similar to RBMX. This approach can be extended beyond the hepatic lineage, by 
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using transcription factor combinations for iPS reprogramming (Takahashi and 
Yamanaka, 2006), conversion to neurons (Vierbuchen et al., 2010), or reprogramming to 
diverse other lineages. Our major goal is to identify additional components of the 
heterochromatin proteome that, like RBMX, oppose the induction of H3K9me3-marked 
genes for other fates.  Of particular interest would be proteins that are involved in impeding 
conversion to specific lineages but not others. Such findings could help shed light on the 
cell type-specific mechanisms of heterochromatin establishment that help to guard against 
changes in cell identity, but that so far have remained elusive. 
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Appendix A. Bookmarking by specific and nonspecific 
binding of FoxA1 pioneer factor to mitotic chromosomes 
This appendix contains a manuscript to which I contributed during my graduate work, 
which was published in Genes and Development (Vol. 27(3), p. 251-260), and in which I 
am listed as the third author. The large majority of the work in this manuscript was 
performed by Juanma Caravaca, Ph.D., under the guidance of Dr. Zaret. I performed the 
RNA polymerase II immunofluorescence experiments as well as the ethynyl uridine RNA 
labeling experiments that are presented in Supplementary Figure 5, and which supported 
the choice of RT-PCR timepoints used in Figure 6. The manuscript was written by Dr. 
Caravaca and Dr. Zaret, and I assisted in editing the manuscript.  
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Bookmarking by specific and nonspecific
binding of FoxA1 pioneer factor to mitotic
chromosomes
Juan Manuel Caravaca,1 Greg Donahue,1 Justin S. Becker,1 Ximiao He,2 Charles Vinson,2
and Kenneth S. Zaret1,3
1Epigenetics Program, Department of Cell and Developmental Biology, University of Pennsylvania, Perelman School of
Medicine, Smilow Center for Translation Research, Philadelphia, Pennsylvania 19104, USA; 2National Cancer Institute,
National Institutes of Health, Bethesda, Maryland 20892, USA
While most transcription factors exit the chromatin during mitosis and the genome becomes silent, a subset of
factors remains and ‘‘bookmarks’’ genes for rapid reactivation as cells progress through the cell cycle. However,
it is unknown whether such bookmarking factors bind to chromatin similarly in mitosis and how different
binding capacities among them relate to function. We compared a diverse set of transcription factors involved in
liver differentiation and found markedly different extents of mitotic chromosome binding. Among them, the
pioneer factor FoxA1 exhibits the greatest extent of mitotic chromosome binding. Genomically, ~15% of the
FoxA1 interphase target sites are bound in mitosis, including at genes that are important for liver differentiation.
Biophysical, genome mapping, and mutagenesis studies of FoxA1 reveals two different modes of binding to
mitotic chromatin. Specific binding in mitosis occurs at sites that continue to be bound from interphase.
Nonspecific binding in mitosis occurs across the chromosome due to the intrinsic chromatin affinity of FoxA1.
Both specific and nonspecific binding contribute to timely reactivation of target genes post-mitosis. These
studies reveal an unexpected diversity in the mechanisms by which transcription factors help retain cell identity
during mitosis.
[Keywords: mitosis; bookmarking; pioneer factor; FoxA1; chromatin; chromosomes]
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When cells enter mitosis, chromosomes condense
(Caravaca et al. 2005) and the genome becomes silent
(Prescott and Bender 1962; Spencer et al. 2000). Only a
fraction of transcription factors are retained on mitotic
chromosomes (Martinez-Balbas et al. 1995; Michelotti
et al. 1997; Burke et al. 2005; Yan et al. 2006; Egli et al.
2008), and a subset of these facilitate rapid gene reac-
tivation post-mitosis (Young et al. 2007; Blobel et al.
2009; Dey et al. 2009; Kadauke et al. 2012). The basis for
the marked differential in transcription factors’ binding
to mitotic chromatin and how it reflects the factors’ roles
in genome reactivation is not clear.
In liver development, binding sites for FoxA and GATA
factors are occupied on the silent liver gene alb1 in
undifferentiated embryonic endoderm (Gualdi et al. 1996;
Bossard and Zaret 1998). Upon hepatic induction, nearby
binding sites for NF-1, C/EBP, and other factors become
occupied, and the liver gene is activated. Among the
factors that promote liver development, only FoxA pro-
teins can bind their target sites on nucleosomes and
enable the other factors to bind (Cirillo and Zaret 1999;
Cirillo et al. 2002); hence, FoxA factors have been called
‘‘pioneer factors’’ (Cirillo et al. 2002; Zaret and Carroll
2011). While GATA4 is dependent on FoxA for binding
nucleosomes (Cirillo and Zaret 1999), it can bind to
compacted chromatin that is inaccessible to the other
factors (Cirillo et al. 2002) and hence can be considered
a subordinate pioneer factor. The structure of the
DNA-binding domain (DBD) of FoxA resembles that
of linker histone (Clark et al. 1993; Ramakrishnan
et al. 1993), and the FoxA C-terminal domain, which
is unlike that of linker histone, interacts with core
histones and promotes local chromatin opening (Cirillo
et al. 2002). The highly related FoxA1 and FoxA2 are
encoded by unlinked genes and both are necessary for
the activation of the hepatic program (Lee et al. 2005);
FoxA1 has been shown to remain bound to mitotic
chromosomes in adult liver cells (Zaret et al. 2011). We
therefore sought to investigate the mechanism and
3Corresponding author
E-mail zaret@upenn.edu
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role of FoxA binding to the mitotic genome in hepatic
cells.
Results
Pioneer factors bind more strongly than other factors
to mitotic chromatin
We previously assessed the interphase chromatin binding
and mobility of GFP-tagged versions of FoxA1, GATA4,
C/EBPa, NF-1, and other proteins that are expressed in
the liver and contain different DBD structures (HMGB1,
c-Myc, and linker histone H1o). Notably, FoxA1 moves
much more slowly in chromatin than the other factors,
correlating with its high nucleosomal binding ability,
although not as slow as H1o (Sekiya et al. 2009). Here,
we expressed the constructs in HUH7 adult human
hepatoma cells that had been blocked in mitosis with
nocodazole and visualized GFP fluorescence in live cells
by high-resolution deconvolution microscopy (Agard
1984). GFP-FoxA1 was seen almost exclusively bound to
chromosomes in the metaphase-arrested cells as well as
in drug-free control cells passing through mitosis, mim-
icking the pattern of GFP-H1o (Fig. 1A). We estimate that
the GFP transfected cells expressed ;10-fold more of the
respective amounts of the transcription factor than the
endogenous protein (data not shown). When we used 20-
fold lower amounts of transfected GFP-FoxA1 plasmid
DNA, we observed much fainter signals but still marked
binding to mitotic chromosomes (Supplemental Fig. 1a).
GFP-GATA4 and GFP-HMGB1 fluorescence was seen
both on the mitotic chromosomes and in the cytoplasm
(Fig. 1B), while GFP-C/EBPa gave fainter signals on
mitotic chromosomes than the other factors. Western
blotting of endogenous C/EBPa showed it to be several-
fold less stable in mitotic hepatoma cells, whereas FoxA1
was equal in abundance in mitotic and asynchronous
cells (Supplemental Fig. 1b). GFP-c-Myc and GFP-NF1
exhibited background fluorescence on the mitotic chro-
mosomes, reflecting factor exclusion (Fig. 1B). Cells re-
leased from the metaphase mitotic block and fixed at
anaphase and telophase showed that GFP-FoxA1 remained
bound to chromosomes throughout mitosis, while a GFP
protein fused to a nuclear localization sequence was
excluded (Supplemental Fig. 2a). Endogenous FoxA1
exhibited similar properties but with a more diffuse
signal that is typical of fixed cells, compared with that
seen when live cells are imaged (Supplemental Fig. 2b).
GFP fused to the FoxA1 DBD was sufficient to bind
mitotic chromosomes (Fig. 1A).
Thus, within this group of regulatory factors for the
liver lineage, the earliest pioneer factor in development is
the most strongly bound to mitotic chromatin; the sub-
ordinate pioneer factor GATA4 is partially bound, similar
to that seen for GATA1 elsewhere (Kadauke et al. 2012);
and later developmental factors are either partially
bound, bound yet unstable in mitosis, or excluded from
the mitotic chromosomes altogether.
Highly transcribed gene targets of FoxA1 remain
specifically bound in mitosis
To assess where endogenous FoxA1 binds the genome
in mitotic cells compared with asynchronously cycling
cells, we performed chromatin immunoprecipitation
(ChIP) coupled with deep sequencing (ChIP-seq) on trip-
licate cell populations, with and without nocodazole
treatment (Supplemental Fig. 3a,b). More than 94% of
the nocodazole-arrested cells were in mitosis, as assessed
by cell morphology and H3Ser10 phosphorylation, while
<2% of the asynchronously cycling wells were in mitosis
(Supplemental Fig. 3a). Using model-based analysis of
ChIP-seq (MACS) (Zhang et al. 2008) to assign peaks, we
discovered 546 FoxA1-bound sites in mitotic cells and
3509 sites in asynchronous cells (Fig. 2A). Eighty-seven
of the called FoxA1 peaks were specific to mitotic cells,
but visual inspection of the unique sequence reads and
quantitative PCR (qPCR) analysis of independent chro-
matin preparations indicated that the FoxA1-bound sites
in mitotic cells are also bound in asynchronous cells
(e.g., Fig. 2B [intergenic site on ch. 5 and MIPEP site at
+92.7 kb, red arrowheads], B [ChIP-qPCR validations are
of mitotic and asynchronous cell chromatin]). Certain
weak FoxA1 peaks in mitosis that were not called by
MACSwere significant by ChIP-qPCR (Fig. 2B,AFP!4.1-
and!2-kb sites and TTR promoter), similar to the weaker
mitotic site at theHNF4a!7-kb site and unlike a negative
control site on ch. 13 (Fig. 2B). ChIP for histone H3 at
Figure 1. Diverse modes of hepatic transcription factor binding
to mitotic chromosomes. (A,B) GFP fluorescence in live HUH7
hepatoma cells visualized by deconvolution microscopy with or
without nocodazole for mitotic arrest. (A) GFP and GFP/bright-
field (BF) views showing that GFP-FoxA1, GFP-FoxA1 DBD, and
GFP-H1o remain quantitatively bound to mitotic chromosomes.
(B) A portion of the cellular GATA4 and HMGB1 is released
from mitotic chromosomes in nocodazole-treated cells; C/EBPa
becomes unstable, yet a portion remains bound; and c-Myc and
NF1 are excluded from the mitotic chromosomes.
Caravaca et al.
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these sites showed comparable signals between the asyn-
chronous and the mitotic chromatin (Supplemental Fig. 3c),
demonstrating that differences seen for FoxA1 were spe-
cific to the factor and not the preparations of chromatin.
FoxA1 peaks that occurred in both mitotic and asyn-
chronous cells were, on average, markedly stronger in
asynchronous cells than the FoxA1 peaks that occurred
only in asynchronous cells (Fig. 2C, where overlapping
peaks were merged). De novo motif analysis of FoxA1
peaks in mitosis revealed a Fox consensus sequence that
was essentially the same as that seen at asynchronous-
only sites (Fig. 2D). We found 601 genes bound by FoxA1
in both asynchronous and mitotic cells and 2722 genes
bound by FoxA1 only in asynchronous cells (Fig. 2E).
Triplicate microarray analyses of HUH7 cells showed
that mitotic and interphase FoxA1 target genes represent
those that are among the most highly expressed in in-
terphase (Fig. 2F). Mitotic FoxA1 targets include transcrip-
tion factor genes that are important for hepatic differenti-
ation, such asHNF4a and FOXA1 itself (Fig. 2G), and genes
for kinase signaling pathways (Supplemental Fig. 3d). In
summary, we estimate that;15% of the FoxA1 sites that
are bound in interphase cells are also bound in mitosis,
corresponding to the strongest bound sites at the more
highly expressed genes in interphase.
FoxA1 target sites that remain bound in mitosis
have a higher intrinsic nucleosome occupancy score
(INOS) than sites bound only in asynchronous cells
To further characterize potential differences between
target sites for FoxA1 that remain bound in mitosis
compared with sites bound only in asynchronous cells,
we first compared the binding events with available
histone modification data in the human ENCODE data-
base. No substantial differences were observed to be
centered over the FoxA1-binding sites (data not shown).
Given the extensive prior data documenting the ability
Figure 2. FoxA1 in mitosis occupies the most
strongly expressed and strongly bound genes in
asynchronous HUH7 cells. (A) Peaks were pooled
from three replicate ChIP-seq samples, revealing
3509 asynchronous FoxA1-binding sites, of which
546 are also bound in mitosis. (B) FoxA1 ChIP-seq
data tracks and ChIP-qPCR confirmation in inde-
pendent chromatin samples with signals normalized
to input and per million sequence reads. Red arrow-
heads depict sites of mitotic binding, and those that
were verified by qPCR are shown on the right. The
circle indicates the negative control site. The break
in the HNF4a and TTR bar graphs is to accommo-
date different scales for the asynchronous (as.) and
mitotic (mi.) data. (C) FoxA1 ChIP-seq signals over
all sites bound in mitotic and asynchronous cells
compared with all sites bound only in asynchronous
cells; the signal is normalized to input DNA quan-
tity and the total number of aligned sequence reads.
FoxA1 binding is much stronger to sites in mitotic
and asynchronous cells than to sites bound in
asynchronous cells only. (D) Common FoxA-binding
motif at sites bound in mitosis versus asynchronous
only. (E) Nearly all of the FoxA1-bound sites in
mitosis are associated with genes either within the
transcribed region or <20 kb upstream. (F) Box and
whisker plots showing that genes bound by FoxA1 in
mitotic and asynchronous cells correspond to those
more highly expressed genes in hepatoma cells; (***)
P < 10!15. (G) FoxA1 remains bound to hepatic
transcription factor genes in mitosis.
Specific and nonspecific binding in mitosis
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of FoxA1 to bind nucleosomal DNA (Cirillo et al. 1998;
Cirillo and Zaret 1999; Chaya et al. 2001), we compared
the FoxA1 mitotic and asynchronous binding data with
a computational model that predicts how well a nucleo-
some could form at underlying 147-base-pair (bp) lengths
of DNA (Kaplan et al. 2009; Tillo and Hughes 2009; Tillo
et al. 2010). Figure 3 shows the average INOS for FoxA1
ChIP-seq peaks in mitotic and asynchronous cells across
1500 bp spanning each binding event. In both cases, there
is a peak in INOS near the center of DNA binding. Peaks
in INOS of;300 bp have been observed at binding events
for other transcription factors (Tillo et al. 2010). A differ-
ence here is that the absolute value of INOS for FoxA1 is
low, indicating that the protein does not generally bind
to CG-rich regions of the genome. Indeed, the target
sequence for FoxA1 is relatively AT-rich (Fig. 2D).
Interestingly, the INOS for FoxA1 in mitotic cells is
significantly higher than that in asynchronous cells (P =
9.5 3 10!6). The higher INOS for mitotic peaks suggests
that the underlying nucleosome is typically more stable
at chromosomal sites where FoxA1 remains bound in
mitotic cells compared with that seen at sites where
FoxA1 binds only in asynchronous cells. This possibility
is consistent with the aforementioned features of FoxA1
binding its target site on nucleosomes in vitro and in vivo
and suggests that more stable nucleosomal targets help
predict mitotic chromosome binding.
Substantial nonspecific mitotic chromosome binding
by FoxA1
We next addressed the apparent conundrum that FoxA1
is stable in mitosis (Supplemental Fig. 1b) and retained
globally on the chromosomes (Fig. 1A) yet dissociates
from many specific interphase binding sites (Fig. 2A).
To investigate changes in the chromatin-binding proper-
ties of FoxA1, we performed fluorescence recovery after
photobleaching (FRAP) assays in unfixed cells on GFP-
FoxA1, with GFP-H1o as a control. GFP-H1o in HUH7
cells exhibited a threefold increase in FRAP half-time in
metaphase compared with interphase (Fig. 4A); a similar
increase was seen for H1c-GFP in other cells (Chen et al.
2005). Thus, linker histone moves more slowly in meta-
phase chromatin, consistent with the chromosomes’ high
degree of compaction. In marked contrast, GFP-FoxA1
exhibited a more than twofold decrease in FRAP half-time
in metaphase (Fig. 4A). Thus, the dramatic compaction of
chromatin in mitosis is associated with an increase in the
mobility of FoxA1 compared with interphase.
We questioned whether the increasedmobility of FoxA1
in mitosis could be visualized in the genomic ChIP-seq
data as an increase in nonspecific DNA-binding signals.
Indeed, when viewed at the chromosomal level, there was
a greater background of nonpeak FoxA1 ChIP-seq reads in
mitotic cells compared with asynchronous cells (Fig. 4B,
blue lines below red arrowheads; Supplemental Fig. 4).
Thus, the increased mobility of FoxA1 in mitosis is as-
sociated with significant amounts of FoxA redistributing
from specific sites to the flanking chromosomal domains.
We questioned whether the nonspecific binding at the
chromosomal level in mitotic cells was dependent on
FoxA1 interactions with DNA. To address this, we trans-
fected HUH7 cells with GFP-tagged variants of FoxA1
that perturb nonspecific DNA binding (FoxA1-RR) or
specific DNA binding (FoxA1-NH) (Sekiya et al. 2009).
FoxA1-RR has alanine substitutions at two residues that
make phosphate contacts with the DNA backbone (Fig.
5A). The FoxA1-RRmutant exhibits a marked decrease in
overall and nonspecific DNA binding but still recognizes
FoxA target sites, albeit more weakly than wild type
(Sekiya et al. 2009). FoxA1-NH has alanine substitutions
at two residues that make base contacts with DNA (Fig.
5A). The FoxA1-NH mutant exhibits normal nonspecific
DNA binding but no longer recognizes FoxA target sites
(Sekiya et al. 2009). Strikingly, when observed in live
mitotic cells, much of the GFP-FoxA1-RR mutant was
cytoplasmic (Fig. 5B). In contrast, the GFP-FoxA1-NH
mutant was largely retained on the mitotic chromosomes
(Fig. 5B), demonstrating that specific binding is not neces-
sary for bulk mitotic retention. From these data, we
conclude that much of the FoxA1 in mitotic chromatin
is bound nonspecifically to the DNA.
To assess the contributions of specific and nonspecific
binding to target site binding in mitosis, we performed
ChIP for the GFP tag in cells transfected with GFP-FoxA1
and the variants (Fig. 5C; Supplemental Fig. 5a). As
expected, wild-type GFP-FoxA1 bound to endogenous
FoxA1 targets in both asynchronous and mitotic cells
(Supplemental Fig. 5b). Of three target sites that possess
a FoxA-binding motif, binding by the GFP-FoxA1-RR
mutant at the AFP !4.1-kb site and the TTR promoter
was diminished, but still significant, in comparison with
the IgG ChIP control (Fig. 5C, red arrowheads). In con-
trast, the GFP-FoxA-NH mutant exhibited a loss of
binding to all of these sites (Fig. 5C). Therefore, despite
a loss in nonspecific DNA binding and significant release
from chromosomes, the FoxA-RRmutant can still bind in
mitosis to sites with FoxA1 motifs. We conclude that
binding by FoxA1 in mitotic chromosomes can take two
forms: nonspecific binding that is not reflected in specific
peaks in the ChIP-seq data and specific binding at a subset
of asynchronous cell FoxA1 target sites.
Figure 3. FoxA1-bound sites in mitotic cells have higher
predicted nucleosome occupancy compared with sites bound
only in asynchronous cells. Average INOS for FoxA1 3509 ChIP-
seq peaks seen only in asynchronous HuH7 cells and 544 peaks
seen in mitotic cells within 6750 bp from the center of the
peak; also shown are 100,000 sequences selected at random
from human genome (hg18). The average INOS profiling of
FoxA1 in mitotic HuH7 cells is higher than seen in asynchro-
nous cells (t-test, P = 9.5 3 10!6).
Caravaca et al.
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Specific and nonspecific mitotic binding promotes
target gene reactivation post-mitosis
Previous knockdown studies of Brd4 (Dey et al. 2009),
MLL (Blobel et al. 2009), andGATA1 (Kadauke et al. 2012)
found that these mitotic bookmarking factors are re-
quired for the timely reactivation of genes to which they
bind in mitosis and are not required for the initial
reactivation of genes to which they are bound only in
interphase. To assess FoxA1 in this context, we compared
the target gene reactivation after mitotic release in cells
transfected for 2 d with a FOXA1 knockdown siRNA
versus a control siRNA (Supplemental Fig. 5c,d). The
relatively short time period is sufficient for determining
effects on nascent transcript induction (see below) but, in
our hands, not long enough for marked effects on steady-
state levels of mRNA. By immunofluorescence, RNA
polymerase II was absent from metaphase chromosomes
in blocked HUH7 cells and then rebound chromatin 80
min after release in some cells (Supplemental Fig. 5e).
Incorporation of ethynyl uridine (EU) (Jao and Salic 2008)
into nascent RNA was undetectable in arrested cells;
sparse staining appeared in some cells by 80 min after
release and was more uniform across the nucleus by 90–
100 min post-release in late telophase (Supplemental Fig.
5e), similar to other cell types (Prasanth et al. 2003). Based
on these findings, we collected triplicate RNA time
points before and after transcriptional reactivation and
analyzed genes by RT-qPCR with primer sets that span
intron–exon junctions to exclusively detect nascent
mRNA. Many genes exhibited a continual increase in
nascent transcripts for hours after mitotic release, while
others exhibited an initial burst of expression (Fig. 6A;
Supplemental Fig. 6).
Regardless of the initial re-expression pattern, most of
the genes that were bound by FoxA1 in mitosis exhibited
a statistically significant dependence on FoxA1 for their
initial activation in late telophase (Fig. 6A; Supplemental
Fig. 6, top rows), demonstrating that FoxA1 functions as
a bookmarking transcription factor. None of the genes
that were not bound by FoxA1 in mitosis or interphase
were dependent on FoxA1 for early reactivation, demon-
strating selectivity for FoxA1 target genes (Fig. 6A;
Supplemental Fig. 6, bottom rows). Interestingly, many
of the genes that were bound by FoxA1 in interphase but
not in mitosis were also dependent on FoxA1 for their
initial activation post-mitosis, although with a wider
variation in response (Fig. 6A; Supplemental Fig. 6, mid-
dle rows). When we grouped all genes assayed in each
category at the earliest time point and assessed the
average fold induction in the presence of FoxA1 siRNA
over that with the control siRNA, both themitotic-bound
Figure 4. Increased mobility and nonspecific binding
of FoxA1 in mitotic cells. (A) Relative fluorescence
intensity (RFI) analysis showing that while GFP-H1o
moves threefold more slowly in mitotic chromatin
compared with interphase nuclei, GFP-FoxA1 moves
2.5-fold more quickly. Error bars denote standard error
of the mean (SEM). Primary FRAP data for RFI analysis.
White circles indicate the bleached area. (B) Unique
FoxA1 ChIP-seq signals from two to 10 reads per
million per 25-bp interval mapped to the left arm of
human ch. 7 depicting higher nonspecific, background
binding in mitotic cells (red arrows) and many more
peaks in asynchronous cells. Input DNA is shown at
two to 20 reads per 25-bp interval.
Specific and nonspecific binding in mitosis
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and asynchronous-only-bound FoxA1 target genes exhibited
a significant difference from the genes not bound by FoxA
(Fig. 6B). Similar results were obtained with a less exten-
sive study using a different siRNA to knock down FoxA1
(Supplemental Fig. 7). We conclude that FoxA1’s in-
creased mobility in mitotic chromatin (Fig. 4A) yet high
nonspecific chromatin-binding capacity (Figs. 5, 6) keep
the factor on chromatin and facilitate rapid reactivation
during mitotic exit. The most highly expressed FoxA1
targets retain FoxA1 binding in mitosis, whereas most
other FoxA1 targets appear to be dependent on nonspe-
cific binding to mitotic chromatin. Importantly, FoxA1
does not indirectly enhance the reactivation of genes to
which it is not bound in interphase. We conclude that the
pioneer factor FoxA1 has mitotic chromatin-binding
features that distinguish its activity from other book-
marking factors that have been characterized.
Discussion
In this study, we demonstrated that FoxA1, a pioneer
factor involved in early steps of liver development, also
bookmarks targets genes during mitosis. FoxA1 employs
two different modes of mitotic binding that contributes
to gene reactivation during exit from mitosis. The
specific binding mode is responsible for mitotic marking
of genes that are highly expressed in interphase, including
important liver genes, and the nonspecific binding mode
keeps FoxA1 in the vicinity of other target genes by
random site retention on mitotic chromosomes. The
nonspecific chromatin binding occurs via the high in-
trinsic affinity of FoxA1 for nucleosomal DNA (Cirillo
and Zaret 1999; Sekiya et al. 2009) and the factor’s in-
creased chromatin mobility in mitosis (Fig. 4). By retaining
FoxA1 on the DNA in mitosis, albeit nonspecifically, the
factor has initial access to its specific target sites that
would precede what would be observed for factors that do
not bind mitotic chromatin and thus could facilitate early
gene reactivation during mitotic exit (Fig. 7).
What determines whether a transcription factor will
remain bound to a particular site in mitosis? The answer
to this question has eluded the field, and there may be
different mechanisms employed by different factors. As
seen by other factors (Kadauke et al. 2012), the binding
sequence motif for FoxA1 is essentially the same at
mitotic-bound sites compared with sites bound only in
interphase (Fig. 2D). We failed to discover histone mod-
ifications at FoxA1 target sites in asynchronous cells that
would predict mitotic binding. However, this negative
result could be due to a limitation of the available
chromatin modifications currently in the online data-
bases or to a lack of correspondence between the cell
lines that have been assayed and HUH7 cells in which
we performed our experiments. Importantly, we were
able to discern that predicted INOSs (Kaplan et al. 2009)
are sufficient to distinguish the subset of sites that
remain bound by FoxA1 in mitosis; i.e., the sites that
retain FoxA1 binding in mitosis had significantly higher
INOSs. While nucleosome mapping in vivo will be re-
quired to assess the validity of these predictions, they are
striking in light of FoxA1 having amarkedly lower off rate
for its target sites on nucleosomes compared with free
DNA (Cirillo and Zaret 1999). Furthermore, sequential
ChIP studies showed that FoxA1 binds a nucleosomal target
site in vivo (Chaya et al. 2001). Because many, but not all,
other transcription factors lack the high intrinsic affinity for
nucleosomal DNA, it seems unlikely that the INOSwill be
a general predictor of mitotic chromosome binding. How-
ever, for this class of protein, it could be useful.
How is nonspecific DNA binding by FoxA1 more
prominent in mitosis than in interphase? Our FRAP
experiments revealed that despite linker histone moving
more slowly in mitotic chromatin, in agreement with
prior studies (Chen et al. 2005), the mobility of FoxA1 in
chromatin is increased compared with interphase. This
observation, coupled with the high intrinsic nucleosome
and chromatin-binding capacity of FoxA1, could be
sufficient to explain a decrement in specific target resi-
dence time with a concomitant increase in nonspecific
chromatin binding. As for what causes an increased
mobility of FoxA1 in mitotic chromatin, we speculate
that a mitosis-specific modification of the protein could
play a role, the overall compaction of chromatin could
help exclude many specific sites, and/or an altered
modification of the chromatin itself could contribute.
Figure 5. FoxA1 mutants that perturb specific or nonspecific
DNA binding reveal significant nonspecific binding to mitotic
chromatin. (A) Crystal structure view of the FoxA DBD depict-
ing residues mutated to perturb specific (NH) and nonspecific
(RR) DNA binding (Sekiya et al. 2009). (B) The FoxA1 mutant
with impaired nonspecific DNA binding is partially released
from mitotic chromosomes, while the FoxA1 mutant with
impaired specific DNA binding is mostly retained. (C) ChIP-
qPCR assays on transfected HUH7 cells in mitosis showing that
the FoxA1-RR nonspecific binding mutant can still recognize
the Afp !4.1-kb and Ttr promoter target sites that contain
FoxA-binding motifs (shown in the top row, red arrowheads),
whereas the FoxA1-NH specific binding mutant cannot. Thus,
even when loss of nonspecific binding results in most of the
FoxA1 being lost from mitotic chromosomes (B), FoxA1 can
bind specifically to target sites in mitotic cell chromatin (C).
Caravaca et al.
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By assaying in parallel diverse types of factors critical
for a single cell lineage, we discovered a diversity of
mitotic chromatin-binding types, including total occu-
pancy, specific and nonspecific binding, partial or total
chromosome exclusion, and differential mitotic stability.
We note that the earliest transcription factors in liver
development, including FoxA1 and HNF1b (Lokmane
et al. 2008), are necessary in the endoderm for hepatic
induction and exhibit high-level binding to mitotic chro-
mosomes (Verdeguer et al. 2010). In contrast, the other
hepatic transcription factors tested exhibit successively
less mitotic binding capacity. This raises the possibility
that the diverse modes of transcription factor binding in
mitosis may mimic binding hierarchies in development.
The mitotic binding hierarchy could be a way to ensure
the initial exclusion of factors that would otherwise
promote an alternate cell fate when a given cell type exits
mitosis.
Materials and methods
Mitotic arrest of HUH7 cells
HUH7 cells were plated in fresh DMEM High Glucose with
L-glutamine (Invitrogen, 11965), 10% FBS (HyClone), and 1%
penicillin–streptomycin (Invitrogen) and grown overnight to
75% confluence. Cells were blocked in S phase by addition of
fresh medium containing 2 mM thymidine (Sigma, T1895). After
24 h, cells were washed three times with PBS and released into
medium containing 0.06 mg/mL fresh nocodazole (Sigma, M1404).
After 18 h, ;94% of the cells were blocked in metaphase
(Supplemental Fig. 3a) and used for imaging or ChIP. Drug
washout experiments showed that the cells remained viable and
proliferative. For mitotic block release studies, arrested cells
were either (1) harvested by gentle shaking and replated into
fresh medium or (2) washed three times with PBS, and fresh
mediumwas added to the cells. Cells were allowed to proceed for
the periods indicated.
Fluorescence imaging of HUH7 cells
HUH7 cells were plated in glass-bottomed microwell dishes
(Mat Tek Corporation) and transfected on the next day with
Figure 6. FoxA1 is necessary for timely reactivation
of target genes as cells exit mitosis. (A) RT-qPCR
analysis of primary transcripts in HUH7 cells treated
with siRNAs for FoxA1 (si6689) or a control siRNA
blocked in mitosis and released for various time points.
Data are normalized to Gapdh and to the ‘‘block’’ time
point prior to mitotic release. The first two genes in
each row exhibited a net increase in synthesis over
time, while the others exhibited an initial burst of
synthesis. The top row depicts genes that are bound by
FoxA1 in mitosis; these are dependent on FoxA1 for
late telophase reactivation. The middle row depicts
genes that are bound by FoxA1 only in asynchronous
cells, many of which depend on FoxA1 for its initial
activation. The bottom row depicts genes that are not
bound by FoxA1 and are independent of FoxA1 for early
reactivation. See Supplemental Figure 5 for more genes
of each type. Error bars denote SEM; asterisks indicate
significance by a one-tailed Student’s t-test: (*) P < 0.05;
(**) P < 0.01. (B) The average nascent transcript in-
duction at 105 min post-mitotic block release is shown
as a ratio of that in the presence of the FoxA1 siRNA
over that for the control siRNA for genes in the three
categories in A and Supplemental Figure 5. Error bars
denote SEM, and asterisks indicate significance by a
one-tailed Student’s t-test: (*) P < 0.05; (**) P < 0.01.
A separate Mann-Whitney test, not shown, revealed
that the FoxA siRNA selectively perturbed mitotic
FoxA1-bound versus unbound to P < 0.00013 and
asynchronous-only bound versus unbound to P < 0.022.
The data show that FoxA1 facilitates the early reactiva-
tion of genes bound in mitosis as well as genes bound
solely in interphase cells and does not indirectly enhance
the reactivation of genes to which it does not bind.
Figure 7. Specific and nonspecific modes of FoxA1 binding to
the mitotic genome allow rapid reactivation of FoxA target
genes during mitotic exit.
Specific and nonspecific binding in mitosis
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GFP-tagged fusion proteins (Sekiya et al. 2009) with FuGENE 6
(Roche). After 48 h of mitotic arrest, asynchronous and
nocodazole-blocked cells were photographed at 1003 using
a Deltavision Core Deconvolution microscope (Applied Pre-
cision) from an Olympus IX70 microscope equipped with a
Photometrics CoolSNAP HQ 12-bit monochrome cooled CCD
camera. We used a 1003 1.4 NA oil immersion PlanSApo lens
(Olympus, #UPLSAPO 100XO) objective with epi-illumination
provided by a 300 W xenon arc lamp. The resulting images were
deconvoluted using the constrained iterative algorithm with
softWoRx (Applied Precision) acquisition software.
For conventional fluorescence microscopy, cells were fixed
with 3.7% formaldehyde (Fisher Scientific) for 20 min, washed
twice with PBS, permeabilized for 10 min in methanol (Fisher
Scientific) at !20°C, and then rinsed three times with PBS. Cells
were stained with 4,6-diamidino-2-phenylindole (DAPI) for 1 min.
After three washes with PBS, the samples were imaged at 403
using a Nikon Optiphot microscope with an Optronics CCD
camera. Alternatively, after the first PBS washes, cells were
incubated with a monoclonal antibody against H3phospho-S10
(Abcam, ab14955) diluted 1/375 in 3% FBS, 5 mM KCl, 100 mM
NaCl, 0.2% Triton X-100%, 1% BSA, and 10 mM Tris-HCl (pH
7.5) for 2 h at 4°C, then rocked 33 with PBS for 10 min at room
temperature and incubated with a secondary antibody conju-
gated to Alexafluor 488 (Invitrogen; A21202) at 1/500 in dilution
buffer for 1 h at room temperature. After rinsing twice with PBS,
cells were stained with DAPI and imaged as above. For RNA
polymerase II, cells were fixed for 30 min in PBS containing 4%
paraformaldehyde and permeabilized for 20 min in PBS contain-
ing 0.5% Triton X-100. Blocking was in PBS, 0.1% Triton X-100
(PBS-T), and 10% goat serum (Sigma, G9023) for 1 h. 8WG16
(Abcam, ab817) was diluted 1:1000 in PBS-T and applied over-
night at 4°C. Cells were washed three times with PBS for 10 min
each and then treated with Alexa Fluor 488 goat anti-rabbit IgG
(1:10,000 in PBS-T; Invitrogen, A11001) for 1 h at room temper-
ature. Cells were washed three times with PBS. DAPI (Sigma,
D9542) at 0.5 mg/mL PBS was applied to the cells for 2 min. Cells
were washed with PBS and imaged at 603 using an Eclipse
TE2000-U inverted microscope (Nikon) and CoolSNAP EZ
camera (Photometrics).
For immunostaining of endogenous FoxA1, HuH7 cells were
washed twice with PBS before fixation in PBS with 4% para-
formaldehyde for 12 min at room temperature and then rehy-
drated in cold PBS, 0.5% Triton X-100 for 10 min. After rinsing
twice with PBS, cells were treated with blocking solution
containing PBS-T, 4% FBS, 10% glycerol, and 0.1 M glycine for
1 h at room temperature. Primary incubation was done with a
goat antibody against FoxA1 (Abcam, ab5089) diluted 1/200 in
blocking solution for 1 h at room temperature. Cells then were
rocked three timeswith PBS-T for 5 min and incubated with
Alexa Fluor 488 anti-goat (1/1000 in blocking solution; Invitro-
gen, A11055) for 1 h at room temperature. Finally, after rocking
the cells three times with PBS-T for 10 min, cells were stained
with DAPI and imaged as for H3phospho-S10.
To visualize new RNA synthesis after release from a mitotic
block, HUH7 cells were synchronized by thymidine–nocodazole
block and released into freshmedium.One hour before the desired
time point for fixation, EU was added to 0.5 mM (Jao and Salic
2008). After this 1-h pulse, the cells were fixed and permeabilized
as for RNA polymerase II. Cells were washed once with PBS, and
the 30-min ‘‘click’’ reaction to Alexa Fluor 594-azide was initiated
and later quenched as specified (Click-It RNA Alexa Fluor 594
imaging kit; Invitrogen, C10330). Cells were then washed three
times with PBS while protected from light and counterstained
with DAPI, washed with PBS, and imaged at 603.
ChIP
Asynchronous and nocodazole/thymidine-blocked cells were
cross-linked with 1% formaldehyde for 20 min at room temper-
ature followed by addition of glycine to 125 mM. After two
washes with PBS, cells were collected and frozen. Cell pellets
were lysed, and genomic chromatin was sonicated to 200–500 bp
(Diagenode Bioruptor). For ChIP-qPCR, 25 mg (for GFP-ChIP) or
35 mg (for FoxA1-ChIP) were precleared with salmon spermDNA
and protein A agarose (Millipore, #16-157). Samples were split,
the first aliquot was incubated with 2 mg of rabbit IgG (Abcam,
ab46540), and the second aliquot was incubated with 2 mg
of rabbit polyclonal to GFP (Abcam, ab290), FoxA1 (Abcam,
ab23738), or Histone H3 (Abcam, ab1791). Samples were rotated
overnight at 4°C and immunoprecipitated with salmon sperm
DNA–protein A agarose and low- and high-salt wash steps.
Cross-linked products were reversed, RNase-treated, and DNA-
purified. Samples were analyzed on an iCycler iQ multicolor
real-time PCR (Bio-Rad) using SYBR Green (Bio-Rad). PCR
primer sets are listed below. We used two biological replicates
for the GFP-ChIP and three independent replicates for the FoxA1
and H3-ChIP.
ChIP-seq
ChIP was performed on triplicate chromatin samples of 335 mg
divided for FoxA1 and IgG immunoprecipitations, and products
were used to generate libraries (Illumina, IP-102-1001) of 100–
200 bp (Bioanalyzer, Agilent) on an Illumina Sequencer. Addi-
tionally, one DNA input library each was made frommitotic and
asynchronous chromatin. Sequence reads were aligned to the
human genome (NCBI Build 36) with ELAND using default
parameters. We uniquely mapped 40,002,286 and 43,176,234
reads for mitotic and asynchronous cells, respectively. Peaks
were called for each lane separately with MACS (Mfold param-
eter 16; false discovery rate [FDR] 5% for mitotic peaks and
0.05% for asynchronous peaks) using the input lanes as back-
ground. A more lenient FDR was used to assess mitotic peaks
because the majority of reads fell into regions of nonspecific
binding (see Fig. 3C), making peak identification for this ChIP
more difficult. The trends observed in Figure 2, C and F, are also
observed when both peak sets are filtered at 5% FDR (data not
shown). Peak sets from each replicate were intersected, and
peaks that share $50% sequence were merged to define distinct
binding sets. RefSeq transcripts were classified as targets if a
FOXA1 peak was present in the gene body or within 20 kb
upstream of the transcription start site. Data track images of
peaks were constructed by pooling sequence reads from all
replicate lanes, assessing tag counts at each position, normaliz-
ing the count per million aligned reads, and subtracting input.
These counts were written into a wiggle file and uploaded to the
University of California at Santa Cruz Genome Browser. Whole-
chromosome views were created similarly, except that sequence
tags were binned at 25-bp intervals prior to normalization.
Motifs were discovered using MEME and TOMTOM. The
presence or absence of the human FoxA1-binding sequence
was assessed using the available site matrix from JASPAR
(MA0148.1). ChIP-seq and gene expression array data have been
uploaded to Gene Expression Omnibus.
Intrinsic nucleosome occupancy calculation
The INOS based on the Lasso algorithm (Kaplan et al. 2009; Tillo
and Hughes 2009; Tillo et al. 2010) was calculated for evaluation
of intrinsic nucleosome occupancy. For each 1500-bp sequence,
we calculated the INOSs for each slide window of 147 bp and
moved the window base by base to get the profiling of INOSs.
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The control set was 100,000 sequences randomly selected from
hg18.
Gene expression microarrays
Total RNA was collected from three different plates of asyn-
chronous Huh7 cells using the RNeasy minikit (Qiagen). Expres-
sion microarrays were performed with a Human Gene 1.OST
array (Affymetrix) at the University of Pennsylvania Microarray
Core Facility and were evaluated using Partek.
Western blot analysis
Primary antibodies used were as follows: FoxA1 (0.001 mg/mL;
Abcam, ab23738), C/EBPa (1:400; Santa Cruz Biotechnology,
sc-61), and vinculin antibodies (1:5000; Sigma-Aldrich, V-9131).
Secondary antibodies used were as follows: goat anti-rabbit
IgG (H+L)-HRP (1:5000; Bio-Rad, 1706515) and goat anti-mouse
IgG-HRP (1:5000; Santa Cruz Biotechnology, sc-2005).
FRAP assays
Cells cultured in glass-bottomed microwell dishes were trans-
fected with GFP-tagged proteins and arrested in mitosis. The
dishes were mounted onto a spinning-disk confocal microscope
with a Yokogawa CSU X1 scan head and an Olympus IX 81 mi-
croscope. The cells were kept at 37°C using an Okolab Uno incu-
bator. Acquisition and hardware were controlled by MetaMorph,
version 7.7 (Molecular Devices). An Andor iXon3 897 EMCCD
camera (Andor Technology) was used for image capture. Solid-
state lasers for excitation (488 nm for GFP) were housed in a
launch constructed by Spectral Applied Research. An Olympus
1003, 1.4 NA UPlanSApo oil immersion objective was used for
all experiments.
FRAPwas performed using the iLas2 system (Roper Scientific),
using a 50-mW diode-pumped crystal laser at 405 nm (Crysta-
Laser, model DL405-050-O) controlled by MetaMorph. Laser
power for bleaching was attenuated to 7.5%. For each experi-
ment, four to six single-prebleach images were acquired before
an area of 1.5 mm2 was bleached. Images were collected over 150
sec (FoxA1) or 227 sec (H1) every 0.3 sec. At least nine cells were
analyzed for each time.
To calculate the relative fluorescence intensity (RFI) in the
bleached area at time t, we used the equation RFI (t) = [IB (t)! IBG
(t)/IB (t0) ! IBG (t0)] [IU (t0) ! IBG (t0)/IU (t) ! IBG (t)]. IB (t) is the
fluorescence intensity in the bleached region at time t, IBG (t) is
the fluorescence intensity in an area containing no cells (back-
ground) at time t, IU (t) is the fluorescence intensity in a
nonbleached region in the same cell at time t, IB (t0) is the
fluorescence intensity of the bleached region before bleaching,
IBG (t0) is the fluorescence intensity in the region containing no
cells before bleaching, and IU (t0) is the fluorescence intensity in
the nonbleached area before bleaching. Curve fitting was per-
formed using Prism 5 (Graphpad Software). Error bars from
individual time points represent standard error of the mean
(SEM).
FoxA1 knockdown
Huh7 cells at 30% confluence were reverse-transfected with
3 nM siRNA (FoxA1 ID: si6689) (Fig. 6; Supplemental Figs. 5, 6)
or s6687 (Supplemental Fig. 7) and negative control #1 Silencer
Select siRNAs (Ambion) using RNAiMAX (Invitogen, 13778-
075). After 58 h, mitotic arrested cells were harvested by shake-
off and plated with fresh medium. Total RNA was collected at
the time points indicated using the RNaEasy microkit (Qiagen).
Nascent mRNA of target genes were analyzed by real-time PCR
using SYBR Green (Applied Biosystems). Primer sets (see below)
were designed to detect primary transcript, nonspliced mRNA
by spanning intron–exon junctions and the adjacent exon.
Expression levels were normalized to the levels of spliced
GAPDH. The data are represented as fold induction over time
0 h: 2DDCt = 2Ctgene_t ! CtGapdh_t/2Ctgene_t0 ! CtGapdh_t0. Error bars
indicate SEM. One asterisk denotes P < 0.05 and two asterisks
represent P < 0.01, calculated using a one-tailed Student’s t-test.
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